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Zusammenfassung	
	
Multiple	Sklerose	(MS)	ist	eine	der	häufigsten	neuroimmunologischen	Erkrankungen,	die	bereits	
im	 jungen	 Erwachsenenalter	 zu	 bleibender	 Behinderung	 führen	 kann.	 Die	 Erkrankung	 ist	
gekennzeichnet	 durch	 entzündliche	 Läsionen,	 De-	 und	 Remyelinisierung	 sowie	 axonale	
Degeneration.	 Aktuelle	 Therapieoptionen	 wirken	 primär	 immunmodulatorisch	 oder	
immunsuppressiv.	In	der	progredienten	Phase,	wenn	die	Entzündung	größtenteils	abgeklungen	
und	axonaler	Schaden	und	Degeneration	die	vorherrschende	Pathologie	ist,	sind	therapeutische	
Möglichkeiten	 rar.	Demyelinisierung,	 Inflammation	und	mitochondriale	Dysfunktion	 führen	zu	
oxidativem	 Schaden	 und	 metabolischem	 Ungleichgewicht	 in	 den	 Axonen.	 Im	 Tiermodell	
Experimentelle	 Autoimmunenzephalomyelitis	 (EAE)	 konnte	 gezeigt	 werden,	 dass	
Transportdefizite,	 die	 mit	 der	 Entzündung	 einhergehen,	 weitverbreitet	 und	 anhaltend	 sind.	
Während	in	der	akuten	Phase	der	Transport	in	beide	Richtungen	unterbrochen	ist,		bleibt	in	der	
chronischen	Phase	der	anterograde	Transport	stärker	beeinträchtigt	als	der	retrograde.		
In	 der	 vorliegenden	 Arbeit	 habe	 ich	 mich	 mit	 den	 Auswirkungen	 des	 chronischen	
Transportdefizits	auf	die	mitochondriale	Verteilung	in	Axonkollateralen	und	Boutons/Synapsen	
beschäftigt.	 EAE	 wurde	 in	 transgenen	 Tieren,	 welche	 an	 Mitochondrien	 gebundenes	
fluoreszierendes	 Protein	 exprimieren,	 induziert.	 Mittels	 Spinalganglieninjektion	 eines	 viralen	
Vektors	 konnte	 eine	 definierte	 Population	 von	 Axonen,	 die	 eine	 entzündliche	 Läsion	
durchqueren	 und	 in	 der	 lumbalen	 grauen	 Substanz	 Kollateralen	 abgeben,	 markiert	 werden.	
Synapsen	und	Entzündungszellen	wurden	durch	Immunfluorezenzfärbung	visualisiert.	
In	 akuter	 EAE	 hatten	 kurz	 anhaltende	 Transportunterbrechungen	 keinen	 Einfluss	 auf	 den	
distalen	 Gehalt	 an	 Mitochondrien,	 während	 langanhaltende	 Transportdefizite	 als	 Resultat	
chronischer	Neuroinflammation	zu	einer	Reduktion	der	distalen	Mitochondrienzahl	und	damit	
zu	 einer	 energetischen	 Minderversorgung	 des	 distalen	 Nervenastes	 führten.	 Darüberhinaus	
zeigten	Axone	ohne	Mitochondriendepletion	ein	anderes	Verteilungsmuster	als	die	Kontrollen	
mit	einem	Shift	der	Mitochondrien	aus	den	Boutons	in	die	dazwischenliegenden	Abschnitte.	Die	
Anzahl	 und	 das	 Volumen	 der	 Mitochondrien	 innerhalb	 der	 Boutons	 waren	 reduziert,	
wohingegen	 die	 Anzahl	 der	 Boutons	 unverändert	 blieb.	 Diese	 Ergebnisse	 deuten	 daraufhin,	
	
	 9	
dass	die	Transportdefizite	zu	einer	distalen	mitochondrialen	Depletion	und	damit	Affektion	der	
grauen	 Substanz	 beitragen,	 die	 bei	 EAE	 und	MS	 beobachtet	werden	 kann.	 Je	mehr	 klinische	
Defizite	sich	in	chronisch	progredienter	MS	über	die	Zeit	anhäufen,	desto	weniger	sprechen	sie	
auf	 antiinflammatorische	 Medikation	 an.	 Zukünftig	 müssen	 neue	 therapeutische	 Ansätze	
geschaffen	 werden,	 die	 zu	 einer	 Wiederherstellung	 des	 axonalen	 Transports,	 der	 axonalen	
Homöostase	 und	 der	 mitochondrialen	 Funktion	 beitragen	 können.	
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Summary	
	
Multiple	Sclerosis	(MS)	 is	one	of	the	most	common	causes	for	neurological	disability	 in	young	
adults,	 hallmarked	 by	 inflammatory	 lesions,	 de-	 and	 remyelination	 and	 axonal	 degeneration.	
Current	treatment	options	are	primarily	directed	at	immunomodulation	or	immunsuppression.	
In	the	progressive	phase,	when	inflammation	has	abated	and	axonal	injury	and	degeneration	is	
the	 dominant	 pathology,	 treatment	 options	 are	 sparse.	 Demyelination,	 inflammation	 and	
mitochondrial	dysfunction	lead	to	oxidative	damage	and	metabolic	imbalance	within	the	axons,	
which	ultimately	results	in	axonal	degeneration.	In	the	animal	model	experimental	autoimmune	
encephalomyelitis	 (EAE)	 it	 could	 be	 shown	 that	 transport	 deficits	 linked	 to	 inflammation	 are	
pervasive	 and	 continuous.	 While	 acutely	 anterograde	 and	 retrograde	 transport	 are	 both	
affected,	in	chronic	EAE	mostly	anterograde	transport	is	reduced.		
The	 implications	 of	 the	 chronic	 transport	 deficits	 on	 mitochondrial	 distribution	 in	 axon	
collaterals	 and	 synapses	 were	 subject	 of	my	 thesis.	We	 induced	 EAE	 in	 genetically	modified	
mouse	 lines	 that	 express	 mitochondrially	 targeted	 cyan	 fluorescent	 protein.	 Via	 dorsal	 root	
ganglion	injection	of	a	viral	vector	for	a	fluorescent	protein	I	was	able	to	follow	a	selective	set	of	
axons	through	an	inflammatory	lesion	passing	off	collaterals	into	the	gray	matter.	Synapses	and	
inflammatory	cells	were	visualized	by	immunofluorescence.		
In	 acute	 EAE,	 short	 lasting	 transport	 interruptions	 do	 not	 affect	 the	 distal	 mitochondrial	
content,	 while	 longer	 lasting	 transport	 deficits	 as	 observed	 in	 chronic	 neuroinflammation	
decrease	the	distal	mitochondrial	content	and	thereby	diminish	the	energy	supply	of	the	distal	
axonal	 arbor.	 Moreover,	 healthy	 appearing	 axons	 not	 depleted	 of	 mitochondria	 showed	 a	
different	 mitochondrial	 distribution	 with	 depleted	 boutons	 and	 increased	 content	 in	 the	
extrasynaptic	 parts.	 While	 mitochondrial	 number	 and	 volume	 within	 the	 boutons	 was	
decreased,	 the	 number	 of	 boutons	 was	 unaltered.	 These	 results	 indicate	 that	 distal	
mitochondrial	 depletion	might	 contribute	 to	 gray	matter	 pathology	 concomitant	with	 clinical	
deficits	seen	in	EAE	and	MS.		As	clinical	deficts	accumulate	over	time	and	are	unresponsive	to	
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anti-inflammatory	treatment	in	progressive	MS,	new	therapeutic	approaches	that	can	recover	
axonal	transport,	restore	the	axonal	homeostasis	and	supporting	mitochondrial	function	should	
be	explored.	
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1	Introduction	
1.1	Early	History	of	MS	
	
As	 Robert	 Carswell	 pondered	over	 a	 spinal	 cord	 specimen	of	 a	 deceased	patient	 in	 1838,	 he	
noted	“a	peculiar	diseased	state”	(Carswell,	1838;	T.	J.	Murray,	2009).	He	saw	brown	atrophied	
patches,	which	were	firm	to	the	touch.	The	only	clinical	fact	he	knew	about	the	patient	formerly	
bearing	those	scars	was	that	he	was	paralyzed.	Before	proceeding	with	many	other	pathological	
curiosities	on	his	table,	he	produced	a	drawing	of	the	cord	and	included	it	on	atrophy	plate	IV	of	
his	Pathological	Anatomy:	Illustrations	of	Elementary	Forms	of	Disease.	This	is	regarded	as	the	
first	illustration	of	the	pathology	of	Multiple	Sclerosis	(MS)	(T.	J.	Murray,	2005).	It	took	another	
30	years	until	Jean-Martin	Charcot	gave	this	peculiar	disease	an	apt	name:	la	sclérose	en	plaque	
disseminée.	The	debatably	earliest	case	described	is	that	of	Lidwina	of	Schiedam,	born	in	1380.	
After	a	fall	while	ice	skating	she	developed	a	series	of	symptoms	that	are	typical	for	the	disease	
course	 of	MS:	 difficulty	walking,	 visual	 problems,	 headaches,	 and	 progression	 to	 a	 complete	
paraparesis,	 only	 to	 name	 a	 few	 (Maeder,	 1979).	 Since	 back	 in	 1380	 she	 had	 no	 physician	
capable	of	diagnosing	and	treating	her,	she	was	canonized	by	the	church	and	thought	to	suffer	
for	 the	sins	of	others.	Following	 this	perhaps	earliest	 case	 report	of	what	 is	 today	called	MS,	
many	other	cases	appeared	throughout	history,	which	were	only	correctly	diagnosed	centuries	
later	and	include	Auguste	d’Esté	and	Heinrich	Heine,	just	to	mention	two	(A.	Compston,	1998;	
Jellinek,	1990;	T.	J.	Murray,	2005;	Stenager,	1996). 
In	 the	 mid-19th	 century,	 Jean-Martin	 Charcot	 and	 Alfred	 Vulpian	 made	 it	 their	 mission	 to	
characterize	 and	 organize	 patients	 they	 have	 encountered	 in	 Paris’	 state-of-the-art	
neuropsychiatric	hospital,	 the	Salpêtrière,	 to	establish	a	classification	of	neurological	diseases	
by	matching	clinical	and	pathological	descriptions	(Kumar,	Aslinia,	Yale,	&	Mazza,	2011;	T.	Jock	
Murray,	2009).	In	the	process	of	their	work,	they	presented	the	first	three	official	cases	of	MS,	a	
disease	 that	 had	 occupied	 the	 attention	 of	 generations	 of	 physicians	 before	 them.	 Hallmark	
symptoms	were	tremor,	slurred	speech	and	abnormal	eye	movements,	later	termed	Charcot’s	
Triad.		 
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1.2	The	cellular	image	of	MS	
	
Light	microscopy	became	popular	at	 the	beginning	of	 the	20th	century,	allowing	 scientists	 to	
take	a	closer	look	at	tissues	and	to	identify	structures	they	never	knew	existed.	Cajal	and	Golgi	
(1906)	 discovered	 a	 dye	 to	 selectively	 visualize	 nerve	 cells	 (Glickstein,	 2006).	 While	 Rudolf	
Virchow	 first	 introduced	 the	 term	myelin	and	described	 the	sheaths	around	nerve	 fibers,	 the	
idea	that	these	might	be	glial	cells	to	insulate	nerve	cells	was	first	suggested	by	Santiago	Ramón	
y	Cajals	brother	in	the	early	1900s	(Cajal,	1913;	A.	Compston,	1998).	Louis	Ranvier	characterized	
the	myelin	 sheath	 and	 James	 Dawson	 in	 Edinburgh	 described	 its	 breakdown	 in	MS	 and	 the	
proximity	of	the	inflammation	to	blood	vessels	(Dawson,	1916;	T.	J.	Murray,	2005).	 
The	middle	of	 the	20th	century	was	a	period,	 in	which	animal	models	 for	diseases	came	 into	
focus.	Thomas	Rivers	(1935)	injected	myelin	into	lab	animals	and	thereby	produced	a	number	
of	symptoms	that	were	similar	to	those	present	in	MS	(Rivers	&	Schwentker,	1935).	This	model	
was	called	experimental	autoimmune	encephalitis	(EAE)	and	is	still	one	of	the	most	commonly	
used	models	 for	MS.	 In	1942,	Elvin	Kabat	at	Columbia	University	 first	used	electrophoresis	 to	
show	that	the	cerebrospinal	fluid	(CSF)	of	MS	patients	contained	a	higher	proportion	of	gamma	
globulin	 (Kabat,	 Moore,	 &	 Landow,	 1942).	 His	 study	 paved	 the	 way	 for	 the	 discovery	 of	
oligoclonal	bands	(OCBs),	which	were	subsequently	identified	by	Lowenthal,	who	thereby	made	
the	first	contribution	to	non-clinical	diagnostic	criteria	(Lowenthal,	Vansande,	&	Karcher,	1960). 
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Fig.	1-1	Historical	images	of	MS	
(A)	 Carswell’s	 illustration	 of	 	 “a	 peculiar	 disease	 state	 of	 the	 cord,	 and	 pons	 Variolii”	 affected	 with	
multiple	sclerosis,	included	in	his	atrophy	plate	IV,	brown	patches	visible	in	the	pons	and	the	spinal	cord,	
a	 cross	 section	 showing	 the	extent	of	 the	 lesion	 from	superficial	 to	profound	 (Carswell,	1838)	 source:	
http://special.lib.gla.ac.uk/exhibns/month/oct2003.html,	 (B)	 Charcot’s	 illustration	 of	 his	 cases	 of	
sclerose	 diseminée	 presented	 in	 his	 lectures	 at	 Salpêtrière,	 plate	 II,	 (Ordenstein,	 1868)	 (C)	 gel	micro-
electrophoresis	 showing	oligoclonal	bands,	1	 is	 from	a	patient	with	MS,	3	 is	normal	 (Lowenthal	et	al.,	
1960)	rights	were	obtained	from	Wiley.	
	
1.3	Etiology	and	Epidemiology	
	
In	the	past	plenty	of	theories	on	the	etiology	of	MS	have	emerged	and	disappeared	just	as	fast.	
Leyden	 proposed	 a	 vascular	 pathology	 in	 1863,	 because	 plaques	 have	 often	 been	 found	 in	
proximity	 to	small	veins	 (Leyden,	1863).	 In	 the	early	1900s	Marburg	suggested	a	 toxin	theory	
due	 to	myelinolytic	 factors,	whereas	 Steiner	 and	 colleagues	 assumed	 that	 spirochetes,	 small	
spiral	 bacteria,	might	 be	 the	 cause	 of	MS	 (Harding,	 Dobin,	 Pollock,	 &	 Ruge,	 1959;	Marburg,	
1906;	Schmidt,	2012).	By	the	1960s,	there	were	two	main	theories	how	the	disease	originates.	
One	proclaimed	that	MS	is	an	autoimmune	disease,	in	which	leucocytes	attack	the	myelin	basic	
protein	(MBP)	and	thus	destroy	the	myelin	sheath	of	the	nerve	cells.	The	other	one	proposed	
the	concept	of	a	viral	cause,	which	was	thought	to	act	as	a	trigger	for	the	immune	system	(T.	
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Jock	Murray,	2009).	Both	concepts	are	still	debated	today	and	do	not	necessarily	exclude	each	
other.	
	
1.3.1	Geographical	factors	
While	the	etiology	of	MS	still	remains	largely	obscure	epidemiological	studies	have	given	a	first	
insight.	After	World	War	 II	 large	amounts	of	data	on	MS	 in	young	soldiers	revealed	a	marked	
geographical	 gradient	of	 disease	prevalence.	 In	 the	northern	parts	 of	 Europe	 and	 the	United	
States	the	disease	was	more	common	than	in	areas	around	the	equator	(Acheson,	Bachrach,	&	
Wright,	 1960;	 A.	 Compston,	 1998).	 A	 revision	 of	 this	 study	 with	 a	 new	 cohort	 of	 veterans	
showed	 an	 attenuation	 of	 this	 latitude	 gradient	 (Alonso	 &	 Hernán,	 2008).	 The	 estimated	
prevalence	of	MS	in	Germany	depends	on	methodology,	population	and	region	of	the	study	and	
varies	between	102,000	 to	143,000	patients,	 corresponding	 to	an	average	prevalence	 rate	of	
149.1	 per	 100,000	 inhabitants	 (Hein	 &	 Hopfenmüller,	 2000;	 Höer	 et	 al.,	 2014;	 S.	 Poser	 &	
Bauersfeld,	1995).	A	recent	analysis	demonstrated	an	increase	in	prevalence	of	MS	in	Europe,	
which	 might	 be	 due	 to	 better-defined	 diagnostic	 criteria	 and	 improved	 detection	 methods	
(Dippel,	Mäurer,	Schinzel,	Müller-Bohn,	&	Larisch,	2015).	In	how	far	this	is	also	determined	by	a	
true	rise	in	prevalence	remains	unclear.	Factors	such	as	an	infection	with	the	Ebstein-Barr	Virus	
(EBV),	exposure	to	sun	and	Vitamin	D	levels	and	genetics	could	contribute	to	the	geographical	
gradient.	
	
1.3.2	Gender	and	MS	
MS	most	 often	 occurs	 in	 the	 age	 group	 between	 20	 and	 40	 (Flachenecker	 et	 al.,	 2008).	 The	
incidence	 in	 women	 is	 approximately	 twice	 as	 high	 as	 in	 men	 (Noseworthy,	 Lucchinetti,	
Rodriguez,	 &	 Weinshenker,	 2000).	 Newer	 studies	 show	 the	 female-to-male	 ratio	 increasing	
from	1.5	to	2.5,	between	the	1960s	and	the	2000s	 (Alonso	&	Hernán,	2008).	 It	 is	well	known	
that	 hormonal	 variations	 induced	 by	 pregnancy	 and	 the	 post-partum	 period	 can	 lead	 to	
alterations	in	the	relapse	rate.	Moreover	there	is	accumulating	evidence	suggesting	that	in-vitro	
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fertilization	could	constitute	a	pathogenetic	 factor	 in	MS	 (Hellwig	et	al.,	2008;	Ladwig,	Dunkl,	
Richter,	&	Schroeter,	2016).		
	
1.3.3	Genetics	in	MS	
The	 cumulated	 occurrence	 of	MS	 in	 families	 and	 concordance	 rates	 in	monozygotic	 twins	 of	
25.3%	 and	 in	 dizygotic	 of	 5.4%	 lead	 to	 the	 assumption	 that	 a	 certain	 predisposition	 for	 the	
disease	 can	 be	 inherited	 (Eichhorst,	 1896;	 Schapira,	 Poskanzer,	 &	Miller,	 1963;	Willer	 et	 al.,	
2003).	 Through	 epidemiological	 studies	 and	 gene	 analyses,	 over	 100	 genetic	 variants	 and	
transmission	 patterns	 have	 been	 discovered	 (Hemmer,	 Kerschensteiner,	 &	 Korn,	 2015).	 One	
group	 found	 an	 association	 with	 the	 segregation	 of	 the	 human	 leukocyte	 antigen	 (HLA)-
DRB1*15	 allele	 (Ebers,	 Sadovnick,	 &	 Risch,	 1995;	 Ghabanbasani	 et	 al.,	 1995).	 A	 multicenter	
study	 revealed	 an	 increased	 risk	 for	 developing	MS	 in	 people	 expressing	 HLA	 class	 II	 alleles	
DRB*1501,	DRB1*0301,	and	DRB*1303	on	their	 innate	 immune	cells	and	a	decreased	risk	 for	
HLA	class	I	allele	A2	(Sawcer	et	al.,	2011).	Kalman	and	Lublin	already	concluded	in	1999,	which	
is	 still	 the	 prevailing	 assumption,	 that	 MS	 has	 a	 complex	 pattern	 of	 inheritance	 that	 is	 not	
determined	by	a	single	gene	but	rather	by	multiple	alterations	in	genes	responsible	for	immune	
response	(Kalman	&	Lublin,	1999).		
	
1.3.4	The	Vitamin	D	theory	
The	 north-south	 gradient	 of	 disease	 frequency	 has	 been	 suggested	 to	 be	 due	 to	 higher	
exposure	to	sunlight	and	therefore	elevated	Vitamin	D	levels	(VanAmerongen,	Dijkstra,	Lips,	&	
Polman,	2004).	Indeed,	studies	have	revealed	that	high	Vitamin	D	levels	are	associated	with	a	
lower	risk	for	MS	(Kassandra	L.	Munger,	Levin,	Hollis,	Howard,	&	Ascherio,	2006).	More	recently	
low	 levels	of	Vitamin	D	have	been	shown	 to	be	associated	with	a	higher	 relapse	 rate	 (Runia,	
Hop,	de	Rijke,	Buljevac,	&	Hintzen,	2012).	Vitamin	D	has	also	proven	beneficial	in	EAE.	Especially	
it	 is	 said	 to	 have	 anti-inflammatory	 properties	 and	 lead	 to	 a	 decreased	 ratio	 of	 T1/T2	
interleukins	 (Cantorna,	Hayes,	&	DeLuca,	1996;	 Soleimani,	 Jameie,	Mehdizadeh,	et	 al.,	 2014).	
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These	 effects	might	 partly	 be	mediated	 by	 natural	 killer	 T	 (NKT)-cells	 via	 interleukin-4	 (IL-4)	
secretion	(Waddell,	Zhao,	&	Cantorna,	2015).	
	
1.3.5	Infection	and	MS	
Pierre	Marie	 introduced	the	 idea	of	an	 infectious	cause	 for	MS	 in	1884	and	to	 this	day	 it	has	
neither	been	clearly	proven	nor	disproven	(A.	Compston,	1998).	However	there	is	evidence	for	
at	 least	a	partial	 role	of	viruses.	HHV-6	 infiltrates	the	CNS	 in	early	childhood,	persists	 livelong	
and	 is	 known	 to	 have	 a	 cross-reactivity	 with	 the	MBP	 (Broccolo,	 Fusetti,	 &	 Ceccherini-Nelli,	
2013;	Tejada-Simon,	Zang,	Hong,	Rivera,	&	Zhang,	2003).	EBV	seems	to	play	a	role	as	well.	In	a	
study	 conducted	 by	 Sundström	 and	 colleagues,	 a	 high	 antibody	 activity	 against	 Ebstein-Barr	
Virus	 nuclear	 antigen	 (EBNA)-1	was	 associated	with	 an	 elevated	 risk	 for	MS,	whereas	 a	 high	
titer	against	the	viral	capsid	antigen	VCA	was	linked	to	a	lower	risk	(Sundström	et	al.,	2004).	In	
addition,	the	time	of	infection	seems	to	play	a	role	(Pender	&	Burrows,	2014).	
	
1.3.6	Nutrition	and	MS	
Wekerle	and	colleagues	 suggested	 the	 initiation	of	MS	pathology	might	be	 influenced	by	 the	
gut	microbiome	(Berer,	Mues,	et	al.,	2011).	Using	a	mouse	model	 that	develops	spontaneous	
EAE	they	found	that	a	line	of	mice	housed	in	a	germ	free	environment	were	protected	from	EAE	
throughout	 their	 lives	 compared	 with	 animals	 held	 under	 specific	 pathogen-free	 (SPF)	
environment.	The	crucial	difference	was	that	the	germ	free	mice	could	not	develop	a	gut	flora.	
When	the	gut	microbiome	was	transferred	from	the	SPF-	to	the	germ	free	mice	they	developed	
spontaneous	 EAE	 just	 the	 same.	 	A	 cross	 reaction	between	bacterial	 species	 in	 the	 intestinal	
flora	could	prime	an	autoimmune	reaction	by	supporting	 the	differentiation	of	 interleukin	17	
(IL-17)	secreting	T-lymphocytes	(Berer,	Mues,	et	al.,	2011).	A	Japanese	group	around	Yamamura	
has	 suggested	 such	 a	 link	 already	 in	 2008,	 when	 they	 treated	 a	 group	 of	 mice	 with	 non-
absorbing	 antibiotics	 starting	 one	 week	 prior	 to	 immunization	 with	 EAE	 and	 found	 an	
amelioration	of	the	clinical	course	of	EAE,	a	reduction	of	mesenteric	Th17	cells	and	a	lower	pro-
inflammatory	 cytokine	 secretion	 from	 the	 draining	 lymph	 nodes	 (Yokote	 et	 al.,	 2008).	
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Furthermore,	 ghrelin,	 a	 gastric	 “hunger”	 hormone	 has	 been	 shown	 to	 influence	 the	 clinical	
severity	of	EAE	(Theil	et	al.,	2009).	
Moreover	a	possible	 link	between	dietary	sodium	intake	and	increased	disease	activity	 in	EAE	
and	 MS	 has	 been	 a	 recent	 focus	 of	 research.	 Macrophage	 infiltration	 of	 the	 CNS	 and	 pro-
inflammatory	 phenotype	 polarization	were	 shown	 to	 be	 elevated	with	 a	 diet	 high	 in	 sodium	
chloride	(Hucke	et	al.,	2016).	Binger,	Kleinewiedfeld	and	colleagues	showed	that	salt	increases	
Th17	cells	and	LPS-induced	macrophages	and	reduces	anti-inflammatory	macrophage	activation	
(Binger	et	al.,	2015;	Kleinewietfeld	et	al.,	2013).	In	an	observational	study	Farez	and	colleagues	
were	 able	 to	 demonstrate	 a	 link	 between	 high	 sodium	 intake	 and	 clinical	 and	 radiological	
disease	activity	in	human	MS	(Farez,	Fiol,	Gaitán,	Quintana,	&	Correale,	2015). 
 
In	summary,	MS	seems	to	have	a	multifactorial	etiology	in	which	a	genetic	predisposition	and	
environmental	 factors	 contribute	 to	 triggering	 an	 autoimmune	 response	 against	 the	 myelin	
sheaths.		
 
1.4	Presentation	and	Course	of	disease	
	
The	course	of	disease	and	the	extent	to	which	the	symptoms	affect	the	patient	are	individually	
variable.	Inflammatory	MS	lesions	can	affect	the	entire	central	nervous	system	(CNS)	and	thus	
present	 with	 a	 wide	 variety	 of	 symptoms,	 depending	 on	 the	 location	 of	 the	 lesions.	
Nevertheless	 there	 are	 predominant	 areas	 that	 are	 more	 often	 affected	 than	 others	 and	
symptoms	 that	 are	 more	 likely	 to	 appear	 early	 on	 in	 the	 course	 of	 disease,	 such	 as	 optic	
neuritis,	pareses	and	sensory	disturbances	and	those	that	occur	later,	such	as	pain	syndromes,	
spasticity,	 ataxia,	 loss	 of	 abdominal	 reflexes,	 optic	 nerve	 atrophy	 and	 bladder	 or	 bowel	
dysfunction	 (C.	 M.	 Poser,	 1965,	 1980).	 Impaired	 sexual	 function,	 fatigue,	 depression	 and	
cognitive	dysfunction	can	also	present	early	on	and	be	very	debilitating.	 
 
Disease	progression	can	be	just	as	variable	as	the	symptoms.	Patients	can	be	mildly	affected	or	
end	 up	 paralyzed.	We	 can	 differentiate	 between	 at	 least	 three	major	 forms:	 1)	 a	 relapsing-
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remitting	 disease	 (RRMS),	 which	 is	 marked	 by	 intermittent	 exacerbations,	 with	 or	 without	
residual	symptoms,	2)	a	secondary	chronic	progressive	form	(SPMS)	which	develops	from	RRMS	
in	 85%	 of	 the	 cases	 after	 15	 years	 and	 is	 characterized	 by	 a	 steady,	 often	 slow	 disease	
progression	 with	 or	 without	 superimposed	 exacerbations	 and/or	 plateaus,	 and	 3)	 a	 primary	
chronic	progressive	 form	 (PPMS)	hallmarked	by	a	progressive	worsening	without	a	preceding	
phase	of	exacerbations	(Lublin	&	Reingold,	1996).	
	
Fig.	1-2	Disease	progression	
Multiphasic	 disease	 course	 of	 MS	 displaying	 characteristics	 of	 different	 phases,	 with	 demyelination	
displayed	 in	green,	axonal	 loss	 in	blue,	 clinical	 threshold	 (dotted	 line),	brain	volume	 (dark	green	 line),	
inflammation	 (red	 line).	 During	 the	 preclinical	 phase:	 high	 inflammation,	 not	 yet	 clinically	 apparent,	
lesions	 on	MRI	 can	 occur,	 axon	 loss	 begins.	 During	 relapsing-remitting	 disease,	 clinical	 exacerbations	
alternate	with	phases	of	remission,	while	 inflammation	peaks	and	then	declines	and	brain	volume	loss	
begins.	RRMS	slowly	transitions	into	secondary	progressive	disease.	Exacerbations	are	superimposed	on	
a	continuous	clinical	progression	until	relapses	stop,	inflammation	wanes,	brain	volume	loss	and	axonal	
loss	 are	 extensive.	 Adapted	 from	 (Alastair	 Compston	 &	 Coles,	 2002;	 Hans	 Lassmann	 &	 van	 Horssen,	
2011).	
	
1.5	Diagnostic	criteria		
	
Even	150	years	after	the	first	mention	of	MS,	diagnosis	is	often	difficult	to	make	right	away.	The	
diagnosis	is	based	on	clinical	and	paraclinical	assessments.		Magnetic	resonance	imaging	(MRI),	
neurophysiological	 testing,	 CSF	 and	 blood	 analysis	 have	 proven	 to	 be	 most	 relevant.	
Dissemination	in	time	(DIT)	and	space	(DIS)	has	to	be	demonstrated	and	other	likely	diagnoses	
have	 to	 be	 ruled	out.	 The	McDonald	 diagnostic	 criteria	 serve	 as	 guidelines	 (McDonald	 et	 al.,	
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2001;	Polman	et	al.,	2011).	A	single	clinical	event,	that	is	likely	to	be	caused	by	a	demyelinating	
process	without	dissemination	in	time	is	called	clinically	isolated	syndrome	(CIS),	which	in	85%	
of	the	cases	marks	the	 initial	appearance	of	MS	(D.	Miller,	Barkhof,	Montalban,	Thompson,	&	
Filippi,	2005).	
	
Clinical	
(attacks)	
Lesions	 Additional	Criteria	to	make	Diagnosis	
2	or	
more
	
Objective	clinical	evidence	of	
≥	2	lesions	of	1	lesion	with	
reasonable	historical	
evidence	of	a	prior	attack	
None,	clinical	evidence	alone	will	suffice;	additional	evidence	desirable	but	must	
be	consistent	with	MS	
2	or	
more
	
Objective	clinical	evidence	of	
1	lesion	
DIS,	demonstrated	by:	≥ ︎1	T2	lesion	in	at	least	2	of	4	MS-typical	regions	of	the	CNS	
(periventricular,	juxtacortical,	infratentorial,	or	spinal	cord);	or	await	a	further	
clinical	attack	implicating	a	different	CNS	site		
1
	
Objective	clinical	evidence	of	
≥	2	lesions	
DIT,	demonstrated	by:	Simultaneous	presence	of	asymptomatic	gadolinium	-
enhancing	(Gd+)	and	nonenhancing	(Gd-)	lesions	at	any	time;	or	a	new	T2	and/or	
Gd+	lesion(s)	on	follow-up	MRI,	irrespective	of	its	timing	with	reference	to	a	
baseline	scan;	or	await	a	second	clinical	attack	
1	
(CIS)
	
Objective	clinical	evidence	of	
1	lesion	
DIT	and	DIS,	demonstrated	by:	
For	DIS:	≥1	T2	lesion	in	at	least	2	of	4	MS-typical	regions	of	the	CNS	
(periventricular,	juxtacortical,	infratentorial,	or	spinal	cord);	or	await	a	second	
clinical	attack	implicating	a	different	CNS	site;	
For	DIT:	Simultaneous	presence	of	asymptomatic	Gd+	and	Gd-	lesions	at	any	time;	
or	a	new	T2	and/or	Gd+	lesion(s)	on	follow-up	MRI,	irrespective	of	its	timing	with	
reference	to	a	baseline	scan;	or	await	a	second	clinical	attack	
0
	
Insidious	neurological	
progression	suggestive	of	MS	
(PPMS)	
One	year	of	disease	progression	plus	2	of	3	of	the	following	criteria:	
1.	Evidence	for	DIS	in	the	brain	based	on	≥	1	T2	lesions	in	the	MS-characteristic	
(periventricular,	juxtacortical,	or	infratentorial)	regions		
2.	Evidence	for	DIS	in	the	spinal	cord	based	on	≥	2	T2	lesions	in	the	cord		
3.	Positive	CSF	(evidence	of	OCBs	and/or	elevated	IgG	index)		
	
Tab.	1-1	McDonald	diagnostic	criteria		
Adapted	from	(Polman	et	al.,	2011),	rights	obtained	from	John	Wiley	and	Sons.		
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1.6	Treatment	
		
1.6.1	Treatment	of	acute	exacerbation	
For	 almost	 a	 century	 empirical	 therapy	was	 the	 basis	 for	 treatment.	 From	 arsenic,	mercury,	
auric	 chloride,	 zinc	 sulfate	 to	 belladonna	 and	 ergotamines,	 every	 available	 remedy	was	 tried	
(Schmidt,	2012).	 The	 relapsing	 remitting	nature	of	 the	disease	made	 it	difficult	 to	distinguish	
between	 real	 improvement	 and	normal	 disease	development.	 In	 1961	with	 the	universalized	
introduction	 of	 controlled	 studies,	 injecting	 adrenocorticotropic	 hormone	 (ACTH)	 proved	
superior	 to	 a	 saline-treated	 group	 and	 finally	 provided	 proof	 of	 an	 effective	 medication	
(Berkovich,	2013;	H.	Miller,	Newell,	&	Ridley,	1961). 
Later	 on	 ACTH	was	 replaced	 by	 cortisone,	which	 is	 still	 the	 gold	 standard	medication	 for	 an	
acute	 exacerbation.	 Glucocorticoids	 act	 anti-inflammatory,	 anti-edematous	 and	
immunosuppressive.	 The	 blood-brain-barrier	 (BBB)	 disruption	 quickly	 abates	 and	 the	 effect	
lasts	approximately	six	to	nine	weeks.	It	can	serve	to	reduce	relapse	duration,	but	cannot	alter	
the	 disease	 course	 or	 residual	 disability	 (Hoffmann,	 2012;	 Ontaneda	 &	 Rae-Grant,	 2009).	
Additional	treatment	options	in	the	acute	phase	are	plasma	exchange	and	immunoadsorption,	
especially	in	steroid	non-responsive	cases	(Koziolek	et	al.,	2012;	Ontaneda	&	Rae-Grant,	2009). 
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Tab.	1-2	Therapeutic	guidelines	by	the	DMSG		
Adapted	from	Leitlinien	für	Diagnostik	und	Therapie	in	der	Neurologie:	Diagnose	und	Therapie	der	
Multiplen	Sklerose,	effective	as	of	January	2012,	valid	until	2017,	translated	into	English	
	
	
1.6.2	Disease	modifying	therapy	in	mild/moderate	RRMS	
First	described	as	antiviral	substances	by	Isaacs	and	Lindenmann,	interferons	(IFNs)	have	been	
the	 first	 substance	 to	 show	disease-modifying	properties	 in	MS	 (Isaacs	&	 Lindenmann,	 1957;	
Jacobs,	O’Malley,	 Freeman,	&	Ekes,	 1981).	 Interferons	 are	 cytokines	produced	by	 leucocytes,	
fibroblasts	and	endothelial	cells	in	response	to	viral	infection	(González-Navajas,	Lee,	David,	&	
Raz,	2012).	After	a	decade	of	studies,	recombinant	IFN-	ß	-1b	was	FDA	approved	for	treatment	
for	RRMS	in	1993	(McGraw	&	Lublin,	2013).	In	the	years	to	come,	IFN-ß-1a	followed	in	different	
modes	of	application	and	doses.	Both	were	also	licensed	for	use	in	CIS	and	SPMS.	Inconsistent	
evidence	 exists	 for	 IFN	 treatment	 in	 PPMS.	 Montalban	 and	 colleagues	 showed	 a	 slower	
progression	and	benefits	in	MRI	for	IFN-ß-1b,	but	a	Cochrane	systematic	review	could	not	verify	
such	beneficiality	and	recommended	a	larger	sample	size	(Montalban,	2004;	Pöhlau,	Hoffmann,	
&	Harzheim,	2012;	Rojas,	Romano,	Ciapponi,	Patrucco,	&	Cristiano,	2010).	Common	side	effects	
under	IFN	therapy	include	flu-like	symptoms,	injection	site	reactions,	headache,	myalgias,	fever,	
and	fatigue	(Giovannoni,	Southam,	&	Waubant,	2012).	
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Glatirameracetate	(GA)	is	the	second	compound	approved	for	use	in	RRMS	and	CIS.	Structurally	
similar	to	the	myelin	basic	protein,	it	was	developed	to	provoke	EAE	in	experimental	animals.	It	
turned	 out	 to	 ameliorate	 rather	 than	 aggravate	 disease	 severity	 (Arnon,	 1996;	 McGraw	 &	
Lublin,	2013;	Teitelbaum,	Meshorer,	Hirshfeld,	Arnon,	&	Sela,	1971).	 It	was	 first	 tested	 in	MS	
patients	 in	 1977,	 and	 in	 1987	was	 shown	 to	 reduce	 relapse	 rates	 (Abramsky,	 Teitelbaum,	&	
Arnon,	1977;	Bornstein	et	al.,	1987).	 Its	mechanism	of	action	is	still	not	entirely	known,	but	it	
has	been	suggested	to	induce	a	beneficial	environment	by	shifting	from	pro-inflammatory	Th1	
cells	to	anti-inflammatory	Th2	cells	by	binding	to	the	major	histocompatibility	complex	(MHC)	II	
domain	of	MBP-recognizing	antigen-presenting	cells	and	stimulating	anti-inflammatory	 type	 II	
monocytes,	and	thereby	lowering	production	of	detrimental	IL-12,	tumor	necrosis	factor	(TNF)	
and	Th17	cells	(Blanchette	&	Neuhaus,	2008;	McGraw	&	Lublin,	2013;	Weber	et	al.,	2007).	GA	
has	 very	 few	 side	 effects	 and	 even	 a	 beneficial	 effect	 on	 fatigue	 (Giovannoni	 et	 al.,	 2012;	
Ziemssen,	Hoffman,	Apfel,	&	Kern,	2008).		
Recently,	 two	 oral	 drugs	 have	 been	 approved	 for	 mild/moderate	 MS.	 Dimethyl	 fumarate	 is	
structurally	 related	 to	 its	 precursor	 fumaric	 acid,	 which	 has	 been	 used	 for	 the	 treatment	 of	
psoriasis	 since	 1994	 in	 Germany	 (di	 Nuzzo,	 Orlando,	 Nasca,	 &	 Nicoletti,	 2014).	 Its	molecular	
mechanism	of	action	is	based	on	activation	of	Nrf2,	a	leucine	zipper	transcription	factor,	which	
delegates	 the	 expression	of	 antioxidant	 proteins	 and	detoxification	 enzymes	 (di	Nuzzo	et	 al.,	
2014;	Scannevin	et	al.,	2012).	Teriflunomide	is	the	active	metabolite	of	Leflunomide,	which	up	
to	this	point	has	been	used	for	treatment	of	rheumatic	arthritis	(di	Nuzzo	et	al.,	2014;	Killestein,	
Rudick,	 &	 Polman,	 2011).	 On	 a	 molecular	 basis,	 teriflunomide	 inhibits	 the	 dihydroorotate	
dehydrogenase	(DHODH),	a	key	enzyme	for	pyrimidine	synthesis.	Normal	cells	have	the	ability	
to	 produce	 pyrimidines	 independent	 of	 DHODH	 and	 can	 thus	 salvage	 deoxyribonucleic	 acid	
(DNA)	synthesis.	However,	blasting	cells	like	inflammatory	lymphocytes	do	not	have	this	ability	
and	perish.	This	explains	the	selective	mechanism	of	action	(Claussen	&	Korn,	2012;	di	Nuzzo	et	
al.,	2014).		
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1.6.3	Disease	modifying	therapy	in	(highly)	active	RRMS	
The	 first	 medication	 for	 highly	 active	 MS	 or	 patients	 who	 failed	 first-line	 treatment	 was	
Natalizumab,	a	humanized	monoclonal	antibody	against	an	integrin	component	(α4	domain	of	
the	very	 late	antigen	 (VLA)-4).	 This	 antigen	 is	predominantly	expressed	on	monocytes	and	T-
cells	 and	 facilitates	 the	passage	 through	 the	BBB	 (Baron,	Madri,	Ruddle,	Hashim,	&	 Janeway,	
1993;	 Fernández,	 2013;	 Léger	 et	 al.,	 1997).	 In	 randomized	 control	 studies,	 treatment	 with	
Natalizumab	 proved	 highly	 effective	 at	 reducing	 the	 annualized	 relapse	 rate	 by	 68%.	 It	 also	
reduced	progression	of	disability	by	42%	and	led	to	fewer	T2	brain	lesions	and	90%	reduction	in	
Gd+	 lesions	 on	MRI	 (Havrdova	 et	 al.,	 2009;	 D.	 H.	Miller	 et	 al.,	 2003;	 O’Connor	 et	 al.,	 2011;	
Polman	et	 al.,	 2006).	 These	 results	make	natalizumab	a	highly	effective	 treatment	option	 for	
patients	with	active	MS.	However,	it	can	only	be	administered	with	caution	due	to	its	risk	for	JC	
virus	reactivation,	which	can	cause	the	often	fatal	progressive	multifocal	leukoencephalopathy	
(PML)	(Van	Assche	et	al.,	2005).	 
In	 the	past	years	several	more	highly	active	substances	have	enriched	MS	treatment	options.	
Alemtuzumab,	 a	 humanized	 monoclonal	 antibody	 against	 CD52	 expressed	 on	 adult	
lymphocytes,	 causes	 prolonged	 lymphocyte	 depletion.	 Formerly	 only	 applied	 in	 hairy	 cell	
leukemia	 it	has	been	approved	for	use	 in	highly	active	MS	since	2014	 in	Germany.	 It	 reduced	
relapse	rate	and	even	improved	the	mean	disability	score	(Coles,	2013;	Coles	et	al.,	2012).	 
Fingolimod	 is	 the	only	orally	available	highly	active	drug.	As	a	 sphingosine-1-phosphate	 (S1P)	
receptor	modulator,	that	exhibits	anti-inflammatory	properties	in	RRMS	it	was	even	suggested	
to	aid	neuronal	repair	(Aktas,	Küry,	Kieseier,	&	Hartung,	2010;	di	Nuzzo	et	al.,	2014).	Approved	
by	the	FDA	in	2010,	Fingolimod	influences	migration	of	lymphocytes	from	the	lymphatic	organs	
via	 the	 S1P1receptor	 and	 retains	 certain	 groups	 of	 lymphocytes	 (i.e.,	 central	 memory	
lymphocytes)	inside	secondary	lymphoid	organs	(Cohen	&	Chun,	2011;	di	Nuzzo	et	al.,	2014).		
	
1.6.4	Immunosuppressive	Therapy	for	SPMS	
As	shown	in	Table	1-3,	there	are	still	very	few	treatment	options	for	the	secondary	progressive	
phase	 and	 none	 that	 can	 effectively	 slow	 disability	 progression	 over	 longer	 periods	 of	 time.	
Apart	 from	 the	 interferones,	 mitoxantrone,	 a	 synthetic	 antracendione	 derivative	 can	 act	
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immunosuppressively	 and	has	 proven	 to	 be	 effective	 in	 chronic	 progressive	MS	 as	well	 as	 in	
highly	active	RRMS.	 It	was	 shown	 to	 reduce	neurological	disability	 to	a	moderate	extent	and	
improve	ambulatory	index	compared	to	placebo	(Scott	&	Figgitt,	2004).	 
	
1.7	Animal	models	of	MS	
	
1.7.1	Experimental	autoimmune	encephalomyelitis	
As	 described	 above,	 the	 history	 of	 MS	 research	 had	 a	 breakthrough	 at	 the	 time	 when	 EAE	
became	 the	 common	 model	 for	 MS	 (Waksman,	 1999).	 Since	 MS	 not	 only	 has	 a	 diverse	
pathogenesis	 uniting	 aspects	 of	 inflammation,	 axon	 degeneration,	 neuronal	 dysfunction,	
demyelination	 and	 gliosis,	 but	 also	 a	 nonlinear	 clinical	 course	 of	 relapses	 and	 remissions	
eventually	proceeding	into	a	phase	of	progression,	it	is	difficult	to	find	a	model	representing	all	
aspect	 of	 this	 complex	 disease. Although	 the	 stepping-stones	 had	 been	 laid	much	 earlier,	 it	
took	almost	30	years	for	the	EAE	model	to	be	acknowledged.	The	idea	originated	in	a	form	of	
paralysis	affecting	patients	after	a	rabies	vaccination.	To	clarify	the	cause	of	these	incidents,	the	
research	group	around	Koritschoner	found	an	inflammation	of	the	spinal	cord	with	the	clinical	
correlate	of	paralysis	in	rabbits	inoculated	with	human	spinal	cord	homogenate	(Koritschoner	&	
Schweinburg,	 1925).	 Only	 a	 few	 years	 later,	 Thomas	 Rivers	 showed	 an	 immune	 reaction	 in	
monkeys	injected	with	rabbit	brain	tissue	(Rivers,	Sprunt,	&	Berry,	1933).	This	became	known	as	
the	active	induction	of	EAE.	Patterson	and	colleagues	took	this	experiment	one	step	further	and	
tried	to	 inject	 lymph	node	cells	 from	actively	 immunized	animals	 into	naive	animals,	with	the	
same	 result.	 The	 rats	 developed	 a	 spinal	 cord	 inflammation	 as	 well.	 This	 was	 consequently	
termed	passive	induction	(Paterson,	1960).	 
In	 1947	 researchers	 found	 that	 the	 use	 of	 Freund’s	 adjuvant	 facilitated	 the	 immunization	
procedure	a	great	deal.	Instead	of	30	to	100	injections	over	the	course	of	several	months,	they	
were	able	to	decrease	the	injections	to	three	at	weekly	intervals	(Kabat,	Wolf,	&	Bezer,	1947).		
In	addition,	the	introduction	of	pertussis	toxin	into	the	immunization	regimen	helped	improve	
its	 effectiveness.	 Today,	 depending	 on	 the	 regimen,	 a	 single	 injection	 is	 sufficient	 (Levine	 &	
Sowinski,	1973).	Not	only	the	adjuvants	have	been	experimented	with,	but	also	the	spinal	cord	
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homogenate	 underwent	 changes.	 It	 was	 analyzed	 and	 encephalitogenic	 components	 were	
identified,	the	MBP	and	the	proteolipid	protein	(PLP)	(Martenson,	Deibler,	&	Kies,	1969;	Olitsky	
&	Tal,	 1952).	Almost	30	 years	 later	 two	additional	 encephalitogenic	proteins	were	 identified:	
myelin	 associated	 glycoprotein	 (MAG)	 and	 the	 myelin	 oligodendrocyte	 glycoprotein	 (MOG)	
(Lebar	 &	 Vincent,	 1981;	 Linnington,	Webb,	 &	Woodhams,	 1984;	 Poduslo,	 1983;	 Stromnes	 &	
Goverman,	2006). 
 
After	 immunization	 the	 course	of	 the	disease	proceeds	as	 follows.	Peripheral	CD4+	 cells	 that	
have	escaped	the	immune	tolerance	are	activated	(Seamons,	Perchellet,	&	Goverman,	2003).	It	
is	 easier	 for	myelin-specific	 CD4+	 T-cells	 to	 pass	 the	 BBB	 than	 for	 naive	 ones	 (Hickey,	 1991;	
Wekerle,	 Linnington,	 Lassmann,	 &	 Meyermann,	 1986).	 Once	 inside	 the	 CNS,	 they	 induce	 a	
neuroinflammatory	response	and	recruit	more	cells.		T-cells,	B-cells,	macrophages	and	plaques	
of	demyelination	can	then	be	found.	This	pathophysiological	picture	shares	many	features	with	
MS		(Raine,	1997;	Sospedra	&	Martin,	2005).	 
Despite	 the	 many	 similarities,	 several	 aspects	 of	 the	 EAE	 model	 are	 still	 lacking.	 First,	 the	
progressive	phase	of	the	disease	is	not	sufficiently	mimicked.	Secondly,	the	role	of	CD8+	T-cells	
and	 B-cells	 has	 not	 yet	 been	 captured	 adequately.	 	 Thirdly,	 EAE	 lesions	 are	most	 commonly	
found	in	the	subpial	areas	of	the	spinal	cord	and	the	model	shows	fewer	brain	lesions	than	MS.	
Lastly,	 therapeutic	 studies	 have	 been	 unsuccessful	 due	 to	 differences	 in	 immunological	
reactions	between	humans	and	mice	(Berer,	Wekerle,	&	Krishnamoorthy,	2011;	Huseby	et	al.,	
2001;	Ransohoff,	2006,	2012;	Ransohoff,	Howe,	&	Rodriguez,	2002). 
	
1.7.2	Other	animal	models	of	MS	
Neurotropic	viruses	are	able	to	cause	demyelinating	disease	and	can	therefore	be	used	in	MS	
research,	 especially	 for	 understanding	 the	mechanisms	 behind	 virally	 induced	 autoimmunity	
that	 can	 sustain	 itself	 in	 the	 absence	 of	 a	 pathogen	 (Bergmann,	 Lane,	 &	 Stohlman,	 2006;	
Ransohoff,	2012).	A	favored	model	for	oligodendrocyte	depletion	is	toxin-mediated.	Cuprizone	
is	an	agent	that,	when	fed	to	mice,	can	block	complex	 IV	 function	 in	mitochondria	and	cause	
selective	 oligodendrocyte	 cell	 death	 with	 ensuing	 demyelination	 (Claudia	 Lucchinetti	 et	 al.,	
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1999;	Matsushima	&	Morell,	2001;	Ransohoff,	2012).	At	cessation	of	treatment,	mechanisms	of	
remyelination	 can	 be	 studied	 (Matsushima	 &	 Morell,	 2001).	 Direct	 injection	 of	
lysophosphatidylcholine	into	white	matter	can	also	cause	immediate	demyelination	followed	by	
spontaneous	 remyelination	 over	 time	 (Blakemore,	 Eames,	 Smith,	 &	 McDonald,	 1977;	
Blakemore	&	Franklin,	2008).	Application	of	H2O2	or	a	nitric	oxide	(NO)	donor,	such	as	spermine	
NONOate,	 has	 been	used	 to	 induce	 immediate	oxidative	damage	 and	 follow	 the	 cellular	 and	
subcellular	processes	in	the	absence	of	demyelination	(Nikić	et	al.,	2011).	
 
A	variety	of	models	exist	to	study	the	pathogenesis	of	MS,	each	of	which	illustrates	aspects	of	
the	 disease	 process.	 However,	 future	 investigations	 need	 to	 be	 directed	 at	 the	 progressive	
stage,	for	which	a	proper	model	has	not	yet	been	developed	(Ransohoff,	2012). 
	
1.8	Pathology		
	
1.8.1	Trigger	factors	
Given	 its	 complexity	 of	 clinical	 symptoms,	 it	 stands	 to	 reason	 that	 its	 pathogenesis	 is	 just	 as	
sophisticated.		It	is	still	the	question	whether	MS	is	mainly	autoimmune	in	origin,	i.	e.,	triggered	
by	 an	 external	 agent	 priming	 the	 immune	 system	 to	 mount	 an	 attack	 on	 the	 CNS,	 a	
degenerative	 process	 intrinsic	 to	 the	 CNS,	 or	 an	 interplay	 of	 both	 (Friese	 &	 Fugger,	 2007;	
Mallucci,	Peruzzotti-Jametti,	Bernstock,	&	Pluchino,	2015).	The	two	main	mechanisms	that	can	
trigger	such	an	inflammatory	CNS	response	are	thought	to	be	molecular	mimicry	or	bystander	
activation.	 Molecular	 mimicry	 is	 a	 process,	 in	 which	 the	 body	 mounts	 an	 attack	 against	 a	
pathogen	 that	 is	 similar	 in	 structure	 to	endogenous	proteins,	 and	 this	 attack	 is	 consequently	
directed	against	the	body’s	own	structures,	i.e.,	myelin	proteins.	Bystander	activation	requires	
the	activation	of	intrinsic	CNS	antigen-presenting	cells,	which	in	turn	prime	T-cells	to	initiate	an	
autoimmune	 response	 (Fujinami	&	Oldstone,	 1985;	 Libbey,	McCoy,	 &	 Fujinami,	 2007;	Münz,	
Lünemann,	 Getts,	 &	 Miller,	 2009;	 Sospedra	 &	 Martin,	 2005;	 Wucherpfennig	 &	 Strominger,	
1995). 
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Several	 possible	 targets	 of	 the	 autoimmune	 response	 have	 been	 discovered.	 Myelin	 basic	
protein	(MBP),	myelin	oligodendrocyte	protein	(MOG),	myelin-associated	glycoprotein	(MAG),	
proteolipid	protein	(PLP),	and	2’	,3’	-cyclic-	nucleotide	3’	-phosphodiesterase	(CNPase)	are	the	
most	 common	 ones	 (Mallucci	 et	 al.,	 2015;	 McCarthy,	 Richards,	 &	 Miller,	 2012;	 Sospedra	 &	
Martin,	2005). 
MBP	 is	 one	 of	 the	 key	 elements	 that	 build	 up	 the	myelin	 sheath.	 It	 has	 been	 a	 focus	 of	MS	
research	since	it	was	found	to	induce	EAE	(Belogurov	et	al.,	2014;	Karin,	Mitchell,	Brocke,	Ling,	
&	Steinman,	1994;	Petry	et	al.,	2000;	Steinman,	1995).	Interestingly,	it	shares	the	MHC	class	II	
and	the	T	cell	receptor	binding	motifs	with	several	viruses,	most	notably	EBV,	which	has	been	
found	in	lesions	and	in	serum	of	MS	patients	(Ascherio	&	Munger,	2007;	Mallucci	et	al.,	2015;	
Peferoen	 et	 al.,	 2010;	 Sargsyan	 et	 al.,	 2010;	 Serafini	 et	 al.,	 2007;	 Willis	 et	 al.,	 2009).	
Furthermore,	 the	risk	of	developing	MS	 is	greater	after	primary	EBV	 infection	and	dependent	
on	 the	 antibody	 titer	 (Levin,	 Munger,	 O’Reilly,	 Falk,	 &	 Ascherio,	 2010;	 K.	 L.	 Munger,	 Levin,	
O’Reilly,	 Falk,	&	Ascherio,	2011).	Nissen	and	colleagues	have	 shown	 that	human	endogenous	
retroviruses	 can	 play	 a	 role	 in	 the	 activation	 of	 the	 immune	 system,	 perhaps	 by	 producing	
proteins	that	can	start	a	process	similar	to	infection	(Nissen	et	al.,	2013).	This	might	also	explain	
the	 positive	 impact	 on	 disease	 through	 antiretroviral	 drugs	 (Maruszak,	 Brew,	 Giovannoni,	 &	
Gold,	2011;	Nexø,	Pedersen,	Sørensen,	&	Koch-Henriksen,	2013). 
	
1.8.2	Immunological	mechanisms	behind	lesion	formation	
Different	hypotheses	on	the	mechanism	of	lesion	formation	have	been	postulated.	The	classical	
hypothesis	 proposes	 that	 the	 initial	 damage	 arises	 from	 the	 adaptive	 immune	 system	 and	 is	
followed	 and	 augmented	 by	 actions	 of	 the	 innate	 immune	 system.	 Peripheral	 T-cells	 with	
encephalitogenic	 potential	 are	 activated	 by	 mechanisms	 of	 molecular	 mimicry,	 bystander	
activation	or	 cross	 reactivity	 (Sospedra	&	Martin,	 2005;	Wucherpfennig	&	 Strominger,	 1995).	
Although	the	location	for	this	activation	is	not	yet	known,	suggested	are	the	gut,	lungs	or	in	the	
skin	(Hemmer	et	al.,	2015).	They	migrate	towards	the	lymph	nodes	from	which	a	small	subset	
invades	the	CNS	and	initiates	the	disease.	Plasma	cells	can	produce	antibodies	directed	against	
myelin	and	glia	cells,	whereas	T-cells	secrete	inflammatory	cytokines	to	promote	glial	damage	
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and	 increase	 permeability	 of	 the	 BBB.	 Disruption	 of	 the	 BBB	 is	 followed	 by	 an	 influx	 of	
monocytes	and	lymphocytes	(Hemmer	et	al.,	2015).	 
 
The	 alternative	 hypothesis	 involves	 intrinsic	 damage	 to	 the	 CNS	 due	 to	 oligodendrocyte	
dysfunction	or	extrinsic	damage	caused	by	a	virus	or	other	pathogen.	This	is	followed	by	initial	
activation	of	the	innate	immune	system	of	the	brain,	which	implies	a	recruitment	of	microglia	
(Mallucci	et	al.,	 2015).	 This	 initial	 inflammation	might	prompt	a	 leakage	of	proteins	 from	 the	
CNS	into	the	CSF	through	the	BBB.	These	proteins	accumulate	in	draining	lymph	nodes,	where	
they	induce	maturation	of	peripheral	B-lymphocytes	reactive	against	CNS	proteins	(Stern	et	al.,	
2014).	 Integrins	are	upregulated	on	 lymphocyte	surfaces	 to	 facilitate	binding	 to	vascular	cells	
adhesion	molecules	 (VCAMs)	on	 the	endothelial	 cells.	 Finally	 the	 lymphocytes	migrate	across	
the	BBB	and	into	the	CNS	(Mallucci	et	al.,	2015;	Ransohoff	&	Engelhardt,	2012;	Wekerle	et	al.,	
1986).	 Once	 inside	 they	 secrete	 pro-inflammatory	 molecules	 such	 as	 IFNγ	 and	 osteopontin	
(OPN),	which	is	followed	by	a	massive	infiltration	of	microglia	and	macrophages	to	the	area	of	
inflammation	(Chabas	et	al.,	2001;	Mallucci	et	al.,	2015).	Macrophages	in	turn	release	IL-8,	CXC-
ligand	 10,	 macrophages	 inflammatory	 proteins	 1a/b	 and	 other	 cytokines	 to	 recruit	 more	
intracerebral	 T-cells,	 macrophages	 and	 dendritic	 cells	 (Aloisi,	 2001;	 Mallucci	 et	 al.,	 2015;	
McMahon,	Bailey,	Castenada,	Waldner,	&	Miller,	2005;	Owens,	Gilden,	Burgoon,	Yu,	&	Bennett,	
2011). 
 
1.8.3	White	Matter	Lesion	classification	
In	an	international	multicenter	study,	Lucchinetti	and	colleagues	collected	and	examined	lesion	
specimen	 from	 biopsies	 and	 autopsies	 in	 order	 to	 classify	 demyelinating	 lesions	 in	 MS	 (C.	
Lucchinetti	et	al.,	2000).	They	found	four	distinctly	different	types.	All	lesions	showed	infiltrates	
of	 T	 lymphocytes	 and	 macrophages,	 diffuse	 immunoglobin	 (Ig)	 reactivity	 and	 reactive	
astrogliosis		as	a	marker	for	BBB	breakdown.	
Type	I	and	Type	II	showed	a	sharply	demarcated	perivenous	T-cell	and	macrophage	infiltration.	
Although	similarly	constructed,	pattern	II	lesions	included	depositions	of	IgGs	and	complement	
at	the	active	rim	of	the	plaque,	suggesting	a	complement	mediated	myelin	degradation	and	an	
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involvement	of	 antibodies.	 	 In	pattern	 I	 the	degradation	was	mainly	 initiated	by	macrophage	
products.	 In	pattern	 III	 lesions,	a	T-lymphocyte	dominant	 infiltrate	could	be	detected	within	a	
vaguely	defined	plaque	area.	The	rim	was	composed	of	concentric	layers	of	demyelinated	and	
myelinated	 tissue	 with	 prominent	 loss	 of	 oligodendrocytes.	 Oligodendrocytes	 could	 not	 be	
detected	 in	 the	 center.	 	 Interestingly,	 only	 the	MAG	myelin	 protein	was	 predominantly	 lost.	
There	were	no	remyelinated	shadow	plaques. 
Pattern	 IV	 infiltrates	 are	 also	 dominated	 by	 T	 lymphocytes	 and	macrophages	without	 Ig	 and	
complement	depositions.	A	small	zone	of	oligodendrocyte	destruction	was	found	at	the	rim	of	
the	active	demyelination	in	the	periplaque	white	matter.	 
 
Interestingly,	 all	 patients	 examined	 at	 autopsy	 revealed	 only	 one	 plaque	 pattern.	 The	 most	
commonly	found	was	pattern	II,	followed	by	III,	I	and	IV.	Pattern	III	was	seen	almost	exclusively	
in	acute	MS,	whereas	patterns	 II	and	I	were	found	in	other	clinical	courses	as	well.	Pattern	III	
also	 indicated	 a	 higher	 relative	 risk	 for	 monophasic	 disease.	 Pattern	 IV	 was	 seen	 in	 PPMS	
patients	with	cognitive,	brainstem	and	cerebellar	impairments. Pattern	I	and	II	lesions	are	those	
represented	by	the	established	animal	models.	 
The	different	pathologies	behind	those	patterns	lead	to	the	assumption	of	different	origins	for	
disease	 pathology.	 Pattern	 I	 and	 II	might	 be	 the	 result	 of	 an	 autoimmune	 attack	 due	 to	 the	
appearance	 of	 antibodies,	 whereas	 pattern	 III	 might	 be	 a	 virus-induced	 dystrophy	 of	
oligodendrocytes	 and	 demyelination.	 Although	 the	 patients	 at	 autopsy	 only	 revealed	 a	
homogenous	 pattern	 type,	 it	 is	 not	 clear	 whether	 the	 type	 remains	 the	 same	 or	 undergoes	
changes	throughout	disease	progression	(C.	Lucchinetti	et	al.,	2000).	Recent	evidence	suggested	
however	that	patients	retained	their	pattern	throughout	the	disease	until	all	lesions	assume	the	
same	morphology	of	 chronically	 inactive	 lesions	 (Metz	et	 al.,	 2014). Keegan	et	 al.	 postulated	
that	 patients	with	 pattern	 II	 lesions,	 due	 to	 their	 antibody	 content,	 are	more	 susceptible	 to	
plasmapheresis	(Keegan	et	al.,	2005).	 
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1.8.4	Gray	matter	lesions	
In	1962	Brownell	and	Hughes	first	reported	that	26%	of	MS	lesions	are	found	in	the	gray	matter	
or	at	the	border	to	the	white	matter	(Brownell	&	Hughes,	1962;	Mallucci	et	al.,	2015).		Only	in	
the	past	years	has	gray	matter	damage	come	into	the	focus	as	a	separate	pathologic	hallmark	
of	MS.	Gray	matter	lesions	are	located	in	the	cortex,	most	often	subpially	in	close	proximity	to	
the	meninges.	B-cells	have	been	found	to	form	aggregates	 in	the	meninges	of	SPMS	patients.	
Supposedly	 these	 cells	 greatly	 influence	 gray	 matter	 pathology	 by	 constantly	 releasing	
cytokines	that	sustain	a	chronic	activation	of	resident	microglia	(Choi	et	al.,	2012;	Peterson,	Bö,	
Mörk,	 Chang,	 &	 Trapp,	 2001).	 B-cell	 accumulations	 have	more	 often	 been	 found	 in	 patients	
with	a	worse	clinical	disease	course	and	more	prominent	cortical	atrophy	(Howell	et	al.,	2011;	
Magliozzi	et	al.,	2007).	A	great	proportion	of	gray	matter	lesions	are	associated	with	extensive	
neuronal	and	synaptic	loss	(Wegner,	Esiri,	Chance,	Palace,	&	Matthews,	2006).	Not	surprisingly,	
gray	matter	 pathology	 is	 thought	 to	 be	 a	main	 factor	 behind	 cognitive	 decline	 and	 physical	
disability	(Calabrese,	Favaretto,	Martini,	&	Gallo,	2013).	 
	
1.8.5	Demyelination	
In	 the	 CNS,	 oligodendrocytes	 produce	 the	 myelin	 layer,	 which	 wraps	 around	 the	 axon	 and	
provides	 trophic	 support,	 helps	 sustain	 homeostasis	 and	 enables	 saltatory	 signal	 conduction	
(Waxman	&	Ritchie,	1993).	Demyelination	can	be	 initiated	by	different	mechanisms.	 	First,	an	
autoimmune	 attack	 on	 myelin	 proteins	 such	 as	 PLP,	 MOG	 or	 MBP	 by	 autoantibodies	 or	
cytotoxic	factors	(TNFα,	NO,	IFNγ)	secreted	from	macrophages	can	cause	direct	damage	of	the	
myelin	 sheath	 (Bitsch,	 Schuchardt,	 Bunkowski,	 Kuhlmann,	 &	 Brück,	 2000;	 Genain,	 Cannella,	
Hauser,	&	Raine,	1999;	C.	Lucchinetti	et	al.,	2000).	Second,	 indirect	myelin	breakdown	can	be	
caused	by	damage	to	oligodendrocytes,	which	is	a	prominent	feature	of	lesion	patterns	III	and	
IV	(C.	Lucchinetti	et	al.,	2000).	 
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1.8.6	Remyelination	
Soon	after	the	 initial	 inflammatory	burst	has	come	to	an	end,	oligodendrocyte	precursor	cells	
(OPCs)	 and	 oligodendrocytes	 initiate	 remyelination	 (Keirstead	 &	 Blakemore,	 1999;	 Smith,	
Blakemore,	 &	 McDonald,	 1979).	 With	 each	 cycle	 of	 demyelination	 and	 remyelination,	 the	
myelin	sheath	becomes	thinner	and	shorter	(Ludwin	&	Maitland,	1984).	Mechanistically,	OPCs	
are	drawn	to	the	demyelinated	lesion	by	growth	factors	and	activation	of	transcription	factors.	
When	they	have	established	contact	 to	the	axon,	 they	begin	expressing	myelin-specific	genes	
and	 finally	 cover	 the	denuded	axon	membrane	 (Mallucci	et	al.,	2015).	 In	 chronic	 lesions,	 this	
process	 is	 rarely	 seen,	 perhaps	 due	 to	 the	milieu	 enriched	with	 substances	 suppressing	OPC	
differentiation	and	recruitment	(Mallucci	et	al.,	2015;	Tepavčević	et	al.,	2014).	New	therapeutic	
strategies	are	aimed	at	enhancing	remyelination,	such	as	the	retinoic	X	receptor	agonist	9-cis-
retinoic	acid	(Huang	et	al.,	2011;	Huang	&	Franklin,	2012).		
	
1.8.7	T-cells	and	B-cells		
Multiple	sclerosis	is	a	T-cell	dominated	disease.	Autoreactive	CD4+	T-cells	directed	against	MBP	
and	MOG	can	induce	EAE	and	likely	act	as	disease	initiator	in	MS	as	well	(Hemmer	et	al.,	2015;	
Mendel,	Kerlero	de	Rosbo,	&	Ben-Nun,	1995).	The	Th1	subtype	secretes	IFNγ	and	produces	an	
inflammation	mainly	 confined	 to	 the	 spinal	 cord,	whereas	Th17	 cells	mainly	 release	 IL17	and	
induce	 an	 inflammation	 of	 the	 brain	 stem,	 cerebrum	 and	 cerebellum	 (Hemmer	 et	 al.,	 2015;	
Legroux	&	Arbour,	2015).	Presumably	CD4+	T-cells	are	primed	in	the	periphery,	the	location	of	
which	 remains	 elusive	 (Hemmer	 et	 al.,	 2015).	 For	 these	 cells	 to	 enter	 the	 CNS	 they	 need	 to	
possess	a	distinct	combination	of	surface	receptors	and	integrins	to	dock	onto	the	vascular	wall	
and	transmigrate	through	the	BBB.	A	role	for	CD8+	T-cells	 in	 inflammation	and	demyelination	
has	been	proposed	as	well	 (Bitsch	et	al.,	2000).	CD8+	T-cells	even	outnumber	CD4+	T-cells	 in	
postmortem	studies	in	brain	of	MS	patients	(Booss,	Esiri,	Tourtellotte,	&	Mason,	1983).		CD8+	T-
cells	are	also	found	predominantly	 in	gray	matter	 lesions	(Calabrese	et	al.,	2015).	MHC	class	 I	
molecules,	 the	docking	 receptors	on	parenchymal	nucleated	 cells	 for	CD8+	T-cells,	 are	 found	
upregulated	on	neurons	reacting	to	external	or	internal	danger	signals	(Siffrin,	Vogt,	Radbruch,	
Nitsch,	&	Zipp,	2010).	Cytotoxic	T-cells	are	found	in	culture	and	in	vivo	studies	in	contact	with	
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degenerating	axons,	which	suggests	 their	 role	 in	axonal	 injury	 (Medana,	Martinic,	Wekerle,	&	
Neumann,	 2001;	 Neumann,	 Medana,	 Bauer,	 &	 Lassmann,	 2002).	 In	 imaging	 studies,	 T-cells	
labeled	with	 superparamagnetic	 iron	 oxide	 nanoparticles	 (ferumoxides)	 have	 been	 shown	 to	
migrate	at	disease	onset	(Anderson	et	al.,	2004).	 
Although	 B-cells	 are	 not	 the	 main	 contributors	 in	 MS	 lesions,	 they	 nevertheless	 have	 been	
ascribed	a	role	 in	mediating	gray	matter	damage,	especially	 in	cortical	 lesions	(Mallucci	et	al.,	
2015).	As	presenters	of	antigens	they	might	play	a	role	 in	exacerbating	demyelination,	 in	 line	
with	the	 finding	that	OCBs	 in	 the	CSF	of	CIS	patients	suggest	an	 increased	risk	 for	conversion	
(Dobson,	 Ramagopalan,	Davis,	&	Giovannoni,	 2013).	 	 The	 effectiveness	 of	 Rituximab,	 a	 CD20	
antibody	directed	against	a	surface	protein	of	B-cells,	in	highly	active	cases	supports	the	role	of	
B-cells	in	MS	(Hauser	et	al.,	2008). 
	
1.8.8	Microglia	and	Macrophages	
Microglia	 can	 adapt	 various	 activational	 states	 depending	 on	 the	 milieu,	 in	 which	 they	 are	
situated	 (Orihuela,	McPherson,	&	Harry,	2015).	They	sustain	 tissue	homeostasis,	phagocytose	
debris,	maintain	synapse	integrity,	promote	neurogenesis,	secrete	essential	growth	factors	and	
support	neuronal	 integrity	 (Graeber,	2010;	Kettenmann,	Hanisch,	Noda,	&	Verkhratsky,	2011;	
Murabe	&	 Sano,	 1982;	Nimmerjahn,	 Kirchhoff,	&	Helmchen,	 2005;	 Ransohoff	&	 Perry,	 2009;	
Tremblay	et	al.,	2011).	Their	even	distribution	allows	them	to	react	immediately	to	any	change	
in	environment	(Tremblay	et	al.,	2011).	Once	activated,	they	retract	their	processes,	adopt	an	
ameboid	shape	and	migrate	towards	the	site	of	damage	(Davalos	et	al.,	2005;	Graeber,	2010;	
Stence,	Waite,	&	Dailey,	2001).	Two	distinct	phenotypes	have	been	distinguished:	the	classically	
activated	 M1	 microglia	 causing	 tissue	 damage	 by	 release	 of	 neurotoxic	 substances	 and	 the	
alternatively	activated	M2	microglia,	that	have	been	shown	to	promote	tissue	repair	and	keep	
inflammation	 at	 bay	 (Cherry,	 Olschowka,	 &	 O’Banion,	 2014;	 Orihuela	 et	 al.,	 2015).	 Their	
versatile	profiles	point	to	a	profound	role	in	the	pathology	of	MS,	not	only	by	abandoning	their	
surveillance	and	supporting	role	and	adopting	a	possibly	detrimental	one,	but	also	by	adopting	
a	 protective	 phenotype,	 which	 might	 aid	 in	 remyelination	 and	 tissue	 repair.	 In	 MS,	
macrophages	and	microglia	represent	the	greatest	proportion	of	inflammatory	cells	in	a	lesion	
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(Lucchinetti	et	al.,	2000).	They	secrete	inflammatory	mediators,	cytokines,	reactive	oxygen	and	
nitrogen	species	(ROS	and	RNS),	which	not	only	damage	the	myelin	sheath	but	also	the	axons	
beneath,	by	creating	oxidative	stress	(Fischer	et	al.,	2012;	H.	Lassmann,	2003;	Nikić	et	al.,	2011).	
It	 is	difficult	to	discern	whether	macrophages	in	a	lesion	are	of	monocytic	or	microglial	origin,	
owing	 to	 their	 similar	 capacities	 and	 immunohistochemical	markers.	 However,	 Yamasaki	 and	
colleagues	 have	 used	 distinct	 gene-expression	 patterns	 and	 morphological	 features	 to	
differentiate	these	and	were	able	to	demonstrate	that	monocyte-derived	macrophages	initiate	
demyelination	 at	 the	 nodes	 of	 Ranvier,	 whereas	 macrophages	 of	 microglial	 origin	 promote	
repair	 processes	 and	 clear	 debris	 (Yamasaki	 et	 al.,	 2014).	 	 This	 emphasized	 the	 dual	 role	 of	
inflammation	 in	 inflammatory	 CNS	 diseases	 such	 as	 MS.	 With	 cumulating	 evidence,	
inflammation	 cannot	 solely	 be	 viewed	 as	 detrimental	 but	 also	 as	 beneficial	 in	 promoting	
remyelination	and	tissue	repair	as	well.	The	goal	 in	 the	search	 for	new	therapeutic	strategies	
should	possibly	be	to	modulate	inflammation	rather	than	to	eradicate	it.	 
	
1.9	Axonal	pathology	
	
1.9.1	Hallmarks	of	axonal	pathology	
Axonal	injury	are	pathologic	changes	of	axonal	structures	that	if	uninhibited	amount	to	axonal	
death	(Harris	&	Sloane,	2012).	With	improved	staining	methods	for	degenerating	axons,	such	as	
the	 amyloid	 precursor	 protein	 (APP),	 Ferguson	 showed	 that	 axonal	 injury	 occurs	 in	 acute	
plaques	and	at	the	active	rim	of	chronic	plaques	in	MS,	namely	in	areas	with	high	inflammation.	
Transport	deficits	lead	to	an	accumulation	of	intracellular	substances	and	distensions	along	the	
axon	 (spheroids)	 appear	 (Ferguson,	 Matyszak,	 Esiri,	 &	 Perry,	 1997).	 If	 those	 focal	 swellings	
continue	 to	 grow	 and	 reach	 a	 threshold,	 the	 axon	will	 begin	 to	 segment	 and	 large	 bulb-like	
formations	will	mark	 the	 point	 of	 transection	 (Lovas,	 Szilágyi,	Majtényi,	 Palkovits,	&	 Komoly,	
2000;	 Peterson	 et	 al.,	 2001;	 B.	 D.	 Trapp	 et	 al.,	 1998).	 Those	 swellings	 can	 be	 visualized	 by	
staining	for	APP,	which	is	an	integral	membrane	protein	found	in	neuronal	synapses	associated	
with	the	endosomal/lysosomal	systems,	synapse	formation	and	neuronal	plasticity.		It	is	carried	
by	 fast	 axonal	 transport	 and	 can	 only	 be	 detected	 when	 transport	 is	 disturbed	 (Ferreira,	
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Caceres,	&	Kosik,	1993;	Haass,	Koo,	Mellon,	Hung,	&	Selkoe,	1992;	Harris	&	Sloane,	2012;	Koo,	
Park,	&	Selkoe,	1993;	Sherriff,	Bridges,	Gentleman,	Sivaloganathan,	&	Wilson,	1994).	A	second	
option	 is	 to	 stain	 for	 non-phosphorylated	 neurofilament	 (B.	 D.	 Trapp	 et	 al.,	 1998).	
Neurofilaments,	 essential	 for	 structure	 and	 shape	 of	 an	 axon,	 are	 usually	 phosphorylated	 in	
order	 to	 increase	 interneurofilament	 spacing,	 which	 leads	 to	 larger	 caliber	 axons,	 and	 thus	
increases	 conduction	 velocity	 and	 enables	 fast	 axonal	 transport	 (Dutta	 et	 al.,	 2006).	 In	
demyelinated	axons,	neurofilaments	lie	free	to	be	dephosphorylated,	so	that	spacing,	diameter,	
conduction	 and	 transport	 subsequently	 decrease	 (de	 Waegh,	 Lee,	 &	 Brady,	 1992;	 Harris	 &	
Sloane,	2012;	Hsieh,	Crawford,	Bouldin,	&	Griffin,	1993).	Several	groups	reported	reduced	axon	
density,	 prevalence	 of	 small	 caliber	 axons	 and	 of	 axon	 loss	 upon	 autopsy	 (Ganter,	 Prince,	 &	
Esiri,	1999;	Klaver	et	al.,	2015;	Lovas	et	al.,	2000).	 
	Today,	axonal	loss	is	considered	to	represent	the	major	factor	behind	permanent	disability	and	
the	secondary	progressive	course	(Ferguson	et	al.,	1997;	Harris	&	Sloane,	2012). 
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Fig.	1-3	Axonal	degeneration		
Demyelination	 caused	 by	 inflammation	 leads	 to	 redistribution	 of	 Nav1.6	 channels	 (orange)	 along	 the	
denuded	membrane,	and	ROS	and	NO	induce	mitochondrial	pathology	and	 interrupt	axonal	transport.	
This	leads	to	swelling	and	energy	failure	and	culminates	in	axonal	transection. 
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1.9.2	Causes	of	axonal	pathology		
There	are	several	possible	mechanisms	that	can	contribute	to	axonal	swelling	and	transection.	 
1.	Demyelination	and	oligodendrocyte	death 
2.	Inflammation 
3.	Metabolic	imbalance 
4.	Dissolution	of	the	cytoskeleton 
5.	Wallerian	degeneration 
First	 of	 all	 demyelination,	 as	 one	 of	 the	 hallmarks	 of	 MS,	 is	 considered	 to	 be	 a	 major	
contributing	 factor	 in	 axonal	 injury.	 This	 is	 not	 only	 the	 case	 because	myelin	 is	 the	 basis	 for	
saltatory	 signal	 conduction	 and	 the	 energy	 failure	 that	 ensues	 with	 demyelination.	 The	
relationship	 between	 axon	 and	 myelin	 goes	 far	 beyond	 facilitating	 the	 flow	 of	 electrical	
currents.	The	ensheathing	myelin	has	been	shown	to	interact	with	the	encapsulated	neuron	by	
secreting	 and	 absorbing	 transmitters,	 toxic	 substances,	 misfolded	 protein	 aggregates,	
neurofilaments	 and	even	mitochondrial	 parts	 and	 thereby	 relieving	 the	axon	of	 its	metabolic	
burden	 (Brahic	&	Roussarie,	2009).	Most	of	our	knowledge	about	 this	 interaction	stems	 from	
the	peripheral	nervous	 system	 (PNS),	where	Schwann	cells	have	been	shown	 to	deliver	 small	
exosomes	to	axons	to	locally	support	regeneration	after	nerve	damage	(Lopez-Verrilli,	Picou,	&	
Court,	 2013).	 This	 relationship	 might	 on	 the	 other	 hand	 also	 be	 disadvantageous	 as	 other	
studies	showed	that	following	axonal	injury	an	upregulation	of		signaling	cascades	in	Schwann	
cells	 might	 lead	 to	 myelin	 fragmentation	 and	 spread	 of	 the	 injury	 (Simons,	 Misgeld,	 &	
Kerschensteiner,	2014)			
	
When	the	myelin	sheath	breaks	down	due	to	an	autoimmune	attack,	saltatory	conduction	will	
first	be	replaced	by	continuous	conduction,	which	 is	not	only	slower	but	also	vastly	 increases	
the	 energy	 demand.	 This	 is	 due	 to	 a	 diffuse	 expression	 of	 voltage	 gated	Nav1.2	 and	Nav1.6	
channels	 and	 adenosine	 triphosphate	 (ATP)	 dependent	 ion-transporters	 to	 counteract	 the	
influx	 of	 positively	 charged	 ions	 (Craner	 et	 al.,	 2004).	 These	 channels	 were	 found	 in	 close	
proximity	 to	 βAPP,	 a	 marker	 for	 axonal	 injury.	 Due	 to	 the	 increased	 energy	 demand	
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mitochondria	are	redirected	to	demyelinated	parts	of	the	axon,	where	mitochondrial	content	is	
found	to	be	elevated	(Zambonin	et	al.,	2011).		 
Meanwhile,	on	the	other	side	of	the	axonal	membrane,	 inflammatory	cells	can	directly	attack	
axons.	As	reported	by	several	studies,	there	appears	to	be	a	direct	correlation	between	axonal	
injury	and	inflammation	(Bitsch	et	al.,	2000).	Inflammatory	cells	release	a	toxic	cocktail	of	NO,	
TNFα,	 and	 IFNγ,	 which	 can	 cause	 further	 damage	 to	 the	 BBB,	 paving	 the	 way	 for	 more	
inflammatory	 cells	 into	 the	 CNS	 (Andrews	 et	 al.,	 2006).	 NO	 interferes	 with	 mitochondrial	
metabolism,	specifically	inhibits	complex	I	and	IV	of	the	respiratory	chain	on	the	one	hand,	and	
causes	conduction	failure	and	structural	damage	in	electrically	active	axons	on	the	other	hand	
(Bolanos,	 Almeida,	 &	 Stewart,	 n.d.;	 D.	Mahad,	 Ziabreva,	 Lassmann,	 &	 Turnbull,	 2008;	 Smith,	
Kapoor,	 Hall,	 &	 Davies,	 2001).	 Moreover,	 NO	 and	 its	 reaction	 products	 can	 modulate	 ion	
channels,	 receptors,	 and	 glycolytic	 enzymes,	 thereby	 increasing	 the	 strain	 on	 mitochondrial	
metabolism	(Pacher,	Beckman,	&	Liaudet,	2007).	TNFα	and	IFNγ	are	cytokines	that	attract	more	
immune	cells	to	the	area	and	can	aggravate	inflammation	(Fraga-Silva	et	al.,	2015).	 
The	 previously	 mentioned	 factors	 lead	 to	 an	 imbalance	 in	 energy	 metabolism.	 Elevated	
intracellular	 Na+	 leads	 to	 a	 reversal	 in	 function	 of	 the	 Na+/Ca2+exchanger	 and	 is	 therefore	
replaced	 by	 Ca2+.	 More	 Ca2+	 is	 released	 from	 axonal	 stores	 through	 glutamate	 signaling	 via	
GluR6	and	by	insertion	of	the	pore-forming	subunit	of	(N)-type	voltage	gated	Ca2+	channels	into	
the	demyelinated	membrane	 (Fern,	 Ransom,	&	Waxman,	 1995;	Ouardouz	 et	 al.,	 2003,	 2009;	
Ouardouz,	Malek,	Coderre,	&	Stys,	2006).	GluR6	receptors	were	found	to	increase	intracellular	
NO,	which	was	shown	to	mediate	the	Ca2+	increase	(Ouardouz	et	al.,	2009).	 
There	are	several	ways,	in	which	elevated	Ca2+	can	amplify	or	even	induce	axonal	injury.	First,	
increased	axonal	Ca2+	leads	to	activation	of	degradative	enzymes	such	as	phosphatases.	These	
dephosphorylate	 neurofilaments,	which,	 as	 described	 above,	 can	 lead	 to	 reduced	 velocity	 of	
fast	 axonal	 transport	 including	 mitochondrial	 transport	 to	 and	 from	 the	 lesion	 (Strack,	
Westphal,	Colbran,	Ebner,	&	Wadzinski,	1997).	Second,	Ca2+	also	activates	the	neural	proteinase	
calpain,	which	is	able	to	degrade	all	major	myelin	proteins	(Shields,	Schaecher,	Saido,	&	Banik,	
1999)	 as	 well	 as	 the	 axonal	 cytoskeleton.	 Third,	 Ca2+	 excess	 can	 destabilize	 mitochondria	
(Horng,	2014;	Witte,	Mahad,	Lassmann,	&	van	Horssen,	2014).		Mitochondrial	function	fails	at	
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this	 point	 for	 a	 number	 of	 reasons.	 Primarily,	 due	 to	 increased	 energy	 demands,	 the	
mitochondria	 in	 the	 lesion	 fail	 to	power	 fast	axonal	 transport	and	 recruit	more	mitochondria	
into	 the	 lesion	area.	Then,	 increased	ROS	production	by	 inflammatory	cells	and	mitochondria	
due	 to	 inhibition	 of	 respiratory	 chain	 function	 leads	 to	 even	more	 oxidative	 damage	 to	 the	
mitochondrial	machinery.	Lastly,	 the	failure	of	mitochondria	to	buffer	calcium	excess	 leads	to	
activation	of	degradative	enzymes.	These	processes	create	a	self-perpetuating	cycle	of	energy	
deficiency,	metabolic	demands	and	mitochondrial	and	axonal	dysfunction	that	ultimately	leads	
to	axonal	transection	(Bruce	D.	Trapp	&	Stys,	2009;	Witte	et	al.,	2014).	Wallerian	degeneration	
sets	in	when	the	distal	process	is	separated	from	the	cell	body	and	degenerates	anterogradely	
(Dziedzic	 et	 al.,	 2010).	 Especially	 in	 normal-appearing	 white	matter	 (NAWM)	 damage,	 it	 has	
been	proposed	to	play	an	important	role	(Evangelou	et	al.,	2000).	 
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Fig.	1-4	Processes	leading	to	axonal	degeneration	
As	 inflammatory	cells	 (microglia	 in	 red,	T-cells	 in	green,	macrophages	 in	orange)	 invade	the	CNS,	 they	
release	 cytokines,	 glutamate,	 and	 ROS	 and	 NO	 and	 thereby	 create	 a	 neurotoxic	milieu.	 ROS	 and	 NO	
damage	 DNA	 and	 inhibit	 mitochondrial	 respiration.	 In	 turn,	mitochondrial	 dysfunction	 causes	 energy	
failure	 of	 the	 axon,	 ATPases	 cease	 to	 work	 and	 fast	 axonal	 transport	 is	 arrested.	 Concurrent	
demyelination	 leads	 to	 loss	 of	 saltatory	 conduction,	 diffuse	 distribution	 of	 Na+	 channels	 along	 the	
denuded	 membrane	 and	 loss	 of	 trophic	 support	 from	 the	 oligodendrocyte.	 Na+	 accumulates	
intracellularly,	which	ultimately	reverts	the	function	of	the	Na+/Ca2+-exchanger	and	leads	to	an	increase	
in	 intracellular	 Ca2+.	 Other	 mechanisms	 contributing	 to	 the	 increase	 in	 Ca2+	 load	 are	 mitochondrial	
release	of	Ca2+,	Ca2+	release	from	intracellular	stores	through	activation	of	glutamate	receptors	and	Na+	
channels,	 and	 through	 Ca2+	 channels	 built	 into	 the	 membrane.	 Ca2+	 activates	 proteases,	 lipases,	 and	
inducible	nitric	oxide	synthase	and	modifies	ion	channels,	which	culminate	to	axonal	transection	and/or	
neuronal	 death	 (adapted	 from	 Ciccarelli	 et	 al.,	 2014;	Waxman,	 2006).	 Permission	was	 obtained	 from	
Elsevier	and	Nature	Publishing	Group. 
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In	summary,	axonal	damage	has	multiple	origins	and	may	be	a	result	of	interplay	between	
demyelination,	mitochondrial	changes,	distal	insults	to	the	neuronal	soma	or	proximal	axon	
districts,	local	meningeal	inflammation,	and	microglial	activation,	which	can	occur	singly	or	as	
additional	factors	in	the	process	of	axonal	pathology. 
	
1.10	Mitochondrial	pathology	
	
1.10.1	Mitochondrial	respiratory	chain	–	a	source	of	oxidative	stress	
Mitochondria	 are	 indispensable	 for	 proper	 function	 and	 integrity	 of	 the	 neuron	 (Nicholls	 &	
Budd,	 2000).	 By	 producing	 ATP,	 they	 maintain	 diverse	 neuronal	 functions	 such	 as	 axonal	
transport,	 assembly	 of	 the	 cytoskeleton,	 and	 fatty	 acid	 oxidation.	 They	 also	 sustain	 synaptic	
function,	 i.e.	 vesicle	 exocytosis	 and	 Ca2+	 buffering,	 facilitate	 neuronal	 conduction,	 regulate	
apoptosis,	and	are	potent	producers	of	ROS	(D.	C.	Chan,	2006;	Li,	Okamoto,	Hayashi,	&	Sheng,	
2004;	Misgeld,	Kerschensteiner,	Bareyre,	Burgess,	&	 Lichtman,	2007;	 Sheng	&	Cai,	 2012).	 	As	
displayed	 in	Fig	1-5	electrons	are	being	transferred	through	a	chain	of	enzymes	(complexes	 I-
IV),	 while	 protons	 (H+)	 are	 being	 pumped	 from	 the	 matrix	 into	 the	 inner	 membrane	 space	
thereby	 generating	 a	 transmembranous	 gradient,	 which	 is	 ultimately	 being	 used	 to	 produce	
ATP	 (Jin	 et	 al.,	 2014).	 Through	 leakage	 of	 electrons	 reactive	 oxygen	 species	 are	 created	 (i.e.	
oxygen	 superoxide).	 To	 counteract	 oxidative	 reactions	 with	 biomolecules	 the	mitochondrion	
contains	 an	 arsenal	 of	 antioxidative	 reactants,	 such	 as	 glutathione	 peroxidase,	 catalase,	 and	
thioredoxin	reductase	 (Hans	Lassmann	&	van	Horssen,	2011).	 	At	physiological	 levels	ROS	are	
involved	 in	 signaling	 cascades	 (Jin	 et	 al.,	 2014).	 In	 pathological	 conditions	 they	 are	 often	
produced	 excessively	 not	 only	 by	 the	 mitochondrion	 but	 also	 by	 external	 sources	 such	 as	
microglia	 and	macrophages.	 This	 leads	 to	 an	 imbalance	with	 a	 relative	 lack	 of	 anti-oxidative	
agents.		
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Fig.	1-5	Mitochondrial	ROS	production	
While	electrons	are	being	transferred	from	complex	 I	onto	complex	 IV	protons	are	channeled	 into	the	
inner	membrane	 space.	 Across	 the	 inner	membrane	 a	 gradient	 is	 created,	which	 forces	 protons	 back	
into	 the	 matrix	 through	 complex	 V,	 where	 the	 energy	 is	 used	 to	 generate	 ATP	 from	 ADP.	 The	 end	
products	 are	 water	 and	 carbondioxide.	 If	 there	 is	 a	 shortage	 of	 reductive	 compounds	 and	 due	 to	
electron	 leakage	 throughout	 the	 process,	 ROS	 are	 generated.	 ROS	 at	 a	 healthy	 level	 help	 regulate	
survival	 pathways	 and	 contribute	 to	 cell	 homeostasis.	 An	 excess	 on	 the	 other	 hand	 can	 lead	 to	 cell	
degeneration	and	apoptosis.	
Adapted	from	(Jin	et	al.,	2014;	Moreira	et	al.,	2010).	Rights	obtained	from	Elsevier.	
	
1.10.2	Mitochondrial	transport:	general	
Owing	to	their	complex	polarized	structure	and	unique	energy	requirements,	neurons	pose	an	
especially	difficult	challenge	for	mitochondrial	distribution	(Hollenbeck	&	Saxton,	2005;	Sheng	
&	Cai,	 2012).	Under	normal	 conditions,	mitochondrial	 distribution	 is	 regulated	by	 the	energy	
demands	 of	 the	 various	 cellular	 compartments,	 accounting	 for	 the	 unequal	 and	 fluctuating	
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allocation	of	mitochondria	(Fabricius,	Berthold,	&	Rydmark,	1993;	Hollenbeck	&	Saxton,	2005;	
Zhang,	 Ho,	 Kintner,	 Sun,	 &	 Chiu,	 2010).	 High	 ATP	 consumption	 and	 therefore	mitochondrial	
accumulations	 are	 found	 in	 the	 nodes	 of	 Ranvier,	 active	 synapses,	 myelination	 boundaries,	
active	 growth	 cones	 and	 newly	 forming	 collaterals	 (Amiri	 &	 Hollenbeck,	 2008;	 Berthold,	
Fabricius,	Rydmark,	&	Andersén,	1993;	Bristow,	Griffiths,	Andrews,	Johnson,	&	Turnbull,	2002;	
Li	et	al.,	2004;	Waxman	&	Ritchie,	1993;	Wong-Riley	&	Welt,	1980).	During	an	acute	demand	
such	 as	 the	 process	 of	 forming	 new	 synapses	 or	 growing	 new	 collaterals,	 mitochondria	 are	
often	 initially	 merely	 relocated	 within	 the	 distal	 axon	 segment	 (Amiri	 &	 Hollenbeck,	 2008).		
However,	a	constant	supply	of	entire	mitochondria	and	repair	parts	can	only	be	maintained	by	
sending	material	from	the	soma.		
As	 the	only	 cell	 organelle	 to	 contain	non-nuclear	DNA,	mitochondria	have	 a	unique	position.	
Mitochondrial	 DNA	 (mtDNA)	 codes	 for	 22	 transfer	 RNAs	 and	 13	 polypeptides	 essential	 to	
oxidative	phosphorylation	(Schon,	DiMauro,	&	Hirano,	2012).	Most	genes	for	the	mitochondrial	
assembly	are	encoded	in	the	nucleus.	 	Consequently	the	overall	majority	of	mitochondria	will	
be	 produced	 and	 assembled	 on	 site	 and	 transported	 to	 the	 distal	 parts	 of	 the	 axon.	
Interestingly,	 several	 groups	 have	 also	 discussed	 the	 possibility	 of	 a	 distal	 protein	 synthesis,	
mitochondrial	 assembly,	 and	 mtDNA	 replication	 (Magnusson,	 Orth,	 Lestienne,	 &	 Taanman,	
2003;	Twiss	&	van	Minnen,	2006).	However	either	way,	distal	mitochondrial	supply	requires	a	
sophisticated	transport	system	(Sheng	&	Cai,	2012).			
Axonal	transport	is	differentiated	into	fast	and	slow,	anterograde	(towards	the	periphery)	and	
retrograde	 (towards	 the	 soma).	 With	 the	 possibility	 to	 visualize	 and	 to	 observe	 in-vivo	
mitochondrial	trafficking	through	the	axon,	mitochondrial	migration	patterns	could	be	followed	
in	 the	 healthy	 and	 diseased	 state	 (Misgeld,	 Kerschensteiner,	 et	 al.,	 2007).	 In	 time-lapse	
recordings	of	acute	explants	of	peripheral	nerves	Misgeld	and	Kerschensteiner	identified	three	
categories	of	mitochondria:	 immobile,	anterogradely	and	retrogradely	traveling	mitochondria.	
The	 immobile	 mitochondria	 constituted	 the	 largest	 population	 with	 87%	 and	 they	 were	
approximately	 double	 the	 size	of	 the	mobile	 fraction	 (3.00µm).	 Those	moving	 anterogradely,	
represented	 two	 thirds	 of	 the	 mobile	 fraction,	 were	 slightly	 shorter	 and	 slower	 than	 the	
retrogradely	 transported	 population.	Mitochondria	 generally	 traveled	with	 occasional	 pauses	
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(Misgeld,	Kerschensteiner,	et	al.,	2007).	 In	cultured	neurons	they	are	moved	from	two	to	five	
µm	per	second	(Brady,	1991,	1993).		
	A	 complex	 interplay	 between	 motor	 proteins,	 anchor	 proteins,	 sensors,	 the	 transported	
organelle	 and	 the	 scaffolding	 along	 which	 the	 organelle	 is	 guided,	 allows	 for	 a	 quick	 switch	
between	moving	and	arresting,	direction	and	speed	(Chada	&	Hollenbeck,	2004;	Hollenbeck	&	
Saxton,	2005).			
	
1.10.3	Mitochondrial	transport:	equipment	
Depending	on	the	direction,	destination	and	cargo	there	exist	different	combinations	of	motor	
and	 anchor	 proteins.	 Anterograde	 transport	 is	 primarily	 steered	 by	motor	 proteins	 from	 the	
kinesin	family	(N.	Hirokawa	et	al.,	1991).	The	dynein	family	is	mostly	responsible	for	retrograde	
transport	 (Pilling,	Horiuchi,	Lively,	&	Saxton,	2006;	Varadi	et	al.,	2004).	Myosin,	a	 third	motor	
protein	 that	 transports	 its	 cargo	 along	 actin	 filaments,	 is	 responsible	 for	 short	 distance	
transport	in	presynaptic	terminals,	growth	cones	and	dendritic	spines	(Sheng	&	Cai,	2012).	Miro	
and	Milton	are	two	adaptor	proteins	that	bind	kinesin	1	to	the	mitochondrion.			
Kinesin	1,	the	motor	for	long	distance	anterograde	mitochondrial	transport,	typically	consist	of	
two	 kinesin	 1	 family	 5	 (KIF5)	 heavy	 chains	 and	 two	 kinesin	 light	 chains	 (Nobutaka	Hirokawa,	
Niwa,	&	Tanaka,	2010).	It	was	first	isolated	from	axoplasm	of	the	squid	giant	axon	and	found	to	
transport	 glass	 beads	 along	 microtubules	 (Vale,	 Reese,	 &	 Sheetz,	 1985).	 	 The	 heavy	 chains	
contain	 the	ATP	hydrolyzing	units	 that	provide	 the	motor	 force	and	 the	 light	 chains	 together	
with	the	carboxy-end	of	the	heavy	chains	recognize	the	cargo	(Nobutaka	Hirokawa	et	al.,	2010).	
There	 are	 six	 kinesin	 families	 that	 participate	 in	 organelle	 transport	 in	 axons,	 two	 of	 which,	
especially	 kinesin	1	 and	3,	 are	 responsible	 for	mitochondrial	 transport	 (Hollenbeck	&	Saxton,	
2005).	Of	 the	three	 isoforms	of	kinesin	1	KIF5A,	KIF5B,	and	KIF5C,	KIF5A	and	C	are	expressed	
only	 in	neurons	and	KIF5B	 is	ubiquitous	 (Nobutaka	Hirokawa	et	 al.,	 2010;	M.-Y.	 Lin	&	Sheng,	
2015).	 	 KIF1B-α	 and	 KLP6	 are	 the	mitochondria-transporting	 isoforms	 of	 the	 kinesin	 3	 family	
(M.-Y.	Lin	&	Sheng,	2015).		
Mutations	to	the	heavy	chain	of	kinesin	can	cause	lower	sodium	channel	activity,	fewer	action	
potentials,	 less	 neurotransmitter	 release	 on	 a	 physiological	 basis	 and	 on	 a	 molecular	 basis	
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reduces	anterograde	and	retrograde	transport,	mitochondrial	density	and	number	of	synaptic	
boutons	(Hurd	&	Saxton,	1996;	M.-Y.	Lin	&	Sheng,	2015).	In	KIF1A	knock-out	mice	the	number	
of	 axonal	 branches	 was	 decreased,	 while	 the	 number	 of	 dendrites	 was	 not	 significantly	
different,	 and	mitochondrial	 transport	 velocity	was	decreased	as	well	 (Karle,	Möckel,	Reid,	&	
Schöls,	 2012).	Mutations	of	 kinesin	3	 family	members	mainly	 alter	mitochondrial	 distribution	
(M.-Y.	Lin	&	Sheng,	2015;	Tanaka,	Sugiura,	Ichishita,	Mihara,	&	Oka,	2011).	
Cytoplasmic	 dynein	 is	 a	 large	 protein	 complex	 consisting	 of	 two	 heavy	 chains	 with	 ATP	
hydrolyzing	 activity,	 responsible	 for	 mobility,	 and	 several	 intermediate	 chains,	 intermediate	
light	 chains	 and	 light	 chains	 for	 cargo	 recognition	 (Nobutaka	 Hirokawa	 et	 al.,	 2010;	 Karki	 &	
Holzbaur,	1999).	 	Unlike	kinesins	the	genetic	variety	 for	the	heavy	chains	 in	dynein	 is	 limited,	
however	 due	 to	 the	 composition	 of	 the	 accessory	 parts	 a	 variety	 of	 binding	 options	 can	 be	
achieved	(Hollenbeck	&	Saxton,	2005).		
In	order	 to	 link	 the	 cargo	 to	 kinesin	1,	 anchor	proteins	are	needed.	Miro	 (mitochondrial	Rho	
GTPase)	 connects	 to	 the	 outer	 membrane	 of	 the	 mitochondrion	 consisting	 of	 two	 GTPase	
domains	 connected	 by	 four	 EF	 hands,	 Ca2+-binding	 domains	 (Reis,	 Fransson,	 &	 Aspenström,	
2009;	 Schwarz,	 2013).	Milton	 forms	 the	 link	 between	Miro	 and	 KIF5	 (Reis	 et	 al.,	 2009).	 The	
coiled-coil	region	of	the	N-terminal	connects	with	the	kinesin	or	dynein/dynactin	complex	and	
the	C-terminal	links	with	Miro	(van	Spronsen	et	al.,	2013).	Together	they	form	the	anterograde	
mitochondrial	 transport	unit.	Mutation	 in	either	 adaptor	 resulted	 in	 transport	deficits.	 dMiro	
mutants	 showed	 depleted	 presynaptic	 terminals	 and	 a	 complete	 loss	 of	Miro1	 resulted	 in	 a	
mitochondrial	 loss	 in	 the	 long	 spinal	 tracts	 (Górska-Andrzejak	 et	 al.,	 2003;	 Guo	 et	 al.,	 2005;	
Sheng	&	 Cai,	 2012).	 Loss-of-function	mutations	 of	Miros	N-	 terminal	 of	 the	GTPase	 domains	
caused	premature	 lethality	and	showed	mitochondrial	accumulations	 in	the	soma	of	neurons,	
as	 well	 as	 reduced	 mobility	 of	 the	 motor	 proteins	 kinesin	 and	 dynein	 and	 mitochondrial	
fragmentation,	while	the	C-terminal	mutation	merely	affected	mobility	of	dynein	(Babic	et	al.,	
2015).	Mutations	of	the	Milton	gene	caused	a	lack	of	mitochondria	within	axons	and	synapses	
(Stowers,	Megeath,	 Górska-Andrzejak,	Meinertzhagen,	&	 Schwarz,	 2002).	 Recently	 trafficking	
kinesin	proteins	(TRAK)	have	been	identified	as	a	mammalian	homologue	of	Milton,	therefore	
presenting	 another	 link	 between	 kinesin	 and	Miro	 (Brickley	 &	 Stephenson,	 2011;	 MacAskill,	
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Brickley,	Stephenson,	&	Kittler,	2009).		TRAK1	interacts	with	kinesin	and	dynein	and	is	found	in	
axons,	while	TRAK2	primarily	binds	to	dynein/dynactin	and	steers	mitochondria	into	dendrites	
(van	Spronsen	et	al.,	2013).	Syntabulin	appears	to	be	an	adaptor	protein,	mainly	responsible	for	
anterograde	 transport.	 It	 colocalizes	 with	 mitochondria	 in	 axons,	 binds	 directly	 to	 KIF5	 and	
enables	its	recruitment	to	mitochondria	(Cai,	Gerwin,	&	Sheng,	2005;	M.-Y.	Lin	&	Sheng,	2015).		
For	dynein	several	adaptor	proteins	have	been	suggested.	Dynactin	for	instance	binds	to	dynein	
and	 mitochondria,	 however	 it	 promotes	 bidirectional	 motility	 associating	 with	 KIF5	 as	 well	
(Pilling	 et	 al.,	 2006).	Miro	 has	 been	postulated	 to	 play	 a	 role	 in	 retrograde	 transport	 as	well	
(Russo	 et	 al.,	 2009).	 Since	 the	 inhibition	 of	 kinesin-1	 reduced	 anterograde	 and	 retrograde	
transport,	a	role	in	retrograde	transport	for	kinesin	was	suggested	as	well	(Pilling	et	al.,	2006).	
Most	likely	the	roles	of	the	motor	proteins	are	even	more	intertwined	than	has	been	assumed.	
Anterograde	and	retrograde	transport	are	probably	regulated	through	a	complex	interaction	of	
various	motor	proteins	and	adaptors	(Sheng	&	Cai,	2012).	
	
Fig.	1-6	Axonal	transport	of	mitochondria	
Mitochondria	and	other	cargoes	bind	 to	kinesin	 (right)	 for	anterograde	 transport	and	dynein	 (left)	 for	
retrograde	 transport.	 Kinesin	 consist	 of	 two	 heavy	 chains	 with	 the	 motor	 unit	 and	 two	 light	 chains	
docking	onto	 the	cargo.	 	Dynein	 forms	a	complex	with	dynactin	and	consists	of	 two	heavy	chains	and	
several	light	and	intermediate	chains.	Dysfunction	in	either	part	of	the	system	can	lead	to	undersupply	
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of	the	synapse	with	cargoes	or	maldistribution	of	mitochondria	along	the	axon.	Adapted	from	(De	Vos,	
Grierson,	Ackerley,	&	Miller,	2008).	Permission	not	required. 
	
1.10.4	Mitochondrial	transport:	regulation	
For	 initiation	 of	 axonal	 transport	 mitochondrial	 proteins,	 synaptic	 proteins	 and	 other	
membrane	bound	structures	have	to	pass	through	the	Golgi	apparatus	in	order	to	receive	their	
clathrin	coat,	that	addresses	them	ready	for	transport	(Rothman	&	Wieland,	1996;	Stenoien	&	
Brady,	1999).	Transport	over	 long	distances	 is	guided	along	microtubules,	which	stretch	 from	
the	soma	(negatively	charged	end)	all	the	way	to	the	periphery	(positively	charged	end)	(Black	
&	 Baas,	 1989;	Hollenbeck	&	 Saxton,	 2005;	Morris	&	Hollenbeck,	 1993).	 Transport	within	 the	
soma	and	dendrites	 is	directed	mostly	along	actin	filaments	(Morris	&	Hollenbeck,	1995).	The	
exact	mechanisms	and	 regulation	behind	 the	 initiation	of	mitochondrial	 transport	 are	 largely	
unknown.	 However	 there	 is	 accumulating	 evidence	 that	 axon	 activity	 can	 influence	
mitochondrial	trafficking.	
Ca2+	 release	 and	 uptake	 is	 certainly	 the	 best-described	 stop-and-go	 signal	 for	 mitochondria.	
Axonal	Ca2+	levels	vary	depending	on	activity,	branching	to	postsynaptic	targets,	mitochondrial	
content,	external	influences	such	as	inflammation	and	myelination	(Cai	&	Sheng,	2009;	Ghosh-
Roy,	Wu,	Goncharov,	Jin,	&	Chisholm,	2010).	Since	Ca2+	is	released	as	a	response	to	the	arrival	
of	 an	 action	 potential	 at	 the	 presynaptic	 terminal,	 mitochondria	 are	 needed	 to	 buffer	
intracellular	Ca2+	accumulations	as	well	as	to	provide	ATP	for	Ca2+	pumps	(Cai	&	Sheng,	2009).	
The	 Ca2+	 concentration	 influences	 mitochondrial	 mobility	 through	 several	 different	
mechanisms,	all	of	which	are	mediated	by	Miro,	which	senses	Ca2+	with	the	EF	hand	motif	and	
induces	 an	 uncoupling	 of	 the	 motor	 complex	 from	 the	 microtubule	 (Macaskill	 et	 al.,	 2009).	
There	are	several	propositions	of	which	conformational	change	causes	this	uncoupling	process.	
Wang	 and	 Schwarz	 propose	 that	Miro’s	 Ca2+-binding	 creates	 a	 conformational	 change	 in	 the	
kinesin	 complex,	 which	 detaches	 the	motor	 terminal	 from	 the	microtubules	 and	 connects	 it	
with	Miro	(Cai	&	Sheng,	2009;	Wang	&	Schwarz,	2009).	MacAskill	suggested	a	slightly	different	
mechanism,	 by	which	 Ca2+	 binds	 to	 the	 EF	 hand	 of	Miro,	which	 in	 turn	 distaches	 from	KIF5,	
therefore	disconnecting	the	anterograde	transport	unit	(Macaskill	et	al.,	2009;	Rintoul,	Bennett,	
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Papaconstandinou,	&	Reynolds,	2006;	Wang	&	Schwarz,	2009).	Likely	this	difference	is	due	to	a	
focus	in	each	project.	Macaskill	has	examined	dendrites	and	Schwarz	and	Wang	looked	at	axons	
(Y.	Chen	&	Sheng,	2013).	The	result	remains	the	same:	Owing	to	this	pathway	mitochondria	can	
be	 recruited	 to	 active	 synapses	 (Cai	 &	 Sheng,	 2009).	 In	 the	 same	 experiment	 glutamate	
signaling	via	N-Methyl-D-Aspartate	(NMDA)	receptors	has	also	been	shown	to	initiate	a	slowing	
of	 mitochondrial	 transport,	 however	 this	 was	 mediated	 through	 Ca2+	 release	 as	 well	 and	
therefore	similar	pathways	as	described	above	(Macaskill	et	al.,	2009).	The	Ca2+	concentration	
cannot	only	influence	the	mobility	and	location	of	mitochondria,	it	also	functions	as	a	regulator	
for	several	different	enzymes	for	the	respiratory	chain	and	glucose	metabolism	pathways	such	
as	 FAD-glycerol	 phosphate	 dehydrogenase,	 pyruvate	 dehydrogenase	 phosphatase	 and	 even	
ATP	synthase	(Boerries	et	al.,	2007;	Tarasov,	Griffiths,	&	Rutter,	2012).	Thereby	the	neuron	 is	
able	to	steer	mitochondria	to	a	destination	with	low	ATP	concentration	and	at	the	same	time	
upregulate	ATP	production	through	Ca2+	levels	(Tarasov	et	al.,	2012).	
	
	Morris	 and	 Hollenbeck	 could	 show	 mitochondrial	 accumulation	 upon	 nerve	 growth	 factor	
(NGF)	 release.	 This	mediation	was	 interrupted	 by	 inhibition	 of	 the	 phosphoinositide	 3	 (PI-3)	
Kinase	 pathway	 (Chada	 &	 Hollenbeck,	 2004).	 This	might	 add	 explanation,	 why	mitochondria	
accumulate	 in	 newly	 forming	 growth	 cones	 (Morris	 &	 Hollenbeck,	 1993).	 Furthermore,	
serotonin	receptor	5-HT1A	activation	could	accelerate	transport	towards	a	certain	target	area	
through	 AKT-glycogen	 synthase	 kinase	 3β	 (GSK3β)	 pathway	 signaling,	whereas	 D2	 dopamine	
receptor	 antagonists	 and	 NO	 have	 been	 shown	 to	 inhibit	 mitochondrial	 transport	 (Chada	 &	
Hollenbeck,	 2004;	 S.	 Chen,	 Owens,	 Crossin,	 &	 Edelman,	 2007;	 Rintoul	 et	 al.,	 2006;	 Zanelli,	
Trimmer,	&	Solenski,	2006). 
	
Mitochondrial	morphology	 itself	 could	 also	 contribute	 to	 transport	 velocity	 and	 direction.	 As	
Misgeld	and	Kerschensteiner	described,	 the	mobile	 fraction	was	significantly	shorter	 than	the	
stationary	 fraction	 of	 axonal	 mitochondria,	 which	 leads	 to	 the	 assumption	 that	 fusion	 and	
fission	processes	might	be	connected	to	transport	regulation	(Misgeld,	Kerschensteiner,	et	al.,	
2007).	One	explanation	could	be	that	 longer	tubular	mitochondria	are	simply	 less	flexible	and	
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therefore	 harder	 to	 be	 carried	 away	 by	 the	 transport	 machinery	 than	 shorter	 ones	 (Cai	 &	
Sheng,	2009).	However	there	exist	molecular	connections	between	mitochondrial	transport	and	
fusion	and	fission.	Miro	has	been	suggested	to	not	only	regulate	transport	via	Ca2+-sensing,	but	
also	 to	 increase	 mitochondrial	 fission,	 whereas	 dynamin-related	 protein	 1	 (Drp1),	 a	 protein	
identified	 in	 Drosophila,	 responsible	 for	 fission	 could	 influence	 transport	 and	 mitochondrial	
targeting	of	the	synapses	as	well	 (Saotome	et	al.,	2008;	Verstreken	et	al.,	2005).	 Interestingly	
Drp1	also	contains	a	GTPase	domain	like	Miro	(Cai	&	Sheng,	2009).	
 
Since	ATP	has	a	low	diffusion	capacity,	mitochondria	must	be	nearby	to	provide	replenishment	
(Hubley,	Locke,	&	Moerland,	1996).	In	areas	with	a	high	energy	demand,	which	might	coincide	
with	 a	 Ca2+-imbalance,	 mitochondrial	 transport	 is	 interrupted	 by	 docking	 to	 a	 microtubule-
based	protein	such	as	syntaphylin	or	to	actin	via	myosin	(Chada	&	Hollenbeck,	2004;	Kang	et	al.,	
2008).	The	transport	velocity	 increases	 in	areas	high	 in	ATP,	whereas	 in	areas	 low	 in	ATP	and	
high	 in	 ADP,	 such	 as	 synapses	 and	 nodes	 of	 Ranvier,	 it	 decreases	 (Mironov,	 2007).	
Consequently,	ATP	depletion	by	glutamate	and	high	ADP	concentrations	were	able	 to	 recruit	
mitochondria	to	the	stationary	pool	(Mironov,	2007).	This	might	be	regulated	through	the	AMP-
activated	protein	kinase	 (AMPK),	which	 is	activated	with	elevated	energy	demand,	 	 increases	
the	 mitochondrial	 flow	 into	 branches	 and	 outgrowing	 dendrites	 (Tao,	 Matsuki,	 &	 Koyama,	
2014).	Syntaphilin	expression	was	also	associated	with	branching,	whereas	depletion	showed	a	
reduction	(M.-Y.	Lin	&	Sheng,	2015).	This	suggests	a	link	between	the	two	processes.		
	
Finally	 also	 extracellular	 glucose	 levels	 can	 influence	 mitochondrial	 location.	 The	 activated	
enzyme	O-GlcNAc	 transferase	 (OGT)	 can	 lower	mitochondrial	motility.	 Its	 activation	 depends	
upon	elevated	extracellular	glucose	levels	and	induces	an	O-GlcN	acetylation	of	Milton,	which	
arrests	mitochondrial	movement	(M.-Y.	Lin	&	Sheng,	2015;	Pekkurnaz,	Trinidad,	Wang,	Kong,	&	
Schwarz,	2014).		
	
How	do	they	stay	on	site	once	they	arrive	at	their	destination	though?	Certain	regions	have	a	
complex	 docking	 apparatus	 in	 place	 in	 the	 presynaptic	 terminal	 called	 the	 mitochondria	
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associated	adherens	complex	(MAC),	first	identified	in	Calyx	of	Held	synapses	(Rowland,	Irby,	&	
Spirou,	 2000).	 In	 other	 places	 mitochondria	 associate	 with	 microtubular	 structures	 and	
neurofilaments.	 Especially	actin	 filaments	 seem	 to	 initiate	mitochondrial	docking,	 since	 it	has	
been	 shown	 that	 actin	 concentration	 is	 high	 in	 places	with	 an	 accumulation	of	mitochondria	
and	 in	 places	 missing	 actin	 mitochondrial	 mobility	 is	 elevated	 (Hollenbeck	 &	 Saxton,	 2005;	
Morris	&	Hollenbeck,	1995).	
One	anchor	that	is	well	described	is	the	axonal	outer-membrane	protein	syntaphilin.	Chen	and	
Sheng	 proposed	 the	 following	 docking	mechanism.	 The	mitochondrion	moves	 anterogradely	
along	the	microtubule	driven	by	kinesin.	Once	it	passes	an	area	of	high	Ca2+	concentration,	Miro	
acts	as	a	sensor	and	uncouples	 from	the	C-terminal	of	KIF5,	which	 leaves	 it	vacant	to	bind	to	
syntaphilin,	which	in	turn	inhibits	the	ATPase	of	the	motor	unit	(Y.	Chen	&	Sheng,	2013).	Upon	
deletion	 axonal	 mitochondria	 were	 more	 mobile	 and	 axons	 contained	 less	 mitochondria,	
whereas	 overexpression	 resulted	 in	 transport	 deficits	 (Y.	 Chen	 &	 Sheng,	 2013).	 Syntaphilin	
could	also	partly	explain	the	discrepancy	in	Ca2+-mediated	docking	mechanism	explained	above.	
It	 is	 limited	 to	 axons,	 dendrites	 have	 different	 docking	 mechanisms	 possibly	 regulated	 by	
glutamate	induced	Ca2+	elevation	resulting	in	a	decoupling	of	KIF5	and	mitochondria	(Y.	Chen	&	
Sheng,	 2013;	 Macaskill	 et	 al.,	 2009;	 Wang	 &	 Schwarz,	 2009).	 If	 Miro	 should	 represent	 the	
primary	 sensor	 and	 in	 a	 neuron-specific	 Miro1	 knock-out	 mouse	 model	 did	 not	 inhibit	 Ca2+	
mediated	 anchoring,	 Miro2	 would	 have	 to	 mediate	 this	 process	 (M.-Y.	 Lin	 &	 Sheng,	 2015;	
Nguyen	 et	 al.,	 2014).	 This	 however	 has	 not	 been	 confirmed	 yet.	 Interestingly,	 syntaphilin	
influences	anterograde	and	retrograde	transport,	although	no	association	with	dynein/dynactin	
has	 been	 shown	 yet.	 Possibly	 this	 is	 due	 to	 an	 inhibition	 of	 binding	 to	 dynein	 by	 a	 constant	
connection	to	KIF5	(Y.	Chen	&	Sheng,	2013).	
	
The	 last	question	 is,	what	directs	mitochondria	away	from	the	synapse	and	back	towards	the	
soma?	Once	the	Ca2+	concentration	returns	to	resting	levels	Chen	and	Sheng	suggest	that	Miro	
once	again	acts	as	a	sensor,	reattaches	KIF5	to	the	microtubules	and	disconnects	the	binding	to	
syntaphilin	 (M.-Y.	 Lin	 &	 Sheng,	 2015).	 They	 hypothesize	 that	 this	 is	 facilitated	 through	 the	
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continuous	 binding	 of	 the	 respective	motor	 proteins	 dynein	 and	 kinesin	 (M.-Y.	 Lin	 &	 Sheng,	
2015).		
	What	happens	to	dysfunctional	mitochondria,	which	ceased	to	produce	sufficient	ATP	and	are	
a	source	of	toxic	ROS?	The	great	majority	of	the	degradation	machinery	is	located	in	the	soma,	
the	dysfunctional	organelle	has	 to	be	 sufficiently	detected	and	 transported	back.	 In	 this	 case	
the	 charge	 of	 the	 mitochondrion	 might	 play	 a	 role.	 Miller	 and	 Sheetz	 have	 noticed	 that	
anterogradely	 moving	 mitochondria	 have	 a	 higher	 membrane	 potential	 compared	 to	
retrogradely	moving	ones	(Cai,	Zakaria,	Simone,	&	Sheng,	2012;	K.	E.	Miller	&	Sheetz,	2004).	In	
that	way	dysfunctional	mitochondria	get	 transported	back	 to	 the	 soma	and	healthy	ones	are	
replenishing	the	distal	demand	(D.	T.	W.	Chang	&	Reynolds,	2006).	NGF	earlier	mentioned	for	
its	arresting	potential	 for	mitochondria	has	also	been	ascribed	a	 role	 in	 locally	modifying	 the	
their	membrane	potential,	thereby	possibly	regulating	their	transport	direction	and	speed	(Cai	
&	 Sheng,	 2009;	 Chada	 &	 Hollenbeck,	 2004).	 When	 the	 membrane	 potential	 was	 decreased	
Pten-induced	 kinase	 1	 (PINK1),	 which	 was	 otherwise	 constitutively	 translocated	 from	 the	
cytosol	to	the	mitochondrial	inner	membrane,	cannot	pass	the	membrane	anymore,	which	lead	
to	an	accumulation	on	the	outer	membrane.	PINK1	accumulations	lead	to	Parkin	recruitment,	
which	in	turn	was	shown	to	induce	mitophagy	(Ashrafi,	Schlehe,	LaVoie,	&	Schwarz,	2014).		This	
data	however	stems	from	non-neuronal	cells.	 In	how	far	this	mechanism	applies	in	neurons	is	
debatable.	Cai	et	al.	report	that	Parkin-targeted	mitochondria	are	mainly	found	in	the	soma	and	
dendrites,	which	 is	where	 the	 lysosomal	 degradative	machinery	 is	 located	 as	well	 (Cai	 et	 al.,	
2012).	PINK	mediated	parkin	recruitment	leads	to	Miro	phosphorylation	and	thereby	transport	
arrest	 (Wang	 et	 al.,	 2011).	 This	 interaction	 of	 Parkin	 and	 PINK1	 with	 Miro	 could	 lead	 to	 a	
promotion	of	retrograde	transport	or	total	arrest	and	local	mitophagy	instead	of	transport	back	
to	the	soma	(Ashrafi	et	al.,	2014;	S.	Liu	et	al.,	2012).	It	is	still	debated	in	how	far	local	mitophagy	
is	employed	for	mitochondrial	quality	control	as	opposed	to	retrograde	transport	(M.-Y.	Lin	&	
Sheng,	2015).		
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1.10.5	Fission	and	Fusion	
There	 are	 various	 ways	 for	 an	 axon	 to	 remove	 misfolded,	 damaged	 or	 dysfunctional	
mitochondrial	 components.	Misfolded	proteins	 can	be	degraded,	 a	dysfunctional	 part	 can	be	
split	off	through	fission,	damaged	components	can	be	replaced	through	fusion	with	a	healthy	
mitochondrion,	 or	 the	 entire	 mitochondrion	 is	 designated	 for	 mitophagy	 (H.	 Chen	 &	 Chan,	
2009;	Detmer	&	Chan,	2007;	Westermann,	2010). Proteins	responsible	for	mitochondrial	outer	
membrane	 fusion	 are	 mitofusins	 1	 and	 2	 (MFN1,	MFN2),	 while	 the	 optic	 atrophy	 protein	 1	
(OPA1)	regulates	the	inner	membrane	fusion	(H.	Chen	et	al.,	2003;	Cipolat,	Martins	de	Brito,	Dal	
Zilio,	&	Scorrano,	2004).	All	 three	proteins	are	part	of	the	dynamin	family	and	have	a	GTPase	
domain,	 a	middle	 domain,	 a	 variable	 domain	with	 a	 transmembrane	 segment	 and	 a	 GTPase	
effector	(GED)	or	coiled-coil	domain	(Praefcke	&	McMahon,	2004).	In	MFN	the	GTPase	and	the	
GED	 point	 towards	 the	 cytosol,	 while	 the	 transmembrane	 region	 locks	 the	 protein	 into	 the	
outer	membrane	 of	 the	mitochondria.	OPA1	 has	 a	 cardiolipin-binding	 domain	 instead	 of	 the	
variable	domain	(Meglei	&	McQuibban,	2009).	The	exact	mechanisms	of	how	fusion	works	are	
not	known	yet.	It	has	been	suggested	that	opposing	MFNs	are	required	that	interlock	and	pull	
the	 membranes	 together	 (Bliek,	 Shen,	 &	 Kawajiri,	 2013;	 Koshiba	 et	 al.,	 2004).	 	 Other	
possibilities	would	be	that	fusion	dynamins	form	a	spiral,	 in	which	membrane	protrusions	can	
form	or	 forced	contact	between	convex	 lipid	 surfaces	could	act	 fusogenic	 (Bliek	et	al.,	2013).	
Meeusen	 and	 colleagues	 found	 out	 that	 for	 outer	 membrane	 fusion	 only	 GTP	 is	 needed,	
whereas	 for	 inner	membrane	 fusion	membrane	potential	 is	 essential	 (Meeusen	et	 al.,	 2006).	
Regulators	for	fusion	proteins	are	ubiquitination	for	outer	membrane	fusion	and	proteolysis	for	
inner	 membrane	 fusion.	 Ubiquitination	 of	 mitofusins	 can	 be	 induced	 by	 stress,	 once	 the	
membrane	potential	 is	decreased	PINK1	and	Parkin	mark	mitofusins	 for	degradation	 (Bliek	et	
al.,	2013).	However	OPA1-cleaving	by	the	metalloproteinase	OMA1	and	thereby	preventing	of	
inner	membrane	 fusion	 is	even	 faster	 than	 the	PINK1/parkin	pathway	 (Griparic,	Kanazawa,	&	
Bliek,	2007).			
	
For	 control	 of	 fission,	 Drp1	 and	 adaptor	 proteins	 are	 essential	 (Kubli	 &	 Gustafsson,	 2012;	
Smirnova,	 Griparic,	 Shurland,	 &	 van	 der	 Bliek,	 2001;	 Y.	 Yoon,	 Krueger,	 Oswald,	 &	McNiven,	
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2003).	As	 the	name	predicts,	Drp1	 is	another	member	of	 the	dynamin	 family.	 It	has	a	similar	
structure,	 the	 variable	 domain	 most	 likely	 serves	 as	 a	 detection	 sequence	 for	 mitochondria	
(Bliek	et	al.,	2013).	Drp1s	form	a	spiral	cluster,	which	activates	GTP	hydrolysis,	which	leads	to	
constriction	of	 the	multimer	 (Mears	et	al.,	 2011).	Both	membranes	are	 separated	during	 this	
constriction	process	(Bliek	et	al.,	2013).	Other	than	fusion,	fission	requires	adaptor	proteins	for	
initiation.	 Fission	 protein	 1	 (Fis1),	mitochondrial	 fission	 factor	 (Mff),	mitochondrial	 dynamics	
proteins	 (MiD49,	MiD51),	mitochondrial	 elongation	 factor	 (MIEF),	 and	 the	 gangliosid-induced	
differentiation	 associated	 protein	 (GDAP1)	 have	 been	 proposed.	 Fis1	 is	 important	 for	
mitochondrial	 fission	 in	 yeast,	 its	 role	 in	eukaryote	 fission	has	been	contested	 (Palmer	et	al.,	
2011).	MIEF1	likely	promotes	fusion	more	than	fission	(Zhao	et	al.,	2011).	On	balance	Fis1,	Mff,	
MiD49	and	51	possibly	independently	regulate	fission	with	partially	redundant	functions	(Bliek	
et	 al.,	 2013;	 Losón,	 Song,	Chen,	&	Chan,	 2013).	 The	 fission	proteins	 and	adaptors	 are	mainly	
regulated	 through	 phosphorylation	 and	 ubiquitination	 but	 also	 other	 modifications	 like	
sumoylation	 and	 nitrosylation	 have	 been	 discussed	 (Bliek	 et	 al.,	 2013;	 Braschi,	 Zunino,	 &	
McBride,	 2009;	 Cho	 et	 al.,	 2009).	 Interactions	 with	 the	 cytoskeleton	 and	 the	 endoplasmic	
reticulum	have	been	described	as	well	(Bliek	et	al.,	2013).		
	
	
Twig	et	al.	have	described	a	circle	of	events,	starting	with	a	single	mitochondrion,	which	fuses	
with	 other	 mitochondria	 to	 form	 a	 network,	 from	 this	 network	 dysfunctional	 parts	 can	 be	
discarded	by	fission.	The	membrane	potential	of	discarded	pieces	is	usually	lower	and	can	thus	
be	 targeted	 for	 mitophagy.	 However,	 recovery	 of	 the	 daughter	 mitochondria	 can	 lead	 to	
reuptake	 into	 the	network	and	 formation	of	 single	unit	mitochondria	 (Twig	et	al.,	2008).	Van	
Bliek	 interpreted	 increased	fusion	and	decreased	fission	as	 favorable	 for	cell	survival	 (Bliek	et	
al.,	2013).	
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Fig.	1-7	Fission	and	Fusion	
In	order	for	two	mitochondria	to	fuse	a	close	alignment	is	needed.	Mfn1	and	2	are	responsible	for	outer	
membrane	fusion	and	OPA1	is	located	on	the	inner	membrane	and	initiates	inner	membrane	fusion.	
Fission	is	initiated	by	adaptor	proteins	such	as	Fis1,	which	recruit	Drp1	to	the	surface	of	the	
mitochondrion.	Drp1	form	a	multimeric	spiral	complex,	which	constricts	the	membrane	and	completes	
fission.		Adapted	from	Chen	and	Chang	2006	(H.	Chen	&	Chan,	2006).		Rights	were	obtained	from	
Elsevier.	
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1.10.6	Mitochondrial	pathology	in	MS	–	chicken	or	egg	
Mitochondrial	pathology	in	MS	has	been	the	focus	of	many	groups	for	the	past	decades.	In	how	
far	 mitochondrial	 pathology	 is	 the	 cause	 or	 the	 consequence	 is	 still	 subject	 of	 debate.	
Mitochondrial	DNA-defects	and	deficient	DNA	repair,	abnormal	mitochondrial	gene	expression	
patterns,	 and	 dysfunctional	 or	 defective	 mitochondrial	 enzymes,	 increased	 free	 radicals	 and	
oxidative	damage,	and	fission	and	fusion	imbalance	can	lead	to	mitochondrial	dysfunction	(Mao	
&	Reddy,	2010).	Judging	by	its	indispensable	function	for	the	neuron	it	is	easy	to	imagine	how	
mitochondrial	dysfunction	can	lead	to	neurodegeneration.	In	many	neurodegenerative	diseases	
a	 link	 with	 mitochondrial	 dysfunction	 has	 already	 been	 established.	 Familial	 forms	 of	
Parkinson’s	 disease,	 Alzheimer’s	 disease,	 Amyotrophic	 lateral	 sclerosis,	 Huntington’s	 disease,	
Friedreich	 ataxia	 and	 hereditary	 spastic	 paraplegia	 have	 been	 reported	 to	 have	 underlying	
mitochondrial	pathology	(Schon	&	Manfredi,	2003).			
Only	 few	mtDNA	 and	 nuclear	 DNA	 alterations	 have	 been	 described	 in	 conjunction	with	MS.	
Age-related	variations	in	mitochondrial	DNA,	the	single	nucleotide	polymorphism	nt13708	G/A,	
an over-representation	 of	 super-haplogroup	U	 and	 carriers	 of	 haplogroup	 JT,	 changes	 in	 the	
nuclear	 encoded	 complex	 I	 gene	 NDUFS2	 and	 the	 uncoupling	 protein	 2	 (UCP2)	 promoter	
polymorphism	866G/A	might	influence	the	susceptibility	for	MS	(Ban	et	al.,	2008;	Mao	&	Reddy,	
2010;	Vogler	et	al.,	2005;	Yu	et	al.,	2008).		
The	 genetic	 component	 influencing	 and	 impairing	 mitochondrial	 function	 appears	 to	 be	
relatively	small	but	might	still	be	very	relevant	 in	some	familial	cases.	This	could	however	not	
explain	the	striking	lack	of	mitochondrial	content	in	the	spinal	cord	of	MS	patients	and	reported	
widespread	mitochondrial	 dysfunction	 in	MS.	 Lack	 of	 sufficient	 energy	 supply	 as	 a	 result	 of	
demyelination,	 Ca2+	 influx	 and	 general	 metabolic	 imbalance	 is	 the	 major	 cause	 for	 axonal	
degeneration.	 A	 gene	 expression	 pattern	 analysis	 revealed	 reduced	 neuronal	 mitochondrial	
gene	expression	and	reduced	respiratory	chain	complex	I	and	III	functional	activity	(Dutta	et	al.,	
2006).	Different	stages	of	de-	and	remyelination	in	active	and	chronic	lesions	have	been	found	
to	 have	 different	mitochondrial	 content.	 In	 active	 lesions	 a	 decreased	mitochondrial	 content	
has	 been	 found,	which	 is	most	 likely	 due	 to	 edema	 and	 tissue	 loss	 (D.	Mahad	 et	 al.,	 2008).		
Moreover	 complex	 I	 and	 IV	 of	 the	 mitochondrial	 respiratory	 chain	 were	 found	 defective	 in	
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acute	 pattern	 III	 lesions	 (D.	 Mahad	 et	 al.,	 2008).	 Following	 demyelination	 an	 increase	 in	
mitochondrial	 content	 has	 been	 observed.	 Chronically	 demyelinated	 axons	 revealed	 an	
increased	 complex	 IV	 activity	 and	 increased	mitochondrial	mass	 (Andrews	 et	 al.,	 2006;	 D.	 J.	
Mahad	 et	 al.,	 2009;	 Ohno	 et	 al.,	 2014).	 Axonal	 syntaphilin	 was	 also	 increased	 in	 chronically	
demyelinated	lesions	(D.	J.	Mahad	et	al.,	2009).	The	complex	IV	activity	was	inversely	correlated	
with	the	inflammatory	cell	density	in	the	lesion	(D.	J.	Mahad	et	al.,	2009).	Upon	remyelination,	
an	increased	content	of	mitochondria	has	been	reported	as	well,	but	not	as	pronounced	as	in	
acute	 and	 chronically	 demyelinated	 axons	 (Zambonin	 et	 al.,	 2011).	 On	 the	 one	 hand	 these	
results	speak	for	a	significant	contribution	of	mitochondrial	changes	to	the	pathology	of	MS,	on	
the	other	it	also	shows	a	compensatory	role	of	mitochondrial	accumulations	in	areas	of	energy	
deficits.	Possibly	those	deficits	can	be	compensated	for	the	duration	of	the	relapsing	remitting	
phase.	Progression	might	be	due	to	a	failure	of	that	compensation	as	shown	in	a	study	on	CSF	
of	MS	 patients,	 which	 found	 lactate,	 sorbitol	 and	 fructose	more	 increased	 in	 SPMS	 patients	
than	in	RRMS	patients	suggesting	a	metabolic	impairment	(Regenold,	Phatak,	Makley,	Stone,	&	
Kling,	 2008).	 Only	 recently	 the	 research	 group	 around	 van	 Horssen	measured	 serum	 lactate	
levels	in	MS	patients	and	healthy	controls	and	found	that	increased	lactate,	as	a	measurement	
of	mitochondrial	 dysfunction,	was	 associated	with	 disease	 severity	 (EDSS),	 upper	 limb	motor	
function,	walking	disability,	loss	of	color	vision	(Petzold	et	al.,	2015).	Additionally	muscle	tissue	
of	 MS	 patients	 showed	 less	 type	 I	 fibers,	 smaller	 fibers	 over	 all	 and	 lower	 succinate	
dehydrogenase	 levels,	which	 is	 part	of	 complex	 II	 of	 the	 respiratory	 chain	 (Kent-Braun	et	 al.,	
1997;	 Mao	 &	 Reddy,	 2010).	 Inactivation	 studies	 on	 the	 permeability	 transition	 pore	 and	 its	
regulator	 cyclophilin	D	 have	 shown	 a	 resistance	 against	 oxidative	 agents	 and	 faster	 recovery	
from	EAE	(Forte	et	al.	2007).	 
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1.12	Synapse	pathology		
	
1.12.1	Synapse	regulation	
Being	 the	 functional	 unit	 of	 the	 neuron,	 synaptic	 integrity	 is	 indispensable	 for	 neuronal	
transmission.	 Synapses	 in	 the	CNS	are	 constantly	being	abandoned	and	 reformed,	depending	
on	their	usage	and	the	environment.	During	neurodegenerative	diseases	like	Huntington’s	and	
Alzheimer’s	 disease,	 synaptic	 loss	 is	 often	 extensive	 and	 has	 been	 described	 to	 positively	
correlate	with	clinical	disease	(Jebelli,	Su,	Hopkins,	Pocock,	&	Garden,	2015).	 
Different	glial	cell	populations	influence	synapse	number	and	integrity	in	different	ways.		
First,	 astrocytes	have	been	 shown	 to	 aid	 in	neuronal	 circuit	 formation	 in	 the	developing	 and	
adult	 brain,	 especially	 excitatory	 glutamatergic	 synapses	 (Jebelli	 et	 al.,	 2015).	 They	 can	
influence	synapse	function	directly	by	modulating	glutamate	and	Ca2+	signaling,	or	they	engulf	
synaptic	material	 and	 thereby	eliminate	excessive	 synapses	 (Chung	et	al.,	 2013;	 Jebelli	 et	 al.,	
2015;	Newman,	 2003).	 In	 ALS	 astrocyte	 dysfunction	 has	 been	 reported	 to	 lead	 to	 glutamate	
excitotoxicity,	 which	 can	 provoke	 neuronal	 damage	 (Jebelli	 et	 al.,	 2015;	 Nagai	 et	 al.,	 2007).	
Elevated	glutamate	concentrations	have	been	found	in	CSF	from	MS	patients	to	correlate	with	
disease	severity,	and	glutamate	excitotoxicity	has	also	been	described	as	a	pathogenetic	factor	
in	mitochondrial	 and	 axonal	 damage	 in	MS	 (Barkhatova,	 Zavalishin,	 Askarova,	 Shavratskii,	 &	
Demina,	 1998;	 Pitt,	 Werner,	 &	 Raine,	 2000;	 Srinivasan,	 Sailasuta,	 Hurd,	 Nelson,	 &	 Pelletier,	
2005;	 Stover,	 Lowitzsch,	 &	 Kempski,	 1997;	 Zhu,	 Luo,	 Moore,	 Paty,	 &	 Cynader,	 2003).	
Furthermore,	astrocyte	glutamate	uptake	is	inhibited	by	ROS	and	RNS	released	by	microglia	and	
macrophages	in	EAE	and	MS	(Piani,	Frei,	Pfister,	&	Fontana,	1993). 
Secondly,	 microglia	 as	 well	 have	 an	 important	 role	 in	 synapse	 elimination	 and	 surveillance.	
Wake	 and	 colleagues	 demonstrated	 how	microglial	 processes	 constantly	 survey	 synapses	 by	
contacting	them	for	approximately	 five	minutes	each	hour.	 Interestingly,	microglial	motility	 is	
dependent	 on	 neuronal	 function.	 With	 reduced	 neuronal	 activity,	 microglial	 dendrite	
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movement	slows	down	(Wake,	Moorhouse,	Jinno,	Kohsaka,	&	Nabekura,	2009).	Briefly,	during	
normal	brain	 function	 in	 the	 resting	 state,	microglia	 can	mediate	 synaptic	plasticity	 via	 TNFα	
release,	 shape	 neuronal	 circuits	 by	 phagocytosing	 synaptic	 structures,	 and	 promote	 synaptic	
growth	 during	 development	 by	 releasing	 growth	 factors	 (Jebelli	 et	 al.,	 2015;	 Paolicelli	 et	 al.,	
2011;	 Stellwagen	 &	 Malenka,	 2006;	 Tremblay	 et	 al.,	 2011).	 Upon	 activation	 by	 hypoxia,	
lipopolysaccharide	(LPS)	or	other	inflammatory	stimuli	microglia	retract	their	processes,	which	
primarily	 leads	 to	 a	 decreased	 surveillance	 function	 and	 secondarily	 to	 loss	 of	 inhibitory	
synapses,	 promotion	 of	 excitatory	 synapses,	 increased	 long-term-synaptic	 depression,	 and	
neuroprotective	signaling	(Z.	Chen	et	al.,	2014;	Jebelli	et	al.,	2015;	Zhang	et	al.,	2010). 
During	neurodegenerative	diseases	and	aging,	microglia	become	dysfunctional	and	then	play	a	
major	part	in	synapse	loss	in	neurodegenerative	disease,	which	is	said	to	occur	simultaneously	
with	inflammation	and	clinical	decline	(Bessis,	Béchade,	Bernard,	&	Roumier,	2007). 
Lastly,	 myelin-forming	 cells	 have	 been	 shown	 to	 influence	 synaptic	 presence	 in	 the	 CNS.	
Especially	 oligodendrocyte	 precursors	 proliferate	 upon	 demyelination	 and	 inhibit	 synaptic	
activity	when	dysfunctional	(Kukley,	Nishiyama,	&	Dietrich,	2010;	Sahel	et	al.,	2015).	Schwann	
cells	 in	the	peripheral	nervous	system	can	sense	neuronal	activity	and	modulate	transmission	
(Feng,	Koirala,	&	Ko,	2005;	Jebelli	et	al.,	2015).	
All	 those	 cells	 can	 influence	 synapses	 from	 the	 outside.	 The	 activity	 of	 the	 neuron	 and	 this	
particular	neuronal	connection	 is	an	 important	 intrinsic	 factor	 for	synapse	stability.	 It	 is	 likely	
that	mitochondrial	content	is	a	determining	factor	for	synapse	integrity.	It	is	possible	that	with	
a	downregulation	of	 supply	of	mitochondria	 for	 the	 synapse	 i.e.	during	acute	 transport	block	
proximal	along	the	axon	the	synapses	would	lack	mitochondria	as	well.	
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2	Important	work	prior	to	mine	
2.1	Focal	axonal	degeneration		
	
Ivana	Nikić	and	colleagues	described	a	new	variant	of	axon	loss	in	inflammatory	EAE	lesions.	
First,	 she	distinguished	between	three	sequential	 stages	and	termed	the	entire	process	 'focal	
axonal	 degeneration'	 (FAD).	 During	 FAD	 the	 axons	 form	 focal	 swellings	 within	 areas	 of	
inflammatory	 cell	 infiltration	 (stage	 1),	 and	 eventually	 start	 to	 fragment	 (stage	 2).	 Using	
confocal	 microscopy	 they	 observed	 mitochondrial	 changes	 that	 occur	 in	 normal-appearing	
axons	 before	 any	 alterations	 of	 the	 axonal	 morphology	 could	 be	 observed	 (stage	 0b).	 	 The	
normal	 appearing	 axon	 with	 normal	 appearing	 mitochondria	 is	 defined	 as	 stage	 0a.	
Mitochondrial	changes	were	measured	by	means	of	the	shape	factor	(length	divided	by	width).	
A	 rounded	 shape,	 which	 coincided	 with	 a	 loss	 of	 internal	 structure,	 confirmed	 by	 electron	
microscopy,	characterized	damaged	mitochondria	(Nikić	et	al.,	2011).			
After	 having	 determined	 the	 individual	 stages,	 they	 focused	 on	 describing	 how	 these	
morphological	 changes	 developed	 over	 time	 and	 space	 and	 discovered	 the	 following	 key	
characteristics:	First,	they	discovered	that	FAD	is	mostly	restricted	to	the	lesion	area	and	thus	
closely	connected	to	the	presence	of	immune	cells	including	activated	macrophages/	microglia.	
It	is	a	reversible	process	that	can	recover	spontaneously	over	time	and	recovery	can	be	further	
facilitated		by	the	addition	of	ROS	scavengers.			Secondly,	ultrastructural	analysis	revealed	that	
axonal	 and	 mitochondrial	 pathology	 can	 occur	 independently	 of	 demyelination.	 Thirdly,	
mitochondrial	pathology	seems	to	be	an	important	contributing	factor	to	axon	degeneration	in	
EAE.	 	 	 Treating	 healthy	 mice	 with	 an	 uncoupling	 agent	 targeting	 the	 respiratory	 chain	 of	
mitochondria	 caused	mitochondria	breakdown	soon	 followed	by	FAD-like	axon	degeneration.	
Finally	they	were	able	to	find	correlates	of	FAD	in	biopsy	tissue	from	MS	patients.	The	human	
tissue	samples	 showed,	 similar	 to	EAE,	many	axons	with	 intact	myelin	 sheaths	 that	displayed	
FAD-like	axonal	and	mitochondrial	changes.	Targeting	mitochondria	seemed	to	be	a	promising	
new	 approach	 for	 treating	 MS.	 This	 required	 more	 research	 on	 mitochondrial	 function	 and	
properties	(Nikić	et	al.,	2011).	
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Fig.	2-1	Focal	axonal	degeneration	in	EAE	adapted	from	Nikić	et	al.	2011	(rights	were	obtained	
from	Nature	Publishing	Group)	
 
2.2	Pervasive	axonal	transport	deficits	
	
Mitochondria	are	highly	dynamic	cell	organelles	that	are	transported	from	the	neuronal	soma	
to	the	periphery	(anterograde	transport)	and	from	the	periphery	back	to	the	soma	(retrograde	
transport).	Catherine	Sorbara	 focused	her	research	on	the	transport	changes	of	mitochondria	
and	other	cell	organelles	 inside	and	outside	of	an	EAE	 lesion	 (C.	D.	Sorbara	et	al.,	2014).	She	
used	in	vivo	two-photon	imaging	of	individual	axons	within	the	spinal	cord	(Davalos	et	al.,	2008;	
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Nikić	 et	 al.,	 2011)	 and	 fluorescently	 labeled	 organelle	 cargoes	 namely	 mitochondria	 (Thy1-
MitoCFP	 mice;	 and	 peroxisomes	 (in	 Thy1-	 PeroxiYFP	 mice)	 to	 assess	 this	 process	 (Misgeld,	
Kerschensteiner,	et	al.,	2007).	
	
2.2.1	Mitochondrial	transport	inside	an	acute	lesion	
By	 imaging	 mitochondrial	 transport	 in	 axons	 that	 cross	 acute	 neuroinflammatory	 lesions,	
Sorbara	 found	 lower	 transport	 rates	 in	 anterograde	 as	 well	 as	 in	 retrograde	 direction.	
Interestingly,	those	changes	could	be	observed	not	only	in	stage	1	(=swollen)	axons,	but	also	in	
stage	 0	 (normal	 appearing)	 axons.	 While	 transport	 speed	 and	 stop	 frequency	 were	 only	
moderately	altered,	the	stop	duration	was	significantly	longer	in	stage	0	EAE	axons	compared	to	
control	 axons.	 This	 helps	 to	 explain	 the	 raised	 mitochondrial	 density	 and	 content	 in	 axons	
(stage	0	and	1)	within	the	lesion	area	compared	to	controls	(relative	to	control	axons:	111%	±	
5%	of	mitochondrial	content	in	stage	0	axons,	128%	±	9%	in	stage	1	axons)	(C.	D.	Sorbara	et	al.,	
2014).		
Similarly,	Witte	 and	 colleagues	 found	 an	 increased	 number	 of	 mitochondria	 in	 axons	 in	MS	
tissue	(Witte	et	al.,	2014).	From	this	knowledge	the	question	arose,	whether	this	accumulation	
originated	 from	 focal	 structural	 changes	 of	 the	 axon,	 cargoes	 or	 microtubule	 tracks.	
Interestingly,	changes	in	transport	preceded	not	only	demyelination	or	dysmyelination	but	also	
mitochondrial	changes	and	alterations	of	the	microtubule	tracks	(Edgar	et	al.,	2004;	Kiryu-Seo,	
Ohno,	Kidd,	Komuro,	&	Trapp,	2010;	Nikić	et	al.,	2011;	Ohno	et	al.,	2014;	Romanelli	et	al.,	2013;	
Witte	et	al.,	2014).		
2.2.2	Mitochondrial	transport	proximal	to	a	lesion	
Dorsal	root	axons	proximal	to	the	lesion	showed	comparatively	elevated	retrograde	and	normal	
anterograde	 transport,	 indicating	 a	 transport	 stop	 at	 the	 site	 of	 the	 lesion	 that	may	 cause	 a	
reversal	of	 transport	 from	 there	back	 to	 the	 cell	 body,	 similar	 to	what	occurs	 following	axon	
transection	in	vitro	(Misgeld,	Kerschensteiner,	et	al.,	2007;	C.	D.	Sorbara	et	al.,	2014).		
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2.2.3	Amelioration	of	transport	deficits	by	anti-inflammatory	drugs	
In	 the	 clinical	 treatment	 of	 an	 exacerbation	 of	MS,	 corticosteroids	 are	 used	 to	mitigate	 the	
severity	and	accelerate	the	process	of	remission.	Catherine	Sorbara	showed	that	the	recovery	
of	 transport	 deficits	 after	 the	 acute	 peak	 of	 EAE	 could	 be	 accelerated	 by	 application	 of	
corticosteroids	 as	 well.	 	 Transport	 deficits	 could	 be	 initiated	 by	 application	 of	 NO	 donors	 in	
healthy	mice	 in	 a	 concentration	 that	would	not	 affect	 the	 axonal	 or	mitochondrial	 structure,	
and	 could	 be	 reversed	 by	 local	 application	 of	 a	 NO	 scavenger.	 This	 suggests	 that	 transport	
deficits	are	associated	with	an	early	 inflammatory	stage	and	represent	a	process	of	reversible	
axonal	dysfunction	(C.	D.	Sorbara	et	al.,	2014).	
	
2.2.4	Mitochondrial	transport	in	chronic	neuroinflammatory	lesions	
In	a	chronic	EAE	model	those	transport	deficits	could	be	shown	to	recover	to	some	extent	after	
the	 acute	 phase,	 but	 not	 entirely.	 Strikingly	 the	 anterograde	 transport	 rates	 appeared	 to	 be	
more	severely	affected	than	the	retrograde	transport	rates.	As	a	result	the	distal	parts	of	the	
axons	 passing	 through	 a	 lesion	 received	 several	 hundreds	 of	mitochondria	 less	 per	 day	 than	
healthy	axons.	This	indicates	that	transport	deficits	could	over	time	lead	to	a	net	deprivation	of	
these	 important	 organelles	 in	 the	 axonal	 segments	 that	 are	 distal	 to	 a	 neuroinflammatory	
lesion	(C.	D.	Sorbara	et	al.,	2014).	
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Fig.	2-2	Transport	deficits	in	and	around	the	lesion	
Schematic	 of	 transport	 deficits	 within	 the	 lesion	 and	 proximal	 to	 it.	 Proximal	 retrograde	 transport	 is	
increased	 while	 anterograde	 transport	 is	 unaltered.	 Inside	 the	 acute	 lesion	 transport	 stops	 entirely.	
During	 recovery	 in	 the	 chronic	 phase	 the	 lesion	 reconstructs	 itself,	 inflammatory	 cells	 are	 spread	out	
more	diffusely	and	transport	continues	with	more	deficits	in	anterogradely	(partly	adapted	from	Sorbara	
et	al.,	2014).	
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3	Material	and	Methods	
 
3.1	Materials	
	
3.1.1	Reagents		
Preparation	of	surgery	
	 Ketamine	hydrochloride	10%	
(Ketamine)	
Bremer	Pharma	GmbH,	Warburg,	Germany	
	 Xylariem	20mg	(Xylazine)	 Riemser	Arzneimittel	AG,	Greifswald-Insel	
Riems,	Germany	
	 Forene	(Isoflurane)	 Abbott	AG,	Baar,	Switzerland	
	 Bepanthen	Augen-	und	
Nasensalbe	5g	(eye	cream)	
Bayer	Vital	GmbH,	Leverkusen,	Germany	
	 Cutasept	F	Lösung	250ml	
(disinfectant	spray)	
Bode	Chemie	GmbH	&	Co,	Hamburg,	
Germany	
DRG-Injection	 	 	
	 rAAV-CAG-mOrange	(monomeric	
Orange)	titer:	9x1012	genome	
copies/ml,	diluted	1:5	in	sterile	
PBS	
produced	by	Anja	Schmalz	(Institute	of	
Clinical	Neuroimmunology)	
	 PBS	10x	(phosphate	buffered	
saline),	pH=	7,2/7,4	
1l	PBS	10x	(pH	7,2/7,4)	
2,6g	NaH2PO4	(M=137.99g/mol)	
14,4g	Na2HPO4x2H2O	(M=177,99g/mol)	
87,5g	NaCl	
	 Isotone	NaCl	(Sodium	Chloride)	
0.9%	500ml	
B	Braun	Melsungen	AG		
	 Immunization	 	
	 myelin	oligodendrocyte	glycoprotein	
(MOG,	N1-125,	expressed	in	E.coli)	
Kindly	provided	by	Dr.	Doron	Merkler,	
University	of	Geneva	or	made	by	in-
house	technician	
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	 NaAcetate	 	
	 Complete	Freund’s	adjuvant	 Sigma-Aldrich,	St.Louis	(Missouri),	USA	
	 Mycobacterium	tuberculosis	H37Ra	 Difco	Laboratory,	Detroit,	MI,	USA	
	 Pertussis	toxin	 Sigma-Aldrich,	St.Louis	(Missouri),	USA	
Perfusion	
	 Heparin-Sodium	25000	Ratiopharm	 Ratiopharm	®	Ulm,	Germany	
	 Paraformaldehyde	4%	 Preparation	described	below	
8%	PFA	(Sigma-Aldrich)	in	dH2O,	
heated	up	to	55°C	and	stirred	
additional	10min,	
filtrated	and	mixed	in	a	1:1	ratio	with	
0,2M	
PB	(Phosphate	buffer),	pH	adjusted	to	
7,2-	7,8	
Cyrofixation,	Immunohistochemistry	and	Storage	
	 0.1%/20%	NaN3/H2O	 Merck	KGaA,	Darmstadt,	Germany	
	 Triton	X-100	C34H62O11	Sigma	S	 Sigma-Aldrich,	St.Louis	(Missouri),	USA	
	 Sucrose	 Sigma-Aldrich,	St.Louis	(Missouri),	USA	
	 Gibco	goat	serum	 Invitrogen	GmbH,	Darmstadt,	Germany	
	 NeuroTrace	®	500/525	fluorescent	
Nissl	stain	
Invitrogen	GmbH,	Darmstadt,	Germany	
	 Rabbit	x	Anti-Synapsin	I	Polyclonal	
antibody	‘AB1543	
Merck	Millipore	(division	of	Merck	
KGaA,	Darmstadt,	Germany)	
	 Synaptophysin	(D35E4)	XP	™	Rabbit	
mAB	#5461	
Cell	Signaling	Technology,	Inc.,	Danvers,	
USA	
	 Alexa-Fluor®	633	goat-anti-rabbit	IgG	
(H+L)	2mg/ml	MPA-21094		
Invitrogen	GmbH,	Darmstadt,	Germany	
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	 Alexa-Fluor®	647	donkey	anti-rabbit	
IgG	(H+L)	2mg/ml	in	0.1M	NaP,	0.1M	
NaCl,	pH	7.5,	5mM	azide	A31573	
Invitrogen	GmbH,	Darmstadt,	Germany	
	 Tissue	Tek	®	OCT	™	Compound	 Sakura	Finetek	Europe	B.V.,	Alphen	aan	
den	Rijn,	The	Netherlands	
	 Vectashield	Mounting	Medium	 Vector	Laboratories,	Inc.,	Burlingame	
(California),	USA	
 
 
3.1.2	Tools	and	materials	
Preparation	of	surgery	 	 	
	 Support	pillow	 Custom-made	
	 Metal	plate	 Custom-made	
	 Cast	Alnico	Button	Magnets	
(magnets)	
Eclipse	Magnetics	Ltd,	Sheffield,	UK	
	 Rubber	bands	 	
	 Micro	Pipettes	Blaubrand	®	
intraMARK	1/2/3/4/5µl	
(micropipettes/glass	capillaries)	
Brand	GmbH	und	Co.	KG,	Wertheim,	
Germany	
	 Plastipak	Syringe	20ml	Luer	Lok	™	
(syringe	for	virus	injection)	
BD™	Becton,	Dickinson	(New	Jersey)	
and	Company,	Franklin	Lakes,	USA	
	 Syringe	2ml	Injekt	®	luer	solo	
(syringe	for	injection	of	Ringer’s	
solution)	
B.	Braun	Melsungen	AG,	Melsungen,	
Germany	
	 Plastipak	Syringe	1ml		(for	Ketamine	
and	Xylazine	application)	
BD™	Becton,	Dickinson	(New	Jersey)	
and	Company,	Franklin	Lakes,	USA	
	 Sterican	®	Hypodermic	needle	
0.3x12mm	BL/LB	30Gx	½“	(KX	
injection)	
B.	Braun	Melsungen	AG,	Melsungen,	
Germany	
	 Hypodermic	needle	Microlance	™	3	
27G	¾“	Nr.	20	(NaCl	Injection)	
BD™	Becton,	Dickinson	(New	Jersey)	
and	Company,	Franklin	Lakes,	USA	
	 Hypodermic	needle	Microlance	™	3	
23G	¾“	Nr.	20	(hydration	during	
BD™	Becton,	Dickinson	(New	Jersey)	
and	Company,	Franklin	Lakes,	USA	
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surgery)	
	 Safety-Multifly®-Set	21Gx	¾“	TW	
0.8x19mm	(blood	collecting	system)	
SARSTEDT	AG	&	Co.,	Nümbrecht,	
Germany	
	 Eppendorf	plastic	tubes		 Eppendorf	
Surgical	Instruments	
	 Feather	stainless	steel	blade	
(surgical	blade)	
Feather	Safety	Razor	Co	LTD	
	 Noyes	Spring	Scissors	(titanium,	
12cm,	14mm	blades,	tip	diameter	
0.275,	angled	up	15013-12)	stainless	
Fine	Science	Tools	GmbH,	Heidelberg,	
Germany	
	 Vannas-Tübingen	Spring	Scissors,	
stainless	15003-08	
Fine	Science	Tools	GmbH,	Heidelberg,	
Germany	
	 Dumont	#3	Forceps	–Inox	Alloy	
(11cm,	straight,	0.17mm	x	0.1mm,	
11231-20)	
Fine	Science	Tools	GmbH,	Heidelberg,	
Germany	
	 Dumont	#5	Forceps	–	DUMOSTAR	®	
Inox	Alloy	(11cm,	straight	tip,	tip	
dimensions	0.1mm	x	0.06mm,	
11251-20)	
Fine	Science	Tools	GmbH,	Heidelberg,	
Germany	
	 Dumont	#2	Laminectomy	Forceps	-	
Inox	Alloy	(12	cm,	straight	tip,	
0.4mm	x	0.06mm,	11223-20)	
Fine	Science	Tools	GmbH,	Heidelberg,	
Germany	
	 Friedman	Pearson	Rongeur	curved,	
0.5mm,	14cm16221-14	
Fine	Science	Tools	GmbH,	Heidelberg,	
Germany	
	 Halsey	Needle	Holder,	Serrated	
Tungsten	Carbide	12501-13	
Fine	Science	Tools	GmbH,	Heidelberg,	
Germany	
	 Sugi	(absorbent	triangles)	 Kettenbach	GmbH	&	Co.	KG,	
Eschenburg,	Germany	
	 Cotton	applicator		 NOBA	Verbandmittel	Danz	GmbH	und	
Co	KG	
	 Olsen-Hegar	Needle	Holder	 Fine	Science	Tools	GmbH,	Heidelberg,	
Germany	
	 Ethicon	Ethilon	monofil	polyamide	
6-0,	667H	(skin	suture)	
Johnson	&	Johnson	Medical	GmbH,	
Norderstedt,	Germany	
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	 Ethicon	Vicryl	pooyglactin	910	4-0	
BB,	20cm	MIC101H	(muscle	suture)	
Johnson	&	Johnson	Medical	GmbH,	
Norderstedt,	Germany	
	
Immunization	 	
	 Luer	lock	1ml	1000	series	GASTIGHT	
syringe	#1001	
Hamilton	Bonaduz	AG,	
Bonaduz/Switzerland	
	 Plastipak	Syringe	1ml		(for	Ketamine	
and	Xylazine	application)	
BD™	Becton,	Dickinson	(New	
Jersey)	and	Company,	Franklin	
Lakes,	USA	
	 Sterican	®	Hypodermic	needle	
0.3x12mm	BL/LB	30Gx	½“	(KX	and	
MOG	injection)	
B.	Braun	Melsungen	AG,	
Melsungen,	Germany	
Perfusion	and	dissection	
	 Cellstar	tubes	50ml,	PP,	graduated,	
conical	bottom,	blue	screw	cap	
Greiner	Bio-One	GmbH,	
Frickenhausen,	
Germany	
	 Cellstar	tubes	15ml,	PP,	graduated,	
conical	bottom,	blue	screw	cap	
Greiner	Bio-One	GmbH,	
Frickenhausen,	
Germany	
	 Haemostat	scissors	12301-13	 Fine	Science	Tools	GmbH,	
Heidelberg,	Germany	
	 Dumont	Forceps	1026-15		 Fine	Science	Tools	GmbH,	
Heidelberg,	Germany	
PFA	preparation	
	 pH-test	sticks	4.5-10.0	C731	 Laborbedarf	ROTH	
	 Magnetic	stirring	bars	 Heidolph	Instruments	GmBH	&	
Co.	KG,	
Schwabach,	Germany	
	 Erlenmeyer	flask	(1l,	2l)	 Schott,	Elmsford	(New	York),	
USA	
	 Whatman®	quantitative	filter	paper,	
ashless,	circles	Grade	41,	150cm	
Whatman®	Sigma-Aldrich,	
St.Louis	(Missouri),	USA	
	 Plastic	funnel	 	
	 Thermometer	 	
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Cryofixation,	Cutting,	Immunohistochemistry	
	 Tissue	Tek	Cryomold	Biopsy,	
Disposable	Vinyl	Specimen	Molds,	
15x15x5mm,	10x10x5mm	
Sakura	Finetek	Europe	B.V.	,	
Alphen	aan	den	
Rijn,	The	Netherlands	
	 VWR	®	Petri	Dishes,	sterile		 VWR	International,	Radnor,	USA	
	 Glass	bottles	500ml	 Schott	Duran,	Elmsford	(New	
York),	USA	
	 Cellstar	tubes	15ml,	PP,	graduated,	
conical	bottom,	blue	screw	cap	
Greiner	Bio-One	GmbH,	
Frickenhausen,	
Germany	
	 Eppendorf	tubes	(1.5ml,	2ml)	 Eppendorf	AG,	Hamburg,	
Germany		
	 Pipettes	and	pipette	tips	(2-20µm,	20-
200µm,	100-1000µm)	
Eppendorf	AG,	Hamburg,	
Germany	
	 FALCON	®	Non-tissue	culture	treated	
plates,	flat	bottom	with	low	
evaporation	lid	(6-	wells,	12-wells,	24-
wells)	
FALCON	®	VWR	International,	
Radnor,	USA	
	 FALCON	®	Cell	culture	Inserts	3.0µm	
pore	size	PET	track-etched	membrane	
FALCON	®	VWR	International,	
Radnor,	USA	
	 Microscopic	slides	76x26mm	Thermo	
Scientific	ground	edges	90°	frosted	end	
Thermo	Fisher	Scientific	Inc,,	
Waltham,	Massachusetts,	USA	
	 Microscope	cover	slips	24x50mm,	
24x32mm	
Gerhard	Menzel	
Glasbearbeitungswerk	
GmbH	&	Co.	KG,	Braunschweig,	
Germany	
	 Laboratory	Film,	Parafilm	PM966	 Pechiney	Plastic	Packaging,	Inc,	
Chicago,	USA	
 
3.1.3	Technical	devices,	Software	
Preparation	for	surgery	
	 Wella	contura	HS61	(Hair	clipper)	 Wella,	Darmstadt,	Germany	
	 Heat	therapy	pump	Model	#TP702	
(for	heating	pad	for	anaesthetized	
Gaymar	Industries,	Orchard	Park	
(New	York),	USA	
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mice)	
	 Grundig	Microban	little	Guard	
(vacuum	cleaner	for	collecting	hair	
while	shaving	mice)	
Grundig,	Nürnberg,	Germany	
	 Vertical	Micropipette	Puller	Model	
P-30	
Sutter	Instrument	Company,	
Novato	(California),	USA	
	 Vortex-Genie	2	 Scientific	Industries,	Inc.,	
Bohemia	(New	
York),	USA	
	 Electrode	Manipulator,	small	
animal	microinjection	system	
David	Kopf	Instruments,	Tujunga	
(California),	USA	
Technical	devices	for	surgery,	immunohistochemistry,	PFA	preparation	 	
	 Olympus	Stereo	Microscope	
SZ51	(zoom	range	0.8-4)	
Olympus	GmbH,	Hamburg,	
Germany	
	 Olympus	KL	1500	LCD	(cold	light	
system	for	stereo	microscopy)	
Olympus	GmbH,	Hamburg,	
Germany	
	 Olympus	SZX16	fluorescence	
stereomicroscope	(zoom	range	
0.8-4,	Dissection	microscope)	
Olympus	GmbH,	Hamburg,	
Germany	
	 X-Cite	Series	120	Fluorescence	
Microscope	Light	Source	
Excelitas	Technologies	Corp.	
U.S.A.	
	 Magnetic	stirring	hotplate	MR	
3001K		
Heidolph	Instruments	GmBH	&	
Co.	KG,	
Schwabach,	Germany	
	 Leica	CM1850	cryostat		
	
Leica	Microsystems	GmbH,	
Wetzlar,	Germany	
	 Ismatec	IP	High	Precision	
Multichannel	Pump	
IDEX	Health	&	Science	GmbH,	
Futtererstr.	16,	97877	
Wertheim,	Germany	
	 AND	EK-2000i	Digital	Lab	Scale	 A&D	Company,	Limited,	Tokyo,	
Japan	
	 IKA	vibrax	VXR	(shaker)	 IKA®-Werke	GmbH	&	CO.	KG,	
Staufen,		Germany	
	
	 Olympus	IX71	inverted	
fluorescence	microscope	
Olympus	GmbH,	Hamburg,	
Germany	
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	 Confocal	microscope		 Olympus	GmbH,	Hamburg,	
Germany	
	 ImageJ/	FIJI	 National	Institutes	of	Health,		
Bethesda,	USA	
	 Fluoview	FV1000	 Olympus	GmbH,	Hamburg,	
Germany	
	 Microsoft	Office	2011	 Microsoft	Inc.,	Redmond,	USA	
 
 
3.1.4	Subjects	
Transgenic	animals	
To	study	acute	EAE	the	following	mice	lines	were	used:		Thy1-MitoCFP-S,	Thy1-MitoCFP-P	mice	
(Jackson	Laboratory	strain	designation:	Tg(Thy1-CFP/COX8A)S2Lich/J)	mice)	
To	 study	 chronic	 EAE	 the	 following	mice	 lines	were	 used:	 	 Biozzi	 ABH	 x	Thy1-MitoCFP-S	 and	
Biozzi	ABH	x	Thy1-MitoCFP-P.	BiozziABH	mice	were	obtained	 from	Harlan	Laboratories	 (strain	
designation	BiozziABH/RijHsd)	and	were	crossed	with	Thy1-MitoCFP-S	or	Thy1-MitoCFP-P	mice.	
F1	mice	were	analyzed.	All	mice	were	between	6-12	weeks	old	when	experiments	began	(C.	D.	
Sorbara	et	al.,	2014).	
Transgenic	mouse	lines	express	a	mitochondrially	targeted	CFP,	cyan	fluorescent	protein,	under	
the	control	of	the	neuron-specific	thy1-promotor	(Misgeld,	Kerschensteiner,	et	al.,	2007).	They	
weighed	between	20g	and	30g	at	the	beginning	of	the	experiments.		The	animals	were	housed	
in	groups	of	two	to	five	and	given	food	and	water	ad	libitum.		In	addition,	they	were	provided	
with	nesting	material	and	possibilities	to	retreat.		
All	experiments	using	mice	were	performed	in	accordance	with	the	institutional	guidelines	and	
approved	by	the	Study	Committee	of	the	Regierung	von	Oberbayern.		
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3.2	Methods	
	
3.2.1	Induction	of	Acute	Experimental	Autoimmune	Encephalomyelitis	
Induction	of	EAE	was	carried	out	by	Catherine	Sorbara	according	to	a	standard	protocol	(Abdul-
Majida	et	al.,	2000).	Here	is	a	brief	overview	of	the	procedure.	
The	 solution	 for	 immunization	 consisted	of	 a	 1:1	mixture	of	 200-350μg	purified	 recombinant	
myelin	oligodendrocyte	glycoprotein	(MOG,	N1-125,	expressed	in	E.coli,	was	kindly	provided	by	
Dr.	Doron	Merkler,	University	of	Geneva	or	made	by	in-house	technician),	diluted	down	to	the	
desired	 concentration	 (µg/µl)	 with	 sodium	 acetate	 and	 complete	 Freund’s	 adjuvant	 (Sigma)	
with	 5	mg/ml	mycobacterium	 tuberculosis	H37	Ra	 (Difco).	 This	 solution	was	mixed	with	 two	
Hamilton	 syringes	 with	 a	 connecting	 duct	 until	 completely	 emulsified	 and	 then	 injected	
subcutaneously	on	each	side	 (2x100μl)	and	on	 the	base	of	 the	 tail	 (50μl).	Pertussis	 toxin	was	
administered	 intraperitoneally	 in	 dosages	 of	 250-400ng	 on	 day	 0	 and	 day	 2	 following	
immunization	(C.	D.	Sorbara	et	al.,	2014).		
	
3.2.2	Induction	of	Chronic	Experimental	Autoimmune	Encephalomyelitis		
A	 chronic	 relapsing	 form	 of	 EAE	 was	 induced	 as	 follows.	 In	 this	 case	 mice	 were	 injected	
subcutaneously	with	emulsion	twice,	on	day	0	and	7.	The	solution	contained	100-200µg	purified	
recombinant	 MOG	 (N1-125).	 On	 day	 0	 and	 day	 1	 following	 each	 immunization	 100-200ng	
Pertussis	toxin	was	injected	intraperitoneally	(Baker	et	al.,	1990;	C.	D.	Sorbara	et	al.,	2014).		
	
	 73	
 
Fig.	3-1	Progression	of	clinical	score	in	EAE	
The	mice	are	placed	on	a	plane	surface	and	observed	for	their	spontaneous	movement.		Motor	function	
of	tail,	hind	limbs	and	fore	limbs	is	evaluated	on	the	displayed	scale.		
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Fig.	3-2	Progression	of	clinical	score	and	weight	in	the	chronic	relapsing	form	of	EAE	
This	representative	disease	course	is	calculated	from	7	Biozzi	ABH	x	Thy1-MitoCFP-S	mice.	The	black	
data	 point	 indicates	 the	 average	 day	 of	 relapse	 after	 remission	 (on	 average	 40	 days	 after	 onset	 of	
disease	and	around	50	days	after	immunization).		Each	point	represents	mean	±	s.e.m..	
	
	
3.2.3	Clinical	Scoring	
The	animals	were	given	a	clinical	score	depending	on	their	level	of	disability	and	weighed	daily.	
The	 standard	 scoring	 system	 for	 EAE,	 described	 by	 Abdul-Majid	 and	 used	 in	 our	 paper	 by	
Sorbara	 as	well,	was	used	with	 the	 following	parameters:	 0,	 no	detectable	 clinical	 signs;	 0.5,	
partial	 tail	weakness;	 1,	 tail	 paralysis;	 1.5,	 gait	 instability	 or	 impaired	 righting	 ability;	 2,	 hind	
limb	paresis;	2.5,	hind	limb	paresis	with	partial	dragging;	3,	hind	limb	paralysis;	3.5,	hind	limb	
paralysis	and	forelimb	paresis;	4,	hind	limb	and	forelimb	paralysis;	5,	death	(Abdul-Majid	et	al.,	
2000;	 C.	 D.	 Sorbara	 et	 al.,	 2014).	 This	 information	 was	 plotted	 on	 a	 graph	 and	 used	 to	
determine	the	time	point	of	injection	and	perfusion	(Fig.	3-2).	
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3.2.4	Surgery	–	Dorsal	Root	Ganglion	(DRG)	Injection		
Preparation		
Glass	 pipettes	 were	 prepared	 with	 a	 solution	 of	 rAAV-CAG-mOrange	 (titer:	 9x1012	 genome	
copies/ml,	diluted	1:5	in	sterile	PBS),	made	visible	by	adding	diluted	methylene	blue.	The	mice	
were	 anesthetized	 via	 intraperitoneal	 injection	 with	 a	 solution	 made	 out	 of	 Ketamine	 and	
Xylazine	(ketamine	87µg	per	g	body	weight,	xylazine	13µg	per	g	body	weight).	Half	the	dosage	
of	anesthesia	was	re-administered	once	per	hour	for	the	duration	of	the	surgery.	The	level	of	
anesthesia	was	tested	with	the	toe	pinch	reflex.		
An	electric	clipper	was	used	to	shave	the	hair	in	the	area	of	surgery.	Remaining	loose	hair	was	
removed	 with	 a	 damp	 swab.	 The	 mouse	 was	 positioned	 on	 a	 custom	 made	 plate	 with	 a	
padding.	 The	 extremities	 were	 fixated	 on	 this	 construction	 with	 elastic	 straps	 connected	 to	
adjustable	magnets.		A	supporting	pillow	was	placed	underneath	the	abdomen	of	the	mouse	in	
order	 to	 widen	 the	 inter-laminar	 spaces.	 To	 prevent	 dryness	 and	 irritation	 of	 the	 eyes,	 an	
ointment	was	applied	(Bepanthen®	Augen-	und	Nasensalbe).		
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Fig.	3-3	Equipment	for	animal	positioning	
The	mouse	is	fixed	upon	the	stage	with	magnet-mounted	rubber	bands.	The	positioning	pillow	is	placed	
underneath	 the	 lower	abdomen,	 in	order	 to	allow	a	widening	of	 inter-laminar	 spaces	 to	 facilitate	 the	
laminectomy.	Skin	and	muscles	are	pulled	to	the	sides	with	customized	magnet-mounted	retractors	to	
give	a	clear	view	of	the	surgical	site.	Image	adapted	from	(Misgeld,	Nikic,	&	Kerschensteiner,	2007).	
	
	
Laminectomy		
This	 procedure	 was	 performed	 under	 a	 surgery	 stereomicroscope	 at	 3-4-fold	 magnification.		
After	disinfection	of	the	shaved	skin	area	with	Cutasept,	a	20mm	long	skin	 incision	was	made	
over	the	 laminectomy	site	extending	from	the	 last	 thoracic	vertebra	Th12	to	the	sacrum.	The	
lumbar	 vertebra	 L5	 was	 located	 and	 an	 incision	 was	 made	 to	 both	 sides	 of	 the	 spinal	
protrusions.	The	muscles	were	scraped	away,	careful	 to	not	break	off	any	bone	 fragments	or	
harm	 the	 spinal	 cord.	 Blood	 was	 wiped	 off	 with	 Sugi®	 absorbent	 swabs.	 A	 pair	 of	 magnet-
mounted	retractors	was	used	to	hold	back	the	muscle	tissue	on	the	sides	to	give	a	clear	view	of	
the	surgical	site.		As	the	vertebral	arch	was	visible,	forceps	were	used	to	gently	lift	up	the	bone	
from	the	dura	of	 the	spinal	cord.	 In	order	 to	not	puncture	 the	dura	or	sever	 the	cord,	 spring	
scissors	with	upwards	aiming	blades	were	 inserted	on	the	 lateral	 sides	of	 the	 lamina	close	to	
the	pedicle.	The	vertebral	arch	was	 incised	and	the	 lamina	was	 lifted	up	to	expose	the	spinal	
cord	underneath.	This	dorsal	laminectomy	was	repeated	one	level	further	cranially	at	L4.		
On	 both	 sides	 the	 remaining	 pieces	 of	 the	 pedicles	 were	 removed	 using	 a	 Rongeur	 thereby	
revealing	the	DRGs.		
The	 pre-prepared	 glass	 pipettes	were	 then	 placed	 in	 a	 stereotactic	 frame	 directly	 above	 the	
surgery	site	and	exactly	positioned	over	the	DRG.	The	DRG	was	fixated	with	forceps	holding	the	
dura	up,	as	the	pipette	punctured	it	and	1µl	of	the	rAAV-CAG-mOrange	solution	was	injected.	
This	procedure	was	repeated	for	each	of	the	four	exposed	DRGs.	
At	 the	end	of	 the	 surgery	 the	 spinal	 cord	was	examined	 for	any	 remaining	pieces	of	bone,	 if	
necessary	 removed	 and	 the	 wound	 was	 closed	 (two	 stitches	 for	 the	 muscle	 layer	 and	 skin	
sutures).	Before	and	after	the	surgery	the	mouse	was	placed	in	a	padded,	pre-heated	cage	and	
500µl-1	ml	of	NaCl	was	injected	subcutaneously	to	rehydrate	the	animal.	
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The	principle	of	 the	surgery	was	the	same	for	control	and	acute	and	chronic	EAE	group,	with	
the	exception	 that	 chronic	EAE	animals	had	already	 lost	 some	weight	at	 the	 time	of	 surgery,	
therefore	required	less	anaesthetic,	more	careful	handling	and	longer	recovery.	
All	the	animals	were	placed	back	in	their	cages.		
For	 pain	 control	 during	 recovery	 the	 animals	 were	 subcutaneously	 injected	 with	 100µl	 of	
Temgesic	(Buprenorphine)	immediately	after	recovery	from	anesthesia	as	well	as	24h	and	48h	
post-surgery.		
	
	
Fig.	3-4	rAAV-CAG—mOrange	Injection	into	the	DRG	
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	(A)	Setup	for	DRG	injection,	(B)	Exposed	spinal	cord	after	laminectomy,	the	glass	pipette	punctuates	the	
dura	and	injection	of	the	virus	 into	the	DRG,	photograph	courteously	provided	by	Fabian	Laage-Gaupp	
(C)	schematic	display	of	DRG	injection	and	consequent	labeling	of	the	sensory	axons	in	the	spinal	cord	
with	an	orange	dye	
	
3.2.5	Perfusion	and	immunohistochemistry	
The	animals	were	 transcardially	perfused	on	day	21	after	 surgery	with	4%	Paraformaldehyde	
(wt/vol)	and	post-fixed	overnight	at	4°C.	After	fixation	the	spinal	cord	was	removed	and	stored	
in	 PBS/	 0.1%	 sodium	 azide	 at	 4°C.	 A	 3mm	piece	 of	 the	 lumbar	 spinal	 cord	was	 isolated	 and	
incubated	 in	 30%	 (wt/vol)	 sucrose	 in	 PBS	 for	 two	 days	 for	 cryoprotection.	 The	 tissue	 was	
embedded	 in	 TissueTek	 (Sakura	 Finetek	 Europe	 B.V)	 solution	 and	 frozen	 at	 -20°C.	 Using	 a	
cryostat	20µm	longitudinal	sections	were	cut.			
For	immunohistochemistry	the	sections	were	inserted	into	wells	(40-50	sections/well)	of	6-well	
plates	and	washed	three	times	for	10	minutes	with	1xPBS	on	the	shaker,	then	blocked	with	5%	
goat	serum	(vol/vol)	in	0.3%	Triton	X	for	1h.	The	sections	were	washed	again	with	0.3%	Triton	X	
(three	 times	 10	 minutes	 on	 the	 shaker).	 The	 primary	 antibody	 against	 synapsin	 I	 (Merck	
Millipore),	 a	 neuronal	 phosphoprotein	 which	 is	 associated	 with	 the	 cytoplasmic	 surface	 of	
synaptic	vesicles	(Huttner,	Schiebler,	Greengard,	&	De	Camilli,	1983)	(concentration	of	1:500)	in	
a	solution	of	2.5%	goat	serum	in	0.3%	Triton	X	was	added	and	incubated	for	12-24h	at	4°C.	The	
tissue	then	was	incubated	with	the	secondary	antibody	(Alexa-Fluor®	633	goat-anti-rabbit	IgG,	
Alexa-Fluor®	 647	 donkey	 anti-rabbit	 IgG,	 Invitrogen	 GmbH)	 at	 a	 concentration	 of	 1:500	 and	
counterstained	 with	 a	 nuclear	 dye	 (NeuroTrace	 ®	 500/525	 fluorescent	 Nissl	 stain,	 1:500,	
Invitrogen	GmbH)	for	12h	at	4°C.		
In	 the	end	 the	 free-floating	 slices	were	washed	with	1xPBS	and	mounted	on	 standard	object	
slide.	 They	were	 sealed	with	 Vectashield	with	 a	 cover	 plate	 and	 nail	 polish	 to	 prevent	 them	
from	drying	out.	Storage	in	between	scans	and	evaluation	was	at	-20°C.		
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Fig.	3-5	Dissected	central	nervous	system	of	a	mouse	
	(A)	Magnified	view	of	the	dorsal	root	ganglion	marked	with	blue	dye	in	order	to	verify	the	success	of	the	
injection,	(B)	Overview	of	the	dissected	nervous	system	of	a	mouse	with	blue	dyed	DRG,	(C)	schematic	
display	of	the	spinal	cord	part	used	for	analysis	(lumbar	cord,	injection	at	L5/6),	scale	bars	are	2mm	in	A	
and	5mm	in	B	
	
3.2.6	Imaging		
Sections	were	chosen	for	evaluation	based	on	the	expression	of	rAAV-CAG-mOrange	allowing	
for	the	visualization	of	dorsal	column	axons	with	collaterals	extending	into	the	gray	matter.	In	
EAE	tissue,	only	those	sections	with	densely	packed	inflammatory	lesions	in	the	dorsal	column	
through	which	rAAV-labeled	axons	passed	were	included	in	the	analysis.	
The	 images	of	the	fixed	tissue	were	taken	with	a	confocal	microscope	with	a	FV	1000	system	
mounted	 on	 an	 upright	 BX61	microscope	 (Olympus)	 equipped	with	 x10/	 0.40,	 ×20/0.85	 and	
×60/1.35	 oil-immersion	 objectives.	 Overview	 images	 were	 taken	 as	 evidence	 that	 the	
aforementioned	 criteria	 were	 met.	 To	 characterize	 the	 mitochondria	 within	 the	 distal	
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collaterals,	several	high-resolution	images	(60x,	2.5	zoom)	were	taken	within	the	gray	matter.	A	
z-projection	was	created	at	intervals	of	0.33	µm.	
	
								
	
Fig.	3-6	Imaging	of	the	distant	collaterals	of	axons	passing	through	a	lesion	
(A)	Schematic	of	the	scanned	section	from	the	spinal	cord	(B)	Confocal	image	of	the	sagittally	cut	lumbar	
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spinal	 cord	of	a	Biozzi	ABH	x	Thy1-MitoCFP-S	mouse	with	chronic	EAE	 (onset+	21days)	 showing	 rAAV-
CAGmOrange-labeled	 axons	 passing	 through	 a	 lesion	 and	 branching	 into	 the	 local	 gray	 matter	
(white:rAAV-positive	axons;	red:	nuclei	labeled	with	NeuroTrace	500/525;	arrowhead:	example	of	distal	
axon	arbor;	mitochondrial	 channel	not	 shown,	 from	Sorbara	et	 a.	 2014).	 (C)	High	 resolution	 image	of	
collaterals	 in	 the	 gray	matter	 (D)	Magnified	 view	 of	 the	 synapsin-positive	 boutons	 and	mitochondria	
within	the	axon	(rAAV-positive	axons,	red;	mitochondria	transgenic	ally	labeled	with	CFP,	green;	boutons	
labeled	with	synapsin	antibody,	blue)	Scale	bars	are	100µm	in	B,	20µm	in	C,	5µm	in	D.	
Rights	were	obtained	from	Elsevier.		
	
3.2.7	Evaluation	
The	scans	were	evaluated	with	 the	 Image	 J	 software.	Here,	 images	were	combined	such	 that	
rAAV-labeled	axons	were	pseudo-colored	in	red,	mitochondria	in	green,	and	synapsin	I-labeled	
structures	in	blue.		
Thirty	to	fifty	collaterals	with	synapsin	I-positive	boutons	(syn+	boutons)	were	chosen	randomly	
within	 a	 frame	 and	 examined	 for	 their	 mitochondrial	 content	 excluding	 synaptic	 structures.	
Synapses	could	be	identified	by	selecting	boutons	(swellings	in	the	course	of	the	collateral)	and	
comparing	with	the	synapsin	I	staining,	which	selectively	reveals	subunits	of	synapses.	
The	 collaterals	were	marked	with	 the	 segmented	 line	 tool	 to	measure	 the	 length.	 The	width	
was	measured	at	three	different	points	with	the	same	axon	and	averaged	in	order	to	calculate	
the	 area.	Mitochondria	 in	 the	 extra	 synaptic	 parts	 of	 the	 axonal	 arbor	were	 counted	 so	 the	
number	of	mitochondria	per	area	could	be	calculated.	Additionally	data	was	collected	on	the	
content	of	mitochondria	within	the	synapses.	
In	 a	 second	 evaluation	 collaterals	 were	 evaluated	 that	 contained	 both	 mitochondria	 and	
synapsin	I-positive	structures.	Then	the	mitochondria	within	the	entire	segment	were	counted.	
Synapsin	I-positive	bouton	structures	were	counted	and	their	width	and	length	was	measured.	
The	approximate	volume	of	a	bouton	was	calculated	by	assuming	an	ellipsoid	shape.		
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Fig.	3-7	Schematic	of	Synapse	and	Mitochondrial	Volume	calculation	
	
((x*y*z)/8)*(4/3)*π	=	volume	of	an	ellipsoid		
(((x*y*z)+(x1*y1*z1)+(xn*yn*zn))/8)*(4/3)*π=volume	of	n>1	ellipsoids	
	
The	same	equation	was	used	for	the	volume	calculation	of	the	mitochondria	(again	assuming	an	
ellipsoid	 shape).	 Furthermore	 the	 number	 of	 mitochondria	 inside	 the	 syn+	 boutons	 and	
between	the	synaptic	structures	was	counted.	
The	following	values	could	be	deducted	from	this	data:	mitochondria	(excluding	syn+	boutons)	
per	axon	area,	mitochondria	(including	syn+	boutons)	per	area,	mitochondria	per	axon	length,	
mitochondrial	 volume	 per	 syn+	 bouton,	 mitochondrial	 volume	 per	 syn+	 bouton	 volume,	
number	of	syn+	boutons	per	axon	length,	syn+	bouton	volume	per	axon.	
	
3.2.8	Statistical	analysis	
All	 evaluations	 were	 calculated	 with	 the	 GraphPad	 Prism	 software.	 The	 D’Agostino-Pearson	
normality	test	was	applied	to	test	for	normal	distribution	of	all	data	sets.	A	nonparametric	test	
was	 chosen	 to	 compare	 the	 means	 between	 groups,	 if	 the	 data	 sets	 were	 not	 distributed	
normally	 	 (Mann-Whitney	 test	 for	 two	samples,	Kruskal-Wallis	 test	with	a	subsequent	Dunn’s	
Multiple	 Comparison	 test	 for	 two	 or	 more	 samples).	 Each	 figure	 legend	 indicates	 the	 test	
chosen	with	its	corresponding	P	value	if	applicable.	
All	data	are	represented	as	the	mean	±	s.e.m..		
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3.2.9	Time	schedule	of	experiments	
	
Fig.	3-8	Time	schedule	for	experiments	(chronic	group)	
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4	Results	
4.1	Establishment	of	the	experimental	approach	
 
There	were	several	parameters,	which	needed	to	be	optimized	before	I	could	begin	to	collect	
my	experimental	data	and,	ultimately,	address	my	scientific	questions.	The	goal	was	to	analyze	
the	mitochondria	and	synapses	in	the	distal	collaterals	of	neurons	in	the	spinal	cord	that	pass	
through	 an	 inflammatory	 EAE	 lesion.	 Therefore	 I	 needed	 a	 defined	 population	 of	 axons	 to	
analyze	fluorescently	labeled	mitochondria	and	a	way	to	visualize	synapses.	
First,	a	defined	population	of	axons	could	be	 labeled	by	 inserting	a	virus	carrying	 the	genetic	
information	for	a	fluorescent	protein	that	is	upon	injection	incorporated	into	the	neuronal	DNA	
and	after	transcription	and	translation	in	the	axon	cytoplasm.		In	order	to	find	the	appropriate	
concentration	for	the	rAAV-CAG	mOrange	virus	with	a	titer	of	9x1012	genome	copies/ml,	 I	set	
up	a	dilution	series	whereby	I	injected	into	DRGs	the	following	dilutions:	1:2,	1:5,	1:10	and	1:20.	
The	1:5	dilutions	turned	out	to	be	best	suited	and	labeled	an	appropriate	amount	of	axons	such	
that	 it	 enabled	me	 to	 follow	 a	 single	 axon	 through	 a	 lesion	 and	 its	 collaterals	 into	 the	 gray	
matter.		
Dilution	 Concentration	 Outcome	
1:2	 4.5x1012	 Very	dense	labeling,	distally	one	could	not	follow	a	single	
collateral	due	to	overlap	between	labeled	collaterals	
1:5	 1.8x1012	 Enough	axons	were	labeled	to	evaluate	approximately	30	
collaterals	per	scanned	frame,	labeling	not	too	dense	to	
identify	individual	collaterals	"	chosen	dilution	
1:10	 9x1011	 Too	few	axons	were	stained	to	evaluate	
1:20	 4.5x1011	 Too	few	axons	were	stained	to	evaluate	
Tab.	4-1	Dilutions	of	rAAV-CAG-mOrange	injected	into	the	DRG	
 
Second,	 our	 laboratory	 had	 access	 to	 transgenic	 mouse	 models	 with	 fluorescently	 labeled	
mitochondria.	 To	 begin,	 I	 used	 Thy1-MitoCFP-P	mice	 because	 this	mouse	 line	 has	 previously	
proven	useful	in	assessing	mitochondria	in	large	caliber	axons	in	the	dorsal	tracts	of	the	spinal	
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cord	(Sorbara	et	al.	2014,	Nikić	et	al.	2011).	To	my	surprise,	this	turned	out	to	be	unsuitable	for	
evaluation	of	distal	axons.	While	the	large	caliber	axons	in	the	dorsal	column	appeared	healthy	
in	 control	 animals,	 the	 distal	 branches	 showed	 focal	 axonal	 dilations	 and	 mitochondrial	
changes.	Consequently,	I	switched	to	the	mouse	line,	which	expresses	a	lower	amount	of	CFP,	
and	showed	no	apparent	morphological	changes	of	axons in	controls,	the	Thy1-MitoCFP-S	mice.		
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Fig.	4-1	Comparison	of	axons	and	mitochondria	in	Thy1-MitoCFP-P	and	Thy1-MitoCFP-S	mice	
(A)-(F)	 Confocal	 3D-image	 projection	 of	 distal	 axon	 collaterals.	 (A,	 C)	 Thy1-MitoCFP-S	 control	 mouse	
showing	 healthy	 looking	 axon	 collaterals	 with	 mitochondria	 (B,	 D)	 Thy1-MitoCFP-P	 control	 mouse	
showing	 few	 mitochondria	 inside	 axons,	 (E,	 F)	 Confocal	 images	 from	 Thy1-MitoCFP-P	 control	 mice	
displaying	swelling	in	large	caliber	axons	stained	with	rAAV-CAG-mOrange	in	the	lumbar	spinal	cord.		
Scale	bars	are	10μm	in	A-H.	
 
Third,	 to	 stain	 the	 synapses	 we	 tested	 two	 possible	 antibodies	 directed	 against	 synaptic	
structures:	 	 first,	 an	 anti-synapsin	 I	 antibody	 (Merck	 Millipore)	 directed	 against	 a	 neuronal	
phosphoprotein	that	coats	synaptic	vesicles	and	secondly	an	anti-synaptophysin	antibody	(Cell	
Signaling	 Technology)	 directed	 against	 an	 integral	membrane	 glycoprotein	of	 the	presynaptic	
vescile	(Huttner	et	al.,	1983;	Wiedenmann,	Franke,	Kuhn,	Moll,	&	Gould,	1986).	For	visualization	
we	also	had	two	matching	secondary	antibodies	whose	emission	colors	were	far	red	(633	goat	–
anti-rabbit,	 Alexa	 Fluor)	 and	 near	 infrared	 	 (647	 goat-anti-rabbit,	 Alexa	 Fluor).	 To	 test	which	
combination	of	primary	and	secondary	antibody	would	be	best	suited	I	stained	several	sections	
of	lumbar	cord	of	two	animals	with	each	of	the	four	combinations.	The	best	match	proved	to	be	
the	 combination	 of	 the	 anti-synapsin	 I	 primary	 and	 the	 Alex633	 goat-anti-rabbit	 secondary	
antibody,	which	was	subsequently	used	for	all	evaluations.	
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Fig.	4-2	Anti-synaptophysin	versus	anti-synapsin	I	antibody	comparison	
(A-D)	Confocal	z-projection	of	gray	matter	 in	a	 lumbar	spinal	cord	section	of	a	healthy	Thy1-MitoCFP-S	
mouse	stained	with	 four	different	antibody	combinations	 (A)	displaying	anti-synaptophysin	as	primary	
and	 goat-anti-rabbit	 633	 as	 secondary	 antibody,	 (B)	 anti-synapsin	 I	 and	 goat-anti-rabbit	 633,	 (C)	 anti-
synaptophysin	 and	 goat-anti-rabbit	 647,	 (D)	 anti-synapsin	 I	 and	 goat-anti-rabbit	 647	 gave	 the	optimal	
staining	result	to	identify	synaptic	structures.	
Scale	bars	are	20µm	in	A-D.	
 
Finally,	since	multiple	sclerosis	is	in	many	cases	a	multiphasic	disease	in	which	an	early	relapsing	
remitting	phase	eventually	turns	into	a	chronic	progressive	phase,	it	is	important	to	study	both	
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phases	 when	 assessing	 the	 distal	 effects	 of	 inflammation	 on	 the	 mitochondria	 in	 its	 animal	
model	EAE.	Part	of	my	goal	was	to	determine,	at	what	time	point	during	the	disease	course	the	
transport	 deficits	 and	 mitochondrial	 changes	 found	 in	 the	 lesion	 affect	 the	 mitochondrial	
density	in	distal	collaterals.	Therefore	I	needed	to	investigate	two	different	groups	of	animals.	
One,	in	which	Thy1-MitoCFP-S	mice	were	immunized	to	induce	an	acute	form	of	EAE.	The	other	
a	chronic	EAE	group,	which	developed	an	early	disease	relapse	followed	by	a	progressive	form	
of	 the	 disease.	 For	 this	 BiozziABH	 x	 Thy1-MitoCFP-S	mice	were	 used.	 In	 both	 cases	 the	 EAE	
groups	needed	to	be	compared	with	respective	healthy	control	animals	on	the	corresponding	
genetic	background.	
The	part	 of	 interest	 in	 the	 spinal	 cord	was	primarily	 the	 lumbar	 region	 corresponding	 to	 the	
level	 of	 DRG	 injection	 (L4/L5).	 I	 intended	 to	 analyze	 the	 local	 collaterals	 that	 branch	 off	 the	
sensory	 axons,	 which	 pass	 through	 the	 dorsal	 column.	 In	 order	 to	 evaluate	 the	 effect	 that	
inflammation	and	thus	a	transport	impairment	has	on	distal	parts	of	the	neuron,	I	had	to	ensure	
that	the	axon	I	was	evaluating	had	passed	through	an	 inflammatory	 lesion.	 Inflammation	was	
analyzed	post-mortem	by	staining	infiltrating	and	resident	cells	with	a	well-established	nuclear	
dye	from	the	NeuroTrace	family	(Romanelli	et	al.	2013).	Lesions	in	EAE	are	characterized	by	an	
accumulation	of	 inflammatory	 cells	 and	 can	 thus	be	 visualized.	 	 It	 became	apparent	 that	 the	
acute	model	(onset	of	disease	+5	days)	showed	different	lesion	severity	and	location	than	the	
chronic	 model.	 This	 was	 especially	 the	 case	 in	 the	 lumbar	 cord.	 In	 the	 acute	 model	
microscopically	 one	 could	 identify	 rather	 large	 and	pronounced	 lesions	 in	 the	dorsal	 and	 the	
ventral	column,	whereas	in	the	chronic	model	(onset	of	relapse	+21	days)	lesions	were	smaller	
and	 more	 diffuse	 in	 the	 lumbar	 part	 of	 the	 spinal	 cord.	 In	 this	 model	 I	 could	 only	 identify	
pronounced	lesions	sometimes	extending	throughout	half	of	the	diameter	of	the	spinal	cord	in	
the	cervical	spinal	cord.	 In	order	to	proceed,	 I	needed	to	establish	criteria	 for	 lesion	size	that	
would	be	 included	 in	my	evaluation	to	ensure	standardization	between	samples.	 	Therefore	 I	
took	overview	pictures	with	tenfold	magnification,	measured	the	area	of	the	dorsal	column	and	
ventral	column	and	counted	the	cells	within	this.		Although	one	could	not	find	as	large	lesions	
as	 in	 the	 acute	model,	 nevertheless	 one	 could	 observe	 a	 threefold	 increase	 in	 inflammatory	
cells	in	the	dorsal	and	ventral	column	compared	to	the	controls.			
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Fig.	4-3	Cellularity	in	dorsal	and	ventral	column	in	chronic	EAE	tissue	is	3-fold	increased		
(A)-(D)	Confocal	z-projection	of	a	longitudinally	cut	lumbar	spinal	cord.	(A)	Thy1-MitoCFP-S	mouse	5	days	
after	acute	EAE	onset	and	its	respective	healthy	control	(B),	(C)	BiozziABH	x	Thy1-MitoCFP-S	mouse	with	
chronic	 EAE	21days	 after	 onset	of	 relapse	 and	 its	 respective	 control	 (D),	 (E)	Quantification	of	 the	 cell	
density	 per	 area	 in	 mm2	within	 the	 dorsal	 and	 ventral	 column	 (n=15-20	 frames,	 3	 mice	 per	 group,	
chronic	EAE	mice	showed	a	3	fold	increase	in	cell	density	in	the	dorsal	and	ventral	column	compared	to	
controls,	Kruskal	Wallis	Test)	
Bars	represent	mean	+	s.e.m.	Scale	bar	is	100μm	in	A,	200µm	in	B-D,		***	P	<	0.001	
 
As	 shown	 in	 Fig.	 4-3	 the	 BiozziABH	 x	 Thy1-MitoCFP-S	 mice	 at	 21	 days	 post	 onset	 had	 a	
significantly	 higher	 density	 of	 inflammatory	 cells	within	 the	 dorsal	 and	 ventral	 columns	 than	
those	of	controls.	This	ensures	for	further	evaluation	that	the	axons	passing	through	the	dorsal	
matter	have	passed	through	sites	of	inflammation.	
	
4.2	Distal	depletion	of	mitochondria	is	observed	in	chronic	but	not	in	
acute	EAE	
 
To	examine	 the	effects	on	acute	and	chronic	neuroinflammation	on	 the	organelle	 content	of	
distal	 axon	 segments,	 I	 studied	 mitochondria	 inside	 distal	 collaterals	 emanating	 from	 axons	
passing	through	a	lumbar,	dorsal	lesion	and	branching	into	the	local	gray	matter	at	the	level	of	
L4/L5.	 	 In	a	first	set	of	evaluations	 I	counted	the	number	of	mitochondria	per	area.	For	these	
BiozziABH	xThy1-MitoCFP-S	mice	at	21	days	after	onset	of	EAE	progression	and	their	respective	
controls	were	used.	For	an	acute	stage	comparison	of	 the	disease	Thy1-MitoCFP-S	mice	were	
used	 at	 onset	 of	 disease	 +	 5	 days	 and	 compared	 with	 their	 controls.	 All	 quantifications	 of	
mitochondrial	changes	in	the	acute	EAE	setting	have	been	performed	by	Catherine	Sorbara	and	
Naomi	Watson,	while	I	performed	the	quantitative	analysis	in	chronic	EAE.	
Together	we	found	a	depletion	of	extra-synaptic	mitochondria	within	the	distal	arbors	of	axons	
in	chronic	but	not	acute	EAE	(mitochondrial	density:	0.257	±	0.017	mitochondria/µm2	in	control	
axons	 for	 acute	 EAE,	 n	 (axon)=219,	 n(animal)=6;	 0.269	 ±	 0.034	mitochondria/µm2	 in	 control	
axons	for	chronic	EAE,	n(axon)=	65,	n(animal)=6;	0.262	±	0.021	mitochondria/µm2	in	acute	EAE	
axons,	 n(axon)=	 100,	 n(animal)=8;	 0.142	 ±	 0.012	 mitochondria/µm2	 in	 chronic	 EAE	 axons,	
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n(axon)=237,	 n(animal)=8),	 ***	 =	 P<0.001).	 Transport	 deficits,	 although	 striking	 in	 the	 acute	
phase,	do	not	affect	the	distal	axonal	supply	significantly	(likely	because	they	do	not	 last	 long	
enough).	 In	 contrast	 chronic	 inflammation	 leads	 to	 transport	 deficits	 that	 persist	 for	 several	
weeks	and	results	in	a	distal	depletion	of	mitochondria.		
Moreover,	I	found	that	when	stratifying	the	data	into	a	group	of	small	diameter	collaterals	and	
another	group	of	large	diameter	collaterals,	by	using	the	mean	width	from	all	axons	as	a	cut-off	
(defined	as	≤0.5477µm	mean	width,	 large	axons	as	>0.5477µm	mean	width)	the	small	caliber	
ones	are	not	significantly	more	affected	than	larger	caliber	axons.		
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Fig.	4-4	Distal	axonal	arbors	are	depleted	of	mitochondria	 in	a	chronic,	but	not	 in	an	acute	
model	of	EAE	
(A)	 Schematic	of	axon	 fragment	 (gray)	and	bouton	containing	mitochondria	 (cyan),	black	bars	 labeling	
the	area	counted	for	the	evaluation.	(B)	Three-dimensional	depiction	of	axon	collaterals	demonstrating	
mitochondrial	density	in	control,	acute	EAE	(Onset	+	5d),	and	chronic	EAE	mice	(Onset	of	progression	+	
21d),	 (mitochondria	 pseudocolored	 in	 cyan,	 axons	 in	 gray),	 image	 taken	 from	Sorbara	 et	 al.	 2014,	 (C)	
Quantification	of	mitochondrial	density	in	distal	axon	arbors	in	acute	(Onset+5d)	and	chronic	EAE	(Onset	
of	progression	+	21d)	and	their	respective	control	groups	Thy1-MitoCFP-S	(acute	model)	and	BiozziABH	x	
Thy1-MitoCFP-S	(chronic	model)	(n	=	65-237	axons	from	6-8	mice	per	group;	the	mitochondrial	density	is	
significantly	decreased	 in	chronic	EAE	compared	 to	control	group,	Kruskal	Wallis	Test),	 graph	adapted	
from	Sorbara	et	al.	2014	(D)	Quantification	of	mitochondrial	density	in	distal	axon	collaterals	according	
to	axon	width	in	chronic	EAE	(Onset	of	progression	+	21d)	models	in	BiozziABH	x	Thy1-MitoCFP-S	and	the	
respective	 control	 group.	 Small	 axons	 were	 defined	 as	 ≤0.5477µm	 mean	 width,	 large	 axons	 as	
>0.5477µm	 mean	 width.	 (n=	 103-134	 axons	 from	 6-7	 mice	 per	 group,	 density	 is	 highly	 significantly	
decreased	in	small	(p<0.0001)	and	in	larger	distal	axon	collaterals	(p<0.05)	compared	to	their	controls,	
mitochondria	in	small	axon	collaterals	are	not	significantly	lower	than	in	larger	collaterals,	Kruskal	Wallis	
Test).	
Graph	C	and	Illustration	B	are	adapted	from	our	publication	Sorbara	et	al.	2014.	Rights	were	obtained	
from	Elsevier.	Bar	represents	mean	+	s.e.m.	Scale	bar	is	5μm	in	(B)	***	P	<	0.001,	*	P<0.05	
 
 
4.3	In	chronic	EAE	a	larger	amount	of	collaterals	is	depleted	of	
mitochondria	
 
Having	 now	established	 that	 the	 density	 of	mitochondria	 is	 lower	 in	 distal	 axon	 segments	 in	
chronic	 EAE,	 I	 next	 assessed	 whether	 the	 depletion	 is	 widespread	 among	 all	 axons	 or	
heterogeneous,	with	some	collaterals	containing	none	at	all	and	others	the	normal	amount	of	
mitochondria.		
For	 this,	 a	 random	 choice	 of	 collaterals	 within	 a	 frame	 was	 evaluated	 for	 their	 content	 of	
mitochondria.	The	collaterals	were	qualitatively	grouped	accordingly,	given	a	score	of	0,	0.5	or	
1		(more	than	two	CFP-positive	structures	within	the	axon	fragment	and	boutons	equates	to	a	
score	of	1,	one	to	two	CFP-positive	structures	within	the	axon	fragment	and	boutons	is	a	score	
of	0.5,	no	CFP-positive	structures	is	given	a	0).		The	percentage	of	all	collaterals	not	containing	
any	visible	mitochondria	from	the	total	number	of	collaterals	was	calculated.	In	chronic	animals	
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there	was	a	significantly	larger	proportion	of	distal	collaterals	without	visible	mitochondria	than	
in	controls.		
 
Fig.	 4-5	A	 larger	proportion	of	distal	 axon	 collaterals	 are	depleted	of	 CFP+	mitochondria	 in	
chronic	EAE	compared	to	healthy	controls	
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(A),	 (B)	Three-dimensional	 rendering	of	axon	collaterals	 illustrating	the	proportion	of	axons	containing	
mitochondria	compared	to	a	chronic	model	of	EAE.	Arrow	heads	indicate	axons	with	mitochondria,	stars	
indicate	 axons	 with	 one	 to	 two	 CFP-positive	 structures,	 arrows	 indicate	 axons	 without	 CFP-positive	
mitochondria	 (C)	Pie	chart	of	 the	percentage	of	axons	containing	visible	CFP+	mitochondria	 in	healthy	
BiozziABH	x	Thy1-MitoCFP-S	control	animals	and		(D)	in	BiozziABH	x	Thy1-MitoCFP-S	chronic	EAE	(Onset	
of	progression	+	21d)	models.	(E)	Semi-quantitative	data	from	(C)	and	(D)	in	a	column	chart	(n=211-219	
from	6-7	 animals,	 healthy	 control	 animals	 had	 significantly	more	 axons	 containing	mitochondria	 than	
animals	with	chronic	EAE,	Mann	Whitney	test)	
Bars	represent	mean	+	s.e.m.	Scale	bar	is	20μm	in	A	and	B	***	P	<	0.001.	
 
4.4	Mitochondrial	distribution	in	distal	collaterals	in	chronic	EAE	is	
disturbed	
 
I	next	sought	to	understand	whether	the	axons	that	did	contain	mitochondria	 in	chronic	EAE,	
also	exhibited	a	striking	decrease	when	compared	to	healthy	controls.	
Firstly,	 the	 total	 amount	 of	 mitochondria	 throughout	 the	 entire	 visible	 axon	 length	 was	
counted.	 This	 included	 synapsin	 I-positive	 boutons.	 Interestingly,	 there	 was	 no	 significant	
difference	in	the	amount	of	mitochondria	in	chronic	and	control	animals.	
 
 
Fig.	 4-6	 The	 total	 number	 of	 mitochondria	 in	 axon	 fragments	 containing	 mitochondria	 is	
similar	in	chronic	EAE	and	control	mice	
(A)	Schematic	of	axon	fragment	and	bouton	with	mitochondria	displayed	in	green,	black	bar	indicating	
the	 parts	 evaluated,	 (B)	 Quantification	 of	mitochondria	 per	 area	 in	 µm2	 in	 chronic	 BiozziABH	 x	Thy1-
MitoCFP-S	 animals	 and	 their	 respective	 controls	 in	 preselected	 axons	 containing	more	 than	 one	 CFP-
positive	 structure	 that	 could	 be	 identified	 as	mitochondria,	 including	 intra-synaptic	mitochondria	 and	
A B 
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those	along	its	length	(n	=	518-608	axons,	6	mice	per	group;	no	significant	difference	in	density	between	
control	and	chronic	EAE	group,	Mann	Whitney	test).		
Bars	represent	mean	+	s.e.m.	
 
Since	no	difference	 in	 total	amount	of	mitochondria	could	be	 identified	between	control	and	
chronic	EAE,	I	then	examined,	if	there	were	any	changes	in	the	mitochondrial	distribution.	Prior	
studies	have	reported	mitochondrial	distribution	along	the	axon	changes	during	demyelination	
and	 remyelination.	 However,	 the	 distal	 effects	 of	 transport	 impairment	 and	 proximal	
inflammation	 on	 mitochondrial	 distribution	 are	 largely	 unknown	 (Zambonin	 et	 al.	 2011).	 To	
answer	 this,	 the	 proportion	 of	 the	 total	 mitochondria	 found	 within	 the	 synapsin	 I-positive	
boutons	was	 calculated.	 From	 this,	 only	 a	 slight	 difference	 in	 distribution	 could	 be	detected.		
The	 trend,	 however,	 is	 consistent.	 Control	 animals	 showed	 a	 slightly	 higher	 percentage	 of	
mitochondria	 inside	 the	 synapsin	 I-positive	 bouton	 than	 chronic	 EAE	 animals,	 as	 would	 be	
expected	given	the	aforementioned	transport	deficit		
Additionally,	 the	 total	 number	 of	 mitochondria	 inside	 the	 synapsin	 I-positive	 boutons	 was	
counted.	 This	 revealed,	 that	 controls	 indeed	 have	more	mitochondria	 per	 synapsin	 I-positive	
bouton	 than	 chronic	 animals.	 Consequently,	 in	 the	 extra-synaptic	 area,	 controls	 showed	 a	
significantly	lower	mitochondrial	density	than	chronic	animals.		
In	 summary,	 it	 can	 be	 concluded	 that	 the	 distal	 collaterals	 of	 axons	 passing	 through	 a	
neuroinflammatory	 lesion,	 in	 a	 chronic	 stage	 of	 EAE,	 undergo	 a	 change	 in	 distribution	 of	
mitochondria,	a	potentially	early	event	before	the	axons	are	completely	depleted.		Whereas	in	
the	healthy	state	mitochondria	are	transported	to	the	place	of	highest	energy	demand,	namely	
the	 synapses.	 	 This	process	appears	 to	be	malfunctioning	 in	distal	parts	of	an	 inflamed	axon.	
The	 chronic	 animals	 showed	 a	 higher	 density	 of	mitochondria	 in	 the	 segments	 between	 the	
synapsin	I-positive	boutons,	but	a	lower	density	of	mitochondria	inside	the	synapsin	I-positive	
boutons	compared	to	healthy	controls.	 
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Fig.	4-7	Overview	of	the	different	distributions	of	mitochondria	in	chronic	EAE	and	controls	
(A-J)	 Three-dimensional	 rendering	of	 a	distal	 collateral	 of	 an	axon	visualized	with	 rAAV-CAG-mOrange	
(red)	in	chronic	BiozziABH	x	Thy1-MitoCFP-S	mice	(A,	C,	E,	G,	I)	and	healthy	controls,	(B,	D,	F,	H,	J)	CFP-
positive	mitochondria	(green)	and	immunofluorescence	staining	for	the	synapsin	I	antigen	(blue)		
Confocal	images	at	60x	magnification	and	2.5	zoom;	Scale	bars	are	8μm	in	A-J.	
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Fig.	4-8	Mitochondrial	distribution	in	distal	axon	fragments	is	disturbed	in	chronic	EAE	
(A-C)	 Schematics	 of	 the	 distal	 axon	 fragment	 (red)	 and	 synapsin	 I-positive	 bouton	 (blue)	 with	
mitochondria	displayed	in	green,	black	bar	indicating	the	parts	evaluated;	(B)	is	corresponding	to	(E),	(C)	
to	(F),	(D)	Proportion	of	mitochondria	inside	synapsin	I-positive	boutons	compared	to	the	total	amount	
of	mitochondria	 in	 distal	 axons	 in	 BiozziABH	 x	 Thy1-MitoCFP-S	 animal	with	 chronic	 EAE	 compared	 to	
healthy	 controls,	 evaluated	 as	 displayed	 in	A	 	 (n	 =	 520-609	 axons,	 6	mice	 per	 group;	 chronic	 animals	
have	 a	 significantly	 lower	 percentage	 of	 mitochondria	 inside	 the	 synapses,	 Mann	 Whitney	 test).	 (E)	
Quantification	of	mitochondrial	density	in	distal	axons	excluding	synapsin	I-positive	boutons,	evaluated	
as	displayed	 in	(B)	 (n	=	547-608	axons,	6	mice	per	group;	chronic	animals	have	a	higher	mitochondrial	
density	 in	 distal	 axon	 fragments,	 synapsin	 I-positive	 boutons	 excluded,	 Mann	 Whitney	 test);	 (F)	
Quantification	of	the	number	of	mitochondria	per	synapsin	I-positive	bouton,	evaluation	as	displayed	in	
(C)	 (n=503-607	 axons,	 6	 mice	 per	 group,	 chronic	 animals	 have	 a	 significantly	 lower	 amount	 of	
mitochondria	 inside	the	synapsin	 I-positive	boutons	compared	to	controls,	Mann	Whitney	test),	 (G,	H)	
three-dimensional	rendering	of	an	axon	collateral	displaying	the	different	distributions	of	mitochondria	
in	 synapsin	 I-positive	 boutons	 and	outside	 in	 axon	 fragments.	 (Immunofluorescently	 labeled	 synapses	
with	 synapsin	 I	 (blue),	 axons	 are	 visualized	 by	 rAAV-CAG	mOrange	 (red)	 and	 CFP+	mitochondria	 are	
displayed	in	green,	confocal	images	taken	at	60x	magnification	and	2.5	zoom)	
Bars	represent	mean	+	s.e.m.	Scale	bars	are	8μm	in	G	and	H	***	P	<	0.001	
 
4.5	Mitochondrial	volume	inside	the	synapse	is	lower	in	chronic	EAE	
 
Previously,	 I	 revealed	 a	 decreased	 number	 of	mitochondria	 in	 synapsin	 I-positive	 boutons	 of	
animals	with	chronic	EAE	compared	to	controls.	However	the	sheer	number	does	not	give	any	
information	about	the	actual	mitochondrial	mass	inside	the	boutons.	The	volume	of	the	CFP	-
positive	cell	organelles	within	boutons	that	were	labeled	with	the	antibody	against	the	synaptic	
protein	 synapsin	 I	 was	 therefore	 calculated.	 The	mitochondrial	mass	 in	 chronic	 animals	 was	
significantly	 decreased	 compared	 to	 healthy	 controls.	 To	 determine	 if	 this	 change	 in	
mitochondrial	mass	has	 any	 effect	 on	 synapse	 volume,	 the	 volume	of	 the	 synapsin	 I-positive	
boutons	was	measured.	The	bouton	volume	was	found	to	be	decreased	as	well	in	chronic	EAE	
(Fig.4-10).	 To	 detect	 whether	 this	 results	 into	 proportionally	 smaller	 boutons	 with	 less	
mitochondrial	 volume	or	a	disproportionately	decreased	mitochondrial	mass,	 I	 calculated	 the	
ratio	of	mitochondrial	volume	and	synapse	volume,	which	was	found	to	be	decreased	in	chronic	
EAE.	From	this,	I	hypothesize	that	in	distal	axons	in	chronic	EAE,	mitochondrial	mass	decreases	
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more	than	the	bouton	size,	which	may	lead	to	improper	synaptic	functioning.	Synapses	seem	to	
not	only	decrease	in	size	but	also	be	devoid	of	mitochondria	as	illness	continues	in	chronic	EAE.		
	
 
 
 
Fig.	4-9	Mitochondrial	volume	is	decreased	in	chronic	EAE	boutons	
(A)	Volume	of	mitochondria	per	synapsin	I-positive	bouton	in	µm3	in	distal	axon	collaterals	in	BiozziABH	x	
Thy1-MitoCFP-S	animal	with	chronic	EAE	compared	to	healthy	controls	(n	=	502-603	axons,	6	mice	per	
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group;	chronic	animals	have	a	significantly	lower	volume	of	mitochondria	inside	the	synapsin	I-positive	
boutons,	 Mann	 Whitney	 test).	 (B)	 Ratio	 of	 mitochondrial	 volume	 to	 bouton	 volume	 in	 distal	 axon	
collaterals	 (n	=	499-608	axons,	6	mice	per	group;	chronic	animals	have	a	significantly	 lower	ratio	 than	
healthy	controls,	Mann	Whitney	test);	(E-J)	three-dimensional	rendering	of	an	axon	collateral	displaying	
the	decreased	ratio	of	mitochondrial	volume	to	bouton	volume	along	the	axon	fragment	in	chronic	EAE	
animals	 (C-E)	 and	 controls	 (F-H)	 (axons	 are	 visualized	 by	 rAAV-CAG	 mOrange	 (red)	 and	 CFP+	
mitochondria	are	displayed	in	green,	confocal	images	taken	at	60x	magnification	and	2.5zoom)	
Bars	represent	mean	+	s.e.m.	.	Scale	bars	are	2μm	in	C-H	***	P	<	0.001,	n.s.	P	>	0.05	
 
 
4.6	The	number	of	synapsin	I-positive	boutons	remains	unchanged	in	
chronic	EAE	
	
Since	the	mean	volume	of	the	bouton	is	affected	by	chronic	EAE	at	21	days	after	the	onset	of	
progression,	I	examined	whether	the	total	number	of	synapses	undergo	any	changes.	For	this,	
the	number	of	synapsin	I-positive	boutons	in	the	distal	axon	collaterals	was	counted	per	micron	
collateral	 length.	 There	 was	 no	 difference	 in	 the	 number	 of	 synapsin	 I-positive	 boutons	 in	
chronic	EAE	animals	compared	to	controls.	As	described	above,	for	this	first	set	of	evaluations,	
a	random	selection	of	collaterals	within	one	frame	was	chosen	for	evaluation,	notwithstanding	
their	 content	 of	 CFP-positive	 organelles	 (mitochondria).	 Then	 to	 closer	 examine	 only	 those	
axons	 containing	mitochondria,	 I	 conducted	 a	 second	 count	 of	 all	 axon	 collaterals	 and	 once	
again	found	no	significant	difference	in	the	synapse	number	between	chronic	EAE	and	control	
animals.		
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Fig.	4-10	Volume	of	synapsin	I-positive	boutons	is	decreased	while	density	is	equal	in	chronic	
EAE	compared	to	control	animals		
(A)	-	(F)	three-dimensional	reconstruction	of	confocal	 images	of	 lumbar	spinal	cord	collaterals	(red)	(A,	
D)	 synapsin	 I	 staining	 (blue)	 (B,	E)	and	their	overlay	 (C,	F)	 in	BiozziABH	x	Thy1-MitoCFP-S	animals	with	
chronic	EAE	(D-F)	compared	to	healthy	controls	(A-C)	displaying	the	decrease	in	volume	of	the	boutons	
while	the	number	is	not	affected.	(G)	Quantification	of	synapsin	I-positive	boutons	per	µm	in	distal	axon	
collaterals	 containing	 CFP-positive	 mitochondria	 	 (n=500-606	 axons,	 6	 mice	 per	 group,	 no	 significant	
difference	in	synapsin	I-positive	bouton	frequency	could	be	detected	between	chronic	EAE	animals	and	
healthy	controls,	Mann	Whitney	test)		(H)	Quantification	of	mean	volume	of	synapsin	I-positive	boutons	
per	axon	(n=502-603	axons,	6	mice	per	group,	bouton	volume	in	chronic	EAE	was	significantly	decreased	
compared	to	healthy	controls,	Mann	Whitney	test),		
Bars	represent	mean	+	s.e.m.	Scale	bars	are	4	μm	in	A-F	n.s.	P	>	0.05,	***	P	<	0.001	
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5	Discussion	
	
5.1	The	distal	effects	of	the	transport	defict	on	mitochondria	
	
This	study	was	aimed	at	examining	 the	distal	effects	of	 the	 transport	block	 in	EAE,	an	animal	
model	 of	 Multiple	 Sclerosis.	 Prior	 to	 this	 study	 we	 found	 an	 inhibition	 of	 anterograde	 and	
retrograde	transport	during	acute	EAE	and	a	recovery	of	both	during	remission.			
In	 the	 chronic	 stage	 of	 EAE	 the	 inflammation	 is	more	 diffuse	 than	what	 is	 observed	 acutely.	
Mechanistically,	 the	transport	block	once	prominent	within	axons	of	an	acute	 lesion	has	now	
lessened	as	Catherine	Sorbara	has	shown	in	her	set	of	experiments	described	earlier.	However,	
full	 recovery	 is	 absent.	 The	 anterograde	 transport	 was	 affected	 more	 severely	 than	 the	
retrograde.	 This	 suggests	 a	 net	 deprivation	 of	 several	 hundreds	 of	 mitochondria	 per	 day	 of	
more	 distal	 parts	 of	 the	 axon	 (C.	 D.	 Sorbara	 et	 al.,	 2014).	 As	 reported	 in	 other	
neurodegenerative	diseases	such	as	Amyotrophic	Lateral	Sclerosis		and	Alzheimer’s	disease,	an	
impairment	to	axonal	transport	of	mitochondria	can	lead	to	a	distal	reduction	of	mitochondrial	
mass	(Calkins,	Manczak,	Mao,	Shirendeb,	&	Reddy,	2011;	Marinkovic	et	al.,	2012).	
The	 implications	of	 the	pervasive	 transport	deficit	 for	mitochondria	 in	 the	distal	 arbor	of	 the	
neuron,	the	synapses	and	the	axon	terminals	in	general	has	been	the	subject	of	this	work.	
	
5.1.1	Distal	mitochondrial	depletion	in	chronic	EAE	
When	examining	mitochondria	 inside	distal	extra-synaptic	parts	of	collaterals	from	axons	that	
passed	through	a	lesion,	I	found	a	significant	reduction	in	number	in	chronic	EAE	compared	to	
healthy	controls.	However	no	significant	loss	of	mitochondria	could	be	detected	in	acute	EAE,	
likely	because	transport	deficits	have	not	lasted	long	enough	to	cause	significant	distal	effects.	
To	 clarify	 if	 the	 decrease	 of	 mitochondria	 was	 limited	 to	 the	 smaller	 axons,	 I	 divided	 the	
collaterals	analyzed	into	a	smaller	and	a	larger	caliber	group,	by	using	the	mean	diameter	as	a	
cut	off	value.	I	could	not	find	any	difference	in	mitochondrial	content	between	the	two	groups	
though.	Most	likely	this	was	because	all	distal	axons	I	included	into	my	evaluation	were	already	
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very	 small.	 When	 analyzing	 the	 relationship	 between	 the	 axon	 caliber	 and	 mitochondrial	
content,	I	found	a	directly	proportional	correlation	in	control	and	chronic	EAE.		
By	 counting	mitochondria	 in	 a	 random	 selection	of	 distal	 collaterals	 regardless	whether	 they	
contained	any	CFP-positive	mitochondria	or	not,	I	included	even	those	axons	in	my	data,	which	
might	 have	 contained	 mitochondria	 but	 did	 not	 express	 the	 fluorescent	 protein.		
Consequentially,	an	axon	collateral	 that	did	not	contain	any	visible	mitochondria	could	either	
imply,	that	the	mitochondria	were	truly	depleted	by	proximal	inflammation	or	they	just	did	not	
express	CFP	and	could	hence	not	be	visualized.	To	better	understand	how	large	the	fraction	of	
collaterals	 was,	 which	 did	 not	 show	 any	 CFP-positive	 mitochondria	 I	 conducted	 a	 semi-
quantitative	 evaluation	 of	 the	 mitochondrial	 count	 of	 every	 collateral	 in	 a	 frame.	 Those	
collaterals	without	any	CFP-positive	mitochondria	classified	as	0,	those	with	one	to	two	as	0.5	
and	those	with	more	than	two	CFP-positive	organelles	were	given	a	score	of	1.	 	Through	this	
evaluation	 I	 found	 that	 animals	 with	 chronic	 EAE	 had	 a	 smaller	 proportion	 of	 collaterals	
containing	 more	 than	 two	 CFP-positive	 mitochondria	 (60%),	 as	 opposed	 to	 healthy	 animals	
(80%).	Collaterals	entirely	without	mitochondria	represented	9%	in	healthy	animals	and	37%	in	
chronic	EAE.		Furthermore	the	collaterals	with	two	or	less	CFP-positive	mitochondria	made	up	
10.5%	 of	 healthy	 animals,	 whereas	 it	 represented	 only	 a	 fraction	 of	 2.8%	 in	 chronic	 EAE	
animals.	Consequently	the	number	of	collaterals	entirely	depleted	of	mitochondria	was	found	
increased	in	chronic	EAE	while	the	fractions	of	axons	collaterals	with	few	or	more	mitochondria	
are	decreased.		
Catherine	 Sorbara	 examined	 possible	 causes	 of	 the	 transport	 deficit.	 First,	 posttranslational	
modifications	 of	 tubulin	 such	 as	 S-acetylation	 and	 thyrosinated	 tubulin	 have	 shown	 to	 be	
present	in	normal-appearing	axons,	however	not	to	a	greater	extent	than	in	control	axons.		
Secondly,	as	described	above	Ca2+	is	an	important	mediator	of	mitochondrial	transport.	Chang	
and	colleagues	postulated	that	not	only	the	cellular	but	also	mitochondrial	Ca2+	level	regulates	
the	speed	of	the	organelle	movement	(K.	T.	Chang,	Niescier,	&	Min,	2011).	 It	 is	 likely	that	the	
transport	 deficit	 is	 partly	 due	 to	 Ca2+	 imbalance.	 Other	members	 of	 our	 lab	 have	 observed,	
raised	Ca2+	levels	in	16%	of	stage	0	axons	in	lesions	in	acute	EAE,	while	as	was	published	in	our	
paper	72%	of	stage	0	axons	in	acute	EAE	already	display	transport	deficits	(C.	Sorbara,	2015;	C.	
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D.	 Sorbara	 et	 al.,	 2014).	 Conclusively,	 Ca2+	 might	 not	 be	 the	 dominant	 factor	 in	 controlling	
transport	deficits.	However,	slight	alterations	might	not	have	been	picked	up	by	the	model	for	
Ca2+-sensing,	which	was	used.		
Thirdly,	 subcellular	 changes	 induced	 by	 NO	 might	 be	 responsible	 for	 the	 transport	 deficit	
detected	 in	 our	 project.	 	 Sorbara	 could	 show	 that	 application	 of	 an	 NO-donor	 could	 arrest	
transport,	 while	 a	 NO	 scavenger	 resulted	 in	 a	 reinitiation	 of	 transport	 (C.	 D.	 Sorbara	 et	 al.,	
2014).	This	suggests	a	connection	between	inflammation	and	early	transport	deficits.	
	
There	 are	 several	 possible	 confounding	 factors	 that	must	 be	 taken	 into	 consideration	 when	
interpreting	 these	 findings:	One	 is	 that	 it	would	 be	 possible	 that	 transection	 of	 axons	 in	 the	
lesions	would	 result	 in	 distal	 depletion.	 Here	 Ivana	Nikić	 described,	 that	 of	 all	 axons	 passing	
through	a	lesion	a	proportion	of	approximately	40%	is	affected	to	a	degree	that	FAD	(stages	1	
and	2)	can	be	observed.	Yet	she	also	showed	that	not	only	morphological	changes	to	the	axon	
but	 also	 on	 a	 subcellular	 level	 to	 the	 mitochondria	 are	 occurring	 very	 early	 during	 the	
inflammatory	 process	 (Nikić	 et	 al.,	 2011).	 Since	 those	 mitochondrial	 changes	 can	 precede	
axonal	 changes	 the	 axon	 might	 appear	 healthy,	 while	 subliminal	 detrimental	 changes	 are	
leading	 to	 axonal	 degeneration	 if	 recovery	 cannot	 salvage	 the	 axon.	 	 However	 after	 30	 days	
only	 a	 very	 small	 percentage	 of	 stage	 1	 axons	 remains.	 Some	of	 them	will	 have	 returned	 to	
stage	 0	 and	 recovered	 and	 some	will	 have	 proceeded	 into	 stage	 2.	 The	 vast	majority	 of	 the	
distal	 parts	 of	 those	 axons	 that	 have	 proximally	 degenerated	 until	 day	 30	 have	 most	 likely	
already	undergone	Wallerian	degeneration.	Hence	 they	do	not	 factor	 into	 the	evaluations	of	
this	 experimental	 setting.	 In	 fact	 the	 confounding	 effect	 of	 transected	 axons	would	 be	more	
difficult	to	exclude	at	the	acute	time	point,	where	we	however	did	not	detect	any	difference	in	
mitochondrial	 content.	 The	distal	 collaterals	 I	was	 looking	 at	 consequently	were	 those	 axons	
that	 survived	 hence	 had	 enough	 mitochondrial	 content	 to	 withstand	 the	 first	 bout	 of	
inflammation.		
A	 second	 possible	 confounding	 factor	 to	 be	 considered	 is	 mode	 of	 visualization	 by	 using	
transgenic	 mice.	 The	 animal	 model	 used	 in	 this	 study	 was	 developed	 by	 Misgeld	 and	
Kerschensteiner	(Misgeld,	Kerschensteiner,	et	al.,	2007).	Since	mitochondrial	dyes	are	difficult	
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to	 apply	 in	 the	 living	 animal,	 this	 model	 constitutes	 a	 unique	 opportunity	 to	 study	 in	 vivo	
mitochondrial	 dynamics	 and	 their	 pathological	 alterations.	 The	 CFP	 gene	 is	 fused	 with	 the	
mitochondrial	targeting	sequence	of	the	cytochrome	oxidase	(COX)	subunit	8A	gene,	regulated	
by	the	thy-1	promoter.	COX8A	is	a	nuclear	encoded	gene	that	transcribes	into	a	subunit	of	the	
cytochrome	c	oxidase	complex	of	 the	mitochondrial	 respiratory	 chain	 (Chinnery	et	al.,	 1999).		
There	are	several	possible	ways	for	the	subunit	 to	be	 integrated	 into	 its	destination	complex.	
Classically,	the	gene	is	transcribed,	translated	and	subsequently	integrated	into	the	respiratory	
chain	complex	of	the	mitochondrion	as	it	is	constructed	in	the	soma.	The	complete	functioning	
organelle	 is	 then	 transported	 to	 its	 destination.	 With	 a	 half-life	 of	 approximately	 24	 days	
synthesis	of	mitochondria	in	the	nucleus	and	transport	to	the	location	of	insult	would	be	far	too	
slow	to	react	to	inflammation.	They	have	the	ability	to	add	new	parts	by	fusion	or	split	off	parts	
by	fission	and	depending	on	energy	demand	they	get	redirected.	It	seems	likely	that	single	parts	
might	as	well	be	recruited	from	the	soma	as	entire	organelles	to	replace	broken	parts.	Recent	
research	on	peripheral	neurons	suggested	an	alternative	way	to	replace	broken	parts,	in	which	
mRNA	 is	 translated	 distally	 by	 a	 peripheral	 ribosome	 machinery	 (Merianda	 &	 Twiss,	 2013;	
Spillane,	 Ketschek,	Merianda,	 Twiss,	 &	Gallo,	 2013).	 Yoon	 and	 colleagues	 demonstrated	 that	
mitochondrial	mRNA	translation	and	thereby	protein	synthesis	can	also	take	place	outside	the	
soma	inside	the	axon	and	can	thus	promote	axon	survival	(B.	C.	Yoon	et	al.,	2012).	Thus	broken	
mitochondria	could	be	repaired	in	three	different	ways:	by	replacing	the	entire	organelle	by	a	
newly	 constructed	 one	 from	 the	 nucleus,	 by	 adding	 single	 parts	 or	 by	 distal	 translation	 of	
mRNA,	which	possibly	provides	a	source	for	more	than	one	single	part	depending	on	how	often	
it	is	translated	and	how	stable	this	mRNA	is.	
Bobylev	 and	 colleagues	 studied	 mRNA	 and	 mitochondrial	 transport	 in	 a	 model	 of	 paclitaxel	
induced	sensory	neuropathy	and	observed	a	decreased	transport	for	mRNA	while	the	transport	
of	 mitochondria	 was	 still	 intact	 (Bobylev	 et	 al.,	 2015).	 If	 this	 process	 functioned	 similarly	 in	
central	 neurons,	 this	 would	 suggest	 that	 our	 observations	 distally	 could	 be	 partly	 due	 to	
interrupted	mRNA	transport.	Since	mRNA	does	not	fluoresce	until	 it	 is	being	translated	into	a	
protein,	 some	 impaired	mitochondria	 could	 simply	 not	 be	 visualized	 anymore	 due	 to	 loss	 of	
fluorescent	 protein	 expression	 and	 not	 due	 to	 loss	 of	 the	 mitochondria	 itself.	 In	 this	 case	
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however	one	would	primarily	expect	 that	 the	brightness	of	 individual	mitochondria	might	be	
lower	 in	 the	affected	axons,	a	change	that	we	did	not	observe	 in	acute	or	chronic	EAE	axons	
neither	at	the	lesions	site	nor	in	more	distal	parts	of	the	axons.		
	
Lastly,	 the	 transgenic	 animals	 used	 do	 label	 a	 large	 proportion	 but	 not	 all	 axons.	 If	 an	 axon	
expresses	CFP-positive	mitochondria	all	mitochondria	are	tagged	but	in	all	animals	some	axons	
do	 not	 express	 CFP.	 For	 the	 quantitative	 analysis	 I	 have	 looked	 at	 a	 restricted	 area	 of	 the	
lumbar	 spinal	 cord	 in	 six	 animals	 per	 group.	 Since	 the	 branched	 tree	 of	 collaterals	 in	 the	
evaluated	 area	 could	 arise	 from	 few	proximal	 axons,	 a	 small	 difference	 in	proximally	 labeled	
axons	 could	 increase	 the	 distal	 difference.	 Such	difference	 in	 the	 individual	 labeling	 patterns	
should	however	of	course	 in	principle	affect	all	groups	analyzed	and	the	low	variability	of	the	
results	observed	within	groups	and	also	between	the	two	control	groups	as	well	as	the	acute	
EAE	group	(see	Figure	4-4)	make	it	very	unlikely	that	large	differences	in	the	peripheral	labeling	
pattern	exist	(and	act	as	a	confounder	of	our	analysis).			
In	conclusion,	it	is	thus	very	likely	that	the	distal	mitochondrial	depletion	I	have	observed	is	due	
to	 a	 true	 lack	 of	 mitochondria	 that	 results	 from	 a	 transport	 stop.	 These	 results	 are	 further	
confirmed	 by	 additional	 analyses	 (performed	 by	 Catherine	 Sorbara	 and	Naomi	Wagner)	 that	
showed	a	similar	decrease	in	mitochondrial	density	in	distal	thoracic	parts	of	the	parent	axons	
in	the	chronic	EAE	model	(Sorbara	et	al.,	2014).		In	this	evaluation	only	CFP-positive	axons	were	
included	and	a	significant	difference	could	be	detected.	
	
5.1.2	Distribution	and	volume	control	in	distal	mitochondria		
Moreover,	my	findings	suggest	that	there	is	a	maldistribution	of	mitochondria	distally.	When	I	
took	 a	 closer	 look	 at	 those	 collaterals	 that	 still	 contained	 CFP-positive	mitochondria,	 I	 found	
significant	 differences	 in	 distribution,	 but	 not	 in	 number.	 In	 those	 healthy	 appearing	 axons	
chronic	 EAE	 and	 control	 animals	 did	 not	 differ	 in	 total	 number	 of	 mitochondria	 per	 axon	
segment.	 In	 controls	 however	 the	majority	 of	mitochondria	was	 located	 inside	 the	 boutons,	
whereas	in	animals	with	chronic	EAE	this	ratio	was	shifted	towards	extrasynaptic	mitochondria.	
In	addition,	the	mitochondrial	volume	inside	the	boutons	was	found	decreased	in	chronic	EAE	
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compared	to	healthy	controls.	To	my	knowledge	there	have	been	no	reports	on	mitochondrial	
distribution	outside	of	a	lesion	in	EAE	yet.		
To	 better	 understand	 the	 implications	 of	 these	 results	 the	 following	 section	 outlines	 the	
crosstalk	between	mitochondrial	volume	control	and	the	axonal	transport	system.	
	
As	described	above	fusion	and	fission	are	closely	linked	with	mitochondrial	motility.	Mutations	
in	fusion	proteins	can	cause	an	interruption	or	reduction	of	transport	and	a	deficient	transport	
can	lead	to	alterations	in	mitochondrial	structure	(Baloh,	Schmidt,	Pestronk,	&	Milbrandt,	2007;	
S.	 Chen,	 Owens,	 &	 Edelman,	 2008;	 Sheng	 &	 Cai,	 2012).	 Several	 examples	 underline	 this	
relationship.	Misgeld	et	al.	described	stationary	mitochondria	that	were	twice	the	size	of	motile	
ones	(Misgeld,	Kerschensteiner,	et	al.,	2007).	Loss	of	function	mutations	in	the	Miro	gene	cause	
mitochondrial	 fragmentation	 (Fransson,	 Ruusala,	 &	 Aspenström,	 2006;	 X.	 Liu	 &	 Hajnóczky,	
2009;	Saotome	et	al.,	2008),	whereas	overexpression	leads	to	decreased	fission	with	elongated	
mitochondria	in	Drosophila	larval	motor	neurons	and	mitochondrial	aggregates	in	dopaminergic	
neurons	(Lee	&	Lu,	2014;	S.	Liu	et	al.,	2012;	Russo	et	al.,	2009).	The	dynein-dynactin	complex	
also	influences	mitochondrial	structure.	In	HeLa	cells	disruption	of	the	complex	leads	not	only	
to	a	redistribution	of	mitochondria	to	the	nuclear	periphery	but	also	to	the	formation	of	highly	
branched	 elongated	 mitochondrial	 structures	 (Varadi	 et	 al.,	 2004).	 In	 a	 mouse	 model	 of	
Charcot-Marie-Tooth	 disease	 with	 mutated	 MFN	 2,	 Detmer	 and	 colleagues	 found	 disturbed	
mitochondrial	 distribution;	 the	 mitochondria	 were	 observed	 in	 tight	 clusters	 in	 the	 axons	
(Detmer,	Vande	Velde,	Cleveland,	&	Chan,	2008).	Both	MFN	2	and	Miro	have	also	been	shown	
to	be	part	of	the	mitochondrial	transport	unit	(Misko,	Jiang,	Wegorzewska,	Milbrandt,	&	Baloh,	
2010).	 Pink1	 and	 parkin	 have	 also	 been	 reported	 to	 modify	 fusion	 and	 fission.	 Through	
PINK/parkin-mediated	degradation	of	MFN	and	OPA1	proteins,	 fusion	 is	 inhibited	 and	 fission	
promoted	through	the	pathway	(N.	C.	Chan	et	al.,	2011;	Kubli	&	Gustafsson,	2012).	
The	complex	interplay	between	fusion,	fission	and	transport	regulation	suggests	that	deficiency	
in	 one	 area	 leads	 to	 problems	 in	 others	 as	 well.	 In	 this	 study	 the	 distal	 depletion	 is	 likely	
explainable	 by	 the	 mere	 decrease	 in	 anterograde	 and	 increase	 in	 retrograde	 transport	 rate	
measured	 by	 Sorbara	 (C.	 D.	 Sorbara	 et	 al.,	 2014).	 	 The	 maldistribution	 however	 could	 be	
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explained	 in	 several	ways.	 It	might	either	be	an	effect	of	 the	proximal	 lesion,	which	 requires	
more	 energy	 to	 repair	 the	demyelinated	or	 otherwise	metabolically	 disturbed	 axon	 and	 thus	
redirects	mitochondria	 to	 retrograde	transport	 to	“help	out”	distally.	 It	could	be	a	 result	of	a	
distal	accumulation	of	dysfunctional	mitochondria	due	to	the	proximal	inflammation,	which	are	
marked	 for	 transport	back	 to	 the	 soma	and	are	 thus	 swept	out	of	 the	 synapses	and	 into	 the	
extrasynaptic	parts.	 It	could	be	the	result	of	a	dysfunctional	 interplay	of	transport	and	anchor	
proteins.	The	distal	transport	machinery	might	be	affected	similarly	as	the	proximal	part	of	the	
axon	 or	 it	 could	 be	 a	 compensatory	 effect	 to	 tissue	 inflammation	 in	 normal	 appearing	 gray	
matter.		
	
Metabolic	imbalance	
Previous	 studies	 on	 mitochondrial	 distribution	 showed	 an	 increased	 mitochondrial	 content	
during	demyelination,	remyelination	and	acute	EAE	(Kiryu-Seo	et	al.,	2010;	C.	D.	Sorbara	et	al.,	
2014;	 Zambonin	 et	 al.,	 2011).	 Namely,	 mitochondria	 accumulate	 in	 lesions	 where	 energy	
demand	is	high	and	fail	to	reach	their	actual	targets	-	the	synapses.		
Studies	 on	 myelinated	 axons	 have	 shown	 that	 mitochondrial	 transport	 is	 arrested	 by	 high	
activity	 of	 Na+/K+	 ATPases	 and	 elevated	 intracellular	 Ca2+	 levels	 (Zhang	 et	 al.,	 2010).	
Demyelinated	 axons	 have	 to	 compensate	 for	 their	 dysfunctional	 conduction	 by	 increasing	
Na+/K+	ATPase	activity	and	 inserting	more	Na+	channels	 into	their	membrane.	This	creates	an	
influx	 of	Na+,	which	 reverts	 the	Na+/Ca2+	 pump	 to	 exchange	Na+	 for	 Ca2+.	 As	 a	 result,	 axonal	
elevated	Ca2+	 leads	to	an	 increase	 in	mitochondrial	density	 in	demyelinated	parts	of	the	axon	
(Andrews	 et	 al.,	 2006;	 Hogan	 et	 al.,	 2009;	 Bruce	 D.	 Trapp	 &	 Stys,	 2009).	 Myelination,	
demyelination	 and	 remyelination	 can	 individually	 influence	 mitochondrial	 velocity	 and	 size,	
possibly	as	a	rescue	mechanism	providing	continuous	energy	to	the	axon	(Sheng	&	Cai,	2012).	
However,	 the	mitochondria	 being	 used	 to	 compensate	 the	 increased	 energy	 demand	 in	 the	
axons	might	therefore	be	lacking	in	the	synapses.		
Noticeably,	Catherine	Sorbara	showed	that	transport	deficits	also	occur	fairly	independently	of	
demyelination,	suggesting	changes	to	the	transport	machinery	as	one	of	the	earliest	events	in	
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EAE	and	possibly	MS	pathology	(C.	D.	Sorbara	et	al.,	2014).	Demyelination	might	therefore	be	
merely	contributing	to	an	already	existing	accumulation	of	mitochondria.		
	
Transport	and	anchoring	machinery	
Most	 likely	the	transport	deficit	not	only	affects	the	depletion	but	also	the	distal	distribution.	
Guo	 and	 colleagues	 demonstrated	 Miro’s	 role	 in	 distal	 mitochondrial	 distribution.	 Fewer	
synaptic	mitochondria	and	a	reduced	Ca2+	-buffering	capacity	has	been	seen	in	D.	melanogaster	
Miro	 mutants	 with	 impaired	 axonal	 transport	 (Guo	 et	 al.,	 2005).	 Since	 Miro	 is	 part	 of	 the	
anterograde	 transport	 system,	 which	 is	 interrupted	 in	 our	 model,	 this	 suggests	 a	 causative	
relationship	between	the	transport	deficit	and	mitochondrial	distribution.	
As	 anterograde	 transport	 was	 shown	 to	 be	 permanently	 reduced,	 proteins	 involved	 in	
anchoring	and	allocation	to	the	place	of	highest	energy	demand	such	as	syntabulin	might	also	
not	reach	their	destination	and	thus	contribute	to	the	difference	in	distribution.	Syntabulin	has	
been	 identified	 as	 an	 anchoring	 protein	 for	 mitochondria	 to	 synapses	 and	 as	 part	 of	 the	
anterograde	 transport	 unit	 (Cai	 et	 al.,	 2005).	 Studies	 on	 syntabulin	 mutant	 mice	 showed	
reduced	 synaptic	 activity,	 slower	 synapse	 recovery	 after	 high-frequency	 firing,	 and	 fewer	
stationary	mitochondria	within	 the	 synapse	 (Ma,	Cai,	 Lu,	 Sheng,	&	Mochida,	 2009).	A	 similar	
result	might	be	reached	by	inhibition	of	transport	of	syntabulin.		
	
Degradation	and	Evacuation	
Not	 only	 a	 functioning	 supply,	 but	 also	 an	 intact	 degradation	 and	 evacuation	 process	 for	
impaired	 mitochondria	 is	 necessary	 for	 axon	 homeostasis.	 The	 two	 main	 mechanisms	 to	
achieve	 that	 are	 mitophagy	 and	 retrograde	 transport.	 Sorbara	 showed	 that	 retrograde	
transport	 is	 elevated	 in	 axons	 proximal	 to	 the	 lesion	 (C.	 D.	 Sorbara	 et	 al.,	 2014).	 The	
mitochondrial	membrane	potential	might	play	a	 role	 in	 transport.	Miller	and	Sheetz	 reported	
that	 depolarized,	 possibly	 damaged	 mitochondria	 are	 being	 transported	 back	 to	 the	 soma	
through	 dynein-dynactin	 mediated	 retrograde	 transport,	 whereas	 mitochondria	 with	 a	 high	
membrane	 potential	 are	 being	 transported	 anterogradely	 (K.	 E.	 Miller	 &	 Sheetz,	 2004).	 The	
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mitochondrial	 depletion	 of	 the	 distal	 synapses	might	 be	 due	 to	 an	 increase	 in	 dysfunctional	
mitochondria	being	transported	back	to	the	soma.		
For	the	distal	compartment	mitophagy	is	crucial	for	immediate	quality	control	to	limit	oxidative	
damage.	 As	 explained	 in	 the	 introduction,	 Drp1	 induces	 fission	 in	 damaged	 mitochondria,	
splitting	off	 the	healthy	part	 (Losón	et	al.,	2013).	Due	to	reduced	membrane	potential,	PINK1	
accumulates	 on	 the	 surface	 and	 directs	 the	 E3	 ubiquitin	 ligase	 parkin	 towards	 the	 damaged	
organelle,	 which	 in	 turn	 targets	 the	mitochondrion	 for	 autophagy	 by	 an	 autophagosome	 (H.	
Chen	&	Chan,	2009).	Under	mediation	by	MFN1/2	and	OPA1,	 the	healthy	salvaged	part	 fuses	
with	other	healthy	mitochondria	parts	(Kubli	&	Gustafsson,	2012).	During	mitophagy,	the	outer	
membrane	proteins	such	as	Miro1	and	Miro2	are	degraded,	and	PINK	can	phosphorylate	Miro,	
attract	parkin	and	thus	target	the	damaged	part	for	proteasomal	degradation	(N.	C.	Chan	et	al.,	
2011).	 Due	 to	 the	 uncoupling	 of	 the	 mitochondria	 from	 its	 transport	 system,	 anterograde	
transport	may	be	inhibited	and	wider	ranging	transport	modifications	can	be	suggested	(N.	C.	
Chan	et	al.,	2011;	Sheng	&	Cai,	2012;	Wang	et	al.,	2011;	Yoshii,	Kishi,	 Ishihara,	&	Mizushima,	
2011).	Ashrafi	and	colleagues	showed	that	Parkin	and	PINK1	were	required	for	the	induction	of	
mitophagy	 in	 distal	 axons.	 PINK1	 and	 Parkin	 are	 however	 also	 components	 that	 have	 to	 be	
transported	 towards	 the	 distal	 compartments	 (Ashrafi	 et	 al.,	 2014).	 Since	 especially	
anterograde	transport	deficits	are	apparent	PINK1,	Parkin,	Miro	and	MFN	might	not	be	at	hand	
in	distal	axon	in	EAE.		This	possible	defect	in	the	degradation	system	could	also	account	partly	
for	 the	 fact	 that	 the	 number	 of	 mitochondria	 I	 counted	 in	 the	 axons	 with	 CFP-positive	
mitochondria	 are	 not	 significantly	 different	 in	 chronic	 and	 control,	 the	 quality	 might	 be	
different	 though.	To	examine	this	 further	electromicroscopy	studies	would	give	better	 insight	
into	the	pathology	of	individual	mitochondria	and	would	not	have	to	rely	on	CFP	tagging.	
	
5.2	The	distal	effects	of	the	transport	deficit	on	synapses	
	
MS	 pathology	 involves	 inflammation	 initiated	 by	 microglia	 and	 macrophages,	 demyelination	
stripping	the	axon	of	its	protective	shield	and	incapacitating	it	to	successfully	transmit	signals.	
Mitochondrial	 changes	 then	 deplete	 the	 axon	 of	 its	 energy	 supply	 and	 disturbing	 its	 Ca2+	
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homeostasis.	 Transport	 deficits	 amplify	 this	 process	 two-fold:	 In	 the	 lesion	 they	 inhibit	
mitochondrial	 relocation	and	 their	proper	distribution	 to	places	of	energy	demand	and	cause	
axonal	 swellings	 culminating	 in	 rupture	 and	 eventually	 axonal	 transection.	 Distal	 from	 the	
lesion	the	local	transport	block	leads	to	a	depletion	(and	altered	distribution)	of	mitochondria	in	
distal	axon	segments	likely	resulting	over	time	in	distal	axonal	and	synaptic	dystrophy.	Indeed	
such	synapse	loss	appears	to	be	widespread	in	advanced	stages	of	MS	(Jürgens	et	al.,	2016)	and	
disturbances	 of	 synaptic	 plasticity	 have	 been	 linked	 to	 clinical	 progression	 (Nisticò,	 Mori,	
Feligioni,	Nicoletti,	&	Centonze,	2014). 
	
5.2.1	Synaptic	pathology	in	EAE	and	MS	
There	 are	 several	 theories	 on	 the	 causes	 of	 synaptic	 dysfunction	 and	depletion. First,	 in	 line	
with	the	findings	of	our	work,	impaired	axonal	transport	can	contribute	to	synaptic	damage	and	
malfunction.	Mitochondria	are	thought	to	play	a	key	role	in	synapse	integrity	and	mitochondrial	
transport	to	and	from	synapses	has	been	shown	to	influence	synaptic	transmission,	density	and	
plasticity	(Li	et	al.,	2004).	Specifically,	mitochondria	are	able	to	relocate	to	dendritic	protrusions	
with	increased	synaptic	activity	with	the	help	of	Drp1	and	OPA1	(Li	et	al.,	2004).	Consequently,	
an	 alteration	 of	 those	 transport	 proteins	 decreased	 synapse	 density.	 In	 the	 loss-of-function	
model	of	 syntabulin,	anterograde	 transport	of	mitochondria	was	 impaired	as	well	as	 synaptic	
function	 (Ma	 et	 al.,	 2009).	 This	 malfunction	 might	 be	 partly	 due	 to	 a	 specific	 disability	 of	
mobilizing	 reserve	 pool	 vesicles	 in	 synapses	 depleted	 of	 mitochondria,	 which	 are	 mainly	
recruited	during	 repetitive	 stimulation.	This	 recruitment	 failure	was	not	due	 to	Ca2+	overload	
but	rather	to	ATP	depletion	(Verstreken	et	al.,	2005).	
In	 order	 to	 secure	 proper	 function	not	 only	 organelles	 but	 also	 synaptic	 proteins	 have	 to	 be	
transported	to	the	synapse	via	axonal	transport.		In	demyelinated	areas	of	hippocampal	tissue	
samples	 from	 MS	 patients,	 synaptic	 molecules	 were	 decreased,	 i.e.,	 synaptophysin,	
synaptotagmin,	post-synaptic	density	protein	(PSD95),	calmodulin-associated	serine/threonine	
kinase	 (CASK),	glutamate	 receptors,	 i.e.,	AMPA-	and	NMDA-receptors,	glutamate	 transporters	
and	also	KIF1A,	another	key	motor	protein	in	fast	axonal	transport.		This	suggests	that	transport	
deficits	 and	 ensuing	 synaptic	 dysfunction	 in	 hippocampal	 neurons	 can	 offer	 a	 molecular	
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explanation	for	deficits	in	learning	and	cognition	in	MS	patients	(Dutta	et	al.,	2011).	Syntabulin	
mediates	presynaptic	protein	allocation	towards	the	synapse	via	association	with	KIF5B	(Ma	et	
al.,	 2009).	 Ma	 and	 colleagues	 have	 demonstrated	 its	 crucial	 role	 in	 presynaptic	 function	 by	
inhibiting	its	expression.	They	found	that	syntabulin	aids	in	synaptic	maturation,	sustains	basal	
transmission	in	mature	neurons,	prevents	synaptic	depression	during	high-frequency	firing,	and	
promotes	 recovery	 of	 vesicle	 and	 short-term	 plasticity	 (Ma	 et	 al.,	 2009).	 Zhu	 and	 colleagues	
showed	 a	 reduction	 in	 synapsin	 I,	 synaptophysin,	 and	 PSD95	 immunoreactivity	 in	 gray	 and	
white	matter	 in	 acute	 EAE	 and	during	 relapse.	 They	 also	 demonstrated	 during	 the	 remission	
phase	of	EAE	a	certain	capacity	 for	 regeneration	of	all	measured	synaptic	proteins,	albeit	not	
completely	 (Zhu	et	al.,	2003).	This	partial	 remission	would	also	be	consistent	with	 the	partial	
recovery	of	mitochondrial	transport	that	was	observed	in	chronic	stages	of	EAE	(Sorbara	et	al.,	
2014).	 
 
In	 addition	 to	 transport	 disturbances	 other	 inflammatory	 mechanisms	 could	 contribute	 to	
synaptic	pathology	in	neuroinflammatory	conditions.	For	example,	glutamate	excitotoxicity	has	
recently	 gained	 attention	 as	 a	 contributing	 factor	 in	 MS	 pathology.	 	 It	 was	 shown	 to	 be	
especially	 harmful	 in	 the	 areas	 of	 most	 synaptic	 input.	 Faddis	 and	 colleagues	 showed	 that	
glutamate	 receptor	 activation	 could	 cause	dendritic	 beading	 and	 subsequent	 loss	 of	 synaptic	
connection,	 whereas	 upon	 deactivation	 synaptic	 connections	 would	 reestablish	 themselves	
(Faddis,	 Hasbani,	 &	 Goldberg,	 1997;	 Hasbani,	 Schlief,	 Fisher,	 &	 Goldberg,	 2001).	 Pitt	 and	
colleagues	 suspected	 that	glutamate	excitotoxicity	 could	be	an	 important	mediator	of	 axonal	
damage,	oligodendrocyte	death	and	clinical	progression	 in	EAE	based	on	the	observation	that	
AMPA/kainate	 antagonists	 were	 able	 to	 ameliorate	 clinical	 symptoms	 (Pitt	 et	 al.,	 2000).	
Glutamate	has	 also	 been	 shown	 to	 correlate	with	 disease	 activity.	 In	 the	CSF	of	MS	patients	
with	active	lesions	on	MRI,	or	during	a	clinical	exacerbation,	glutamate	levels	were	significantly	
elevated	 compared	 to	 those	 in	 patients	with	 no	 signs	 of	 active	 lesions	 on	MRI	 or	 during	 the	
clinically	stable	remission	phase	(Sarchielli,	Greco,	Floridi,	Floridi,	&	Gallai,	2003).	 
There	 are	 several	 possible	 contributors	 to	 the	 glutamate	 excess	 in	 an	 inflammatory	 setting.						
(1)	Microglia	and	macrophages	release	large	quantities	upon	activation.	(2)	Demyelinated	axons	
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reverse	 the	 Na+-dependent	 glutamate	 transporter,	 which	 decreases	 the	 uptake	 capacity	 for	
glutamate	and	possibly	even	triggers	its	release	into	the	extracellular	space.	(3)	Astrocytes	can	
not	 only	 take	 up	 but	 also	 release	 glutamate	 triggered	 by	 Ca2+-dependent	 or	 -independent	
mechanisms	 (Kostic,	 Zivkovic,	 &	 Stojanovic,	 2013).	 During	 EAE,	 glutamate	 transmission	 in	
cerebellar	Purkinje	cells	 is	 increased,	owing	to	prolonged	spontaneous	excitatory	postsynaptic	
currents	 (sEPSC).	 This	 is	 caused	 mainly	 by	 reduced	 re-uptake	 by	 receptors	 such	 as	 the	
glutamate	 aspartate	 transporter/	 excitatory	 amino	 acid	 transporter	 1	 (GLAST/EAAT1)	 on	
astrocytes,	which	are	downregulated	by	 IL-1β	 signaling	abundant	 in	EAE	cerebellum	 (Georgia	
Mandolesi	et	al.,	2013)	.		
 
Finally,	in	addition	to	glutamate	release,	microglia	and	macrophages	can	contribute	to	synaptic	
pathology	in	MS	via	other	inflammatory	mechanisms.	As	described	by	Stagi	and	colleagues,	the	
increased	 production	 of	 NO	 by	 microglia	 in	 a	 neuroinflammatory	 lesion	 can	 inhibit	 the	
anterograde	 transport	 of	 EGFP-tagged	 synaptophysin	 and	 synaptotagmin,	 as	 seen	 in	
hippocampal	 neuron	 cultures.	 Intact	 cargo	 transport	 of	 synaptic	 vesicle	 proteins	 is	 a	
prerequisite	 for	 proper	 synaptic	 function.	 Its	 inhibition	 by	 inflammation	 might	 thus	 lead	 to	
synaptic	 dysfunction	 (Stagi	 et	 al.,	 2005).	 A	 recent	 study	 further	 demonstrated	 that	 synaptic	
density,	 complement	 cascade	 proteins	 C1q	 and	 C3,	 and	 increased	 immunoreactivity	 for	
mitochondrial	heat	shock	protein	70	(mtHSP70)	are	inversely	correlated	in	hippocampal	tissue	
samples	from	MS	patients	(Michailidou	et	al.,	2015).	 
Furthermore,	 microglial	 cytokine	 release	 of	 IL1β	 has	 been	 shown	 to	 modulate	 synaptic	
plasticity.	 Specifically,	 it	 favors	 long-term	 potentiation	 over	 long-term	 depression	 upon	
repetitive	 stimulation	 (Nisticò	et	al.,	2014).	 It	 can	only	be	 speculated	 to	what	extent	 this	 is	a	
beneficial	 or	 detrimental	 response.	 Indeed	 Chen	 and	 colleagues	 also	 show	 evidence	 for	 the	
protective	 functions	 of	microglia.	 They	 propose	 that	 due	 to	 stripping	 of	 inhibitory	 synapses,	
neuronal	 synchronicity	 is	 increased,	and	neuronal	pro-survival	molecules	 (Bcl-2,	Mcl-1,	pBAD)	
and	neurotropic	 factors	 (BDNF,	FGF-2)	are	released	(Z.	Chen	et	al.,	2014).	Zhu	and	colleagues	
were	able	to	demonstrate	extensive	dendritic	beading	 in	 the	white	matter	of	 rat	spinal	cords	
during	 acute	 EAE,	 and	 a	 recovery	 during	 remission,	 suggesting	 that	 dendritic	 damage	 is	 less	
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dependent	on	demyelination	but	 rather	driven	by	 inflammation	 and	 glutamate	 accumulation	
(Zhu	 et	 al.,	 2003).	 However	 the	 same	 changes	 could	 not	 be	 found	 in	 gray	matter,	 although	
similar	 levels	of	 inflammation	were	observed	(Zhu	et	al.,	2003).	While	there	was	 less	beading	
the	 gray	 matter	 showed	 similar	 depletion	 of	 presynaptic	 proteins	 such	 as	 synapsin	 I	 and	
synaptophysin,	which	were	 pervasive	 and	 longer	 lasting	 than	 the	 beading	 (Zhu	 et	 al.,	 2003).	
Likely	 the	depletion	of	 synaptic	 proteins	was	due	 to	 transport	 deficits.	 Accordingly,	 synapses	
are	not	only	deprived	of	mitochondria,	but	also	of	essential	synaptic	proteins.	 
	
Fig.	5-1	Synapse	pathology	in	MS	
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(A)	 Mitochondria	 (green	 ovals),	 synaptic	 proteins	 and	 neurotransmitters	 (blue	 circles)	 are	 being	
transported	 towards	 the	 synapse	 along	 the	 axon,	 during	 inflammation	 transport	 might	 fail	 and	 the	
synapse	 is	undersupplied,	healthy	state	displayed	 in	B	and	D,	 inflammatory	state	displayed	 in	C	and	E.	
Microglia,	macrophages	and	T-cells	secrete	inflammatory	mediators	such	as	glutamate,	IFNγ,	TNFα	and	
IL1,	 that	 induce	a	 thinning	of	synaptic	contacts	 (C),	glutamate	excitotoxicity	 leads	 to	prolonged	EPSCs,	
due	to	transport	deficits	the	synapse	 is	deprived	of	mitochondria	 (E),	which	 leads	to	failure	of	reserve	
vesicle	mobilization.	Synaptic	currents	are	depicted	as	blue	arrows.	Adapted	partly	from	(G.	Mandolesi,	
Grasselli,	Musumeci,	&	Centonze,	2010;	Sheng	&	Cai,	2012). 
	
5.2.2	Synapses	last	longer	than	their	content	
In	 the	 second	part	of	 this	 study	 I	 focused	on	 the	 implications	of	 the	 transport	deficit	 for	 the	
synapses	 in	 the	 gray	 matter.	 The	 structures	 analyzed	 were	 protrusions	 along	 the	 axon	
collaterals	 staining	 positive	 for	 synapsin	 I.	 I	 found	 the	 bouton	 volume	 along	 with	 the	
mitochondrial	 volume	 inside	 these	 boutons	 to	 be	 decreased	 in	 chronic	 EAE	 compared	 to	
controls,	 albeit	 not	 quite	 proportionally	 since	 the	 ratio	 of	 mitochondrial	 volume	 to	 bouton	
volume	 was	 also	 lower	 in	 chronic	 EAE.	 This	 supports	 my	 results	 on	 decreased	 number	 of	
mitochondria	 inside	 the	 boutons	 in	 chronic	 EAE.	 Furthermore	 I	 compared	 the	 number	 of	
synapses	 in	chronic	EAE	and	control	animals	and	found	no	significant	difference	between	the	
two	groups.		
Synaptic	pathology	is	a	difficult	subject	to	address	by	means	of	immunohistochemistry,	not	only	
because	staining	might	be	inconsistent,	but	also	because	function	is	not	directly	deducible	from	
appearance.	I	have	used	an	antibody	against	a	presynaptic	protein,	synapsin	I,	as	explained	in	
detail	 above.	 Immunohistochemical	 staining	 results	 are	 largely	 dependent	 on	 timing,	
temperature,	 exposure	 to	 light	 and	 also	 tissue	 treatment	 beforehand.	 Additionally	 once	 the	
staining	 procedure	 is	 finished,	 over	 time	 and	 after	 each	 freeze-thaw	 cycle	 the	 antibody	
fluorescence	fades.		Finally	during	scanning	exposure	time	and	laser	settings	should	remain	the	
same	throughout	the	entire	experiment.	Since	I	could	not	guarantee	those	prerequisites,	I	did	
not	 include	 any	 data	 on	 staining	 intensity.	 Better	 methods	 for	 quantification	 of	 synaptic	
function	 would	 be	 the	 patch	 clamp	 method	 that	 measures	 ion	 currents,	 by	 detecting	 the	
postsynaptic	 current	 (PSC),	 or	 by	 the	 synaptic	 release	 probability-	 the	 likelihood	 of	 vesicle	
fusion	after	the	occurrence	of	an	action	potential	at	the	presynaptic	bouton	(Branco,	Marra,	&	
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Staras,	 2010).	 With	 immunohistochemistry	 one	 can	 only	 infer	 information	 about	 the	
performance	of	the	synapse.			
	
What	can	be	assessed	fairly	well	by	means	of	immunohistochemistry	is	bouton	size.	There	are	
only	few	and	inconsistent	publications	on	regulation	of	bouton	size	in	the	CNS.	One	stated	that	
inactivity	 leads	 to	 increased	 bouton	 size	 in	 hippocampal	 neurons	 due	 to	 accumulation	 of	
vesicles	 (Murthy,	Schikorski,	Stevens,	&	Zhu,	2001).	Vice	versa	a	 lack	of	vesicles	or	organelles	
could	decrease	synaptic	size,	as	our	study	is	suggesting.	Grillo	and	colleagues	stated	that	rather	
size	 fluctuations	 than	 the	 size	 itself	 was	 altered	 in	 aging	 mouse	 cortex	 (Grillo	 et	 al.,	 2013).	
Examining	 my	 own	 results	 for	 fluctuations	 reveals	 that	 the	 variance	 of	 synapsin	 I-positive	
bouton	 volume	 in	 chronic	 EAE	mice	 is	 not	 different	 to	 controls	 (F-Test	 of	 synapsin	 I-positive	
bouton	volume:	control	SD	=	1.744,	chronic	SD	=	1.66,	coefficient	of	variation	control:	62.63%,	
chronic:	67.67%,	the	variances	are	not	significantly	different	P>0.05).			
Mhatre	and	colleagues	 reported	altered	synaptic	morphology,	a	 reduction	 in	 total	number	of	
synaptic	 connections	 (boutons)	 and	 decreased	 mitochondrial	 intensity	 in	 a	 Drosophila	
melanogaster	AD	model	(Mhatre	et	al.,	2014).	 	Contrary	to	the	results	 in	this	model	of	AD,	 in	
this	 study	 I	 have	 not	 found	 a	 significant	 difference	 between	 the	 number	 of	 boutons	 per	
collateral	 between	 the	 chronic	 and	 control	 group.	 This	 does	 not	 exclude	 ongoing	 synaptic	
pathology	though.	Ziehn	and	colleagues	quantified	synapse	density	by	determining	the	amount	
of	synapsin	 I-positive	punctae	within	an	 image	(Ziehn,	Avedisian,	Tiwari-Woodruff,	&	Voskuhl,	
2010).	They	 found	a	 reduction	of	 synapsin	 I-positive	punctae	 in	hippocampal	 segment	CA1	 in	
EAE.	When	examining	my	synapsin	I	images,	I	found	a	significant	decrease	of	mean	gray	value,	
when	comparing	 chronic	EAE	 scans	with	 controls.	 This	 result	 could	not	be	utilized	and	 is	not	
shown	here	due	to	too	many	confounding	factors	such	as	different	time	points	of	staining	and	
parameters	of	scanning.	Nevertheless	one	can	speculate	that	due	to	transport	deficits	not	only	
mitochondria	 are	 lacking	 in	 the	 distal	 arbors	 of	 axons	 passing	 through	 lesions,	 but	 also	 pre-
synaptic	 proteins	 such	 as	 synapsin	 I.	 	 As	 Stagi	 et	 al.	 showed,	 inflammation	 can	 inhibit	 the	
anterograde	 transport	 of	 synaptophysin	 and	 synaptotagmin	 and	 Zhu	 and	 colleagues	
demonstrated	 the	 reduction	of	 several	 synaptic	markers	with	 the	most	 pronounced	effect	 in	
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the	white	matter	 and	 ventral	 gray	matter	 of	 the	 lumbar	 spinal	 cord	 in	 acute	 EAE	 and	 upon	
recovery	(Stagi	et	al.,	2005;	Zhu	et	al.,	2003).		
My	results	suggest	that	there	is	a	distal	mitochondrial	deprivation	of	the	synapses	possibly	due	
to	 the	 proximal	 transport	 dysregulation.	 One	 can	 speculate	 that	 synaptic	 proteins	 such	 as	
synapsin	 I	might	 be	 decreased	 as	well.	 	 Since	 the	 content	 of	 the	 bouton	 is	 vital	 for	 synaptic	
function,	 one	 can	 deduct	 that	 the	 lack	 of	 mitochondria	 might	 be	 an	 indirect	 indicator	 for	
synaptic	 dysfunction.	 	 Since	 I	 could	 not	 find	 a	 difference	 in	 number	 of	 boutons,	 one	 can	
postulate	that	this	synaptic	pathology	begins	with	a	deprivation	of	their	content	and	a	decrease	
in	volume.	It	 is	 likely	that	as	pathology	continues	number	of	synapses	would	diminish	as	well.	
Figure	5-2	displays	a	synopsis	of	the	results	of	this	study.	
	
	
	
	 118	
	
	
Fig.	5-2	Summary	of	the	results	
(A)	Schematic	displaying	the	experimental	setting	(B,	C)	there	is	a	distal	deprivation	of	mitochondria	in	
the	distal	arbors	of	axons	passing	through	a	lesion	in	chronic	EAE	(C)	compared	to	healthy	controls	(B),	
more	collaterals	show	no	CFP-positive	mitochondria	at	all	(D,	E)	distal	collaterals	in	chronic	EAE	(E)	that	
contain	CFP-positive	mitochondria	display	less	mitochondria	in	the	synapsin	I-positive	boutons	and	more	
in	the	extra-synaptic	parts	compared	to	control	(D),	bouton	volume	is	also	decreased,	while	the	number	
is	not	significantly	different.	
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5.3	Gray	matter	pathology	–	the	uncommon	suspect	
 
The	 distal	 axonal	 parts	 that	 were	 examined	 in	 this	 experiment	 were	 part	 of	 the	 normal	
appearing	 gray	 matter	 (NAGM).	 NAGM	 also	 exhibits	 neuronal	 injury	 independent	 of	
demyelination,	similar	to	findings	in	NAWM	(Magliozzi	et	al.,	2010;	Witte	et	al.,	2014). 
Bo,	Van	Horssen,	and	their	colleagues	have	shown	that	subpial	gray	matter	demyelination	can	
be	extensive	 in	progressive	patients,	 despite	 lacking	 lymphocyte	 infiltration	and	BBB	damage	
(Bø,	 Geurts,	 Mörk,	 &	 van	 der	 Valk,	 2006;	 Bø,	 Vedeler,	 Nyland,	 Trapp,	 &	 Mørk,	 2003;	 van	
Horssen,	Brink,	de	Vries,	van	der	Valk,	&	Bø,	2007).	The	lesions	were	associated	with	axonal	and	
dendritic	transections,	demyelination,	neuronal	apoptosis,	decreased	synaptic	density	and	glial	
cell	loss	(Bø	et	al.,	2003;	van	Horssen	et	al.,	2007;	Wegner	et	al.,	2006).		On	MRI	scans,	cortical	
thinning	could	be	detected	(Calabrese	et	al.,	2007).	Moreover,	gray	matter	atrophy	is	probably	
associated	with	 long-term	 deficiency	 and	 occurs	 early	 in	 the	 disease	 (Calabrese	 et	 al.,	 2007;	
Fisniku	et	al.,	2008;	Rudick,	Lee,	Nakamura,	&	Fisher,	2009).		
Looking	 at	 the	 clinical	 picture	 the	 chronic	 EAE	 mice	 exhibited,	 I	 found	 possible	 coherencies	
between	my	 chosen	 parameters	 of	 gray	matter	 pathology	 and	 disease	 score.	 Comparing	 the	
mean	 values	 of	mitochondrial	 and	bouton	 volume	of	 each	 animal	with	 its	 disease	 score,	 the	
data	suggests	that	both	are	correlated	with	disease	severity.	Animals	with	EAE	scores	of	3.5	and	
3	had	smaller	mean	values	for	mitochondrial	volume	per	bouton	and	bouton	volume	than	the	
animals	with	a	disease	score	of	2.5.	This	is	consistent	with	the	human	form	MS,	where	physical	
disability	 and	 cognitive	 impairment	 have	 also	 been	 shown	 to	 correlate	 with	 gray	 matter	
changes	(Horakova,	Kalincik,	Dusankova,	&	Dolezal,	2012).	These	groups	could	however	not	be	
statistically	 compared	 due	 to	 the	 small	 number	 of	 animals	 in	 each	 group.	 To	 verify	 this	
hypothesis	a	larger	group	size	is	necessary.	
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EAE	score	 Mitochondria/		
Bouton	
Mitochondrial	
Volume/Bouton	
Synapse	Volume	 Mitochondria/	
area	
2.5	(n=2)	 2.65	 0.46	 3.07	 0.22	
3	(n=4)	 2.45	 0.27	 2.24	 0.26	
3.5	(n=1)	 2.03	 0.23	 1.71	 0.21	
Tab.	 5-1	 Correlation	 between	 EAE	 score	 and	 measured	 parameters	 in	 CFP+	 mitochondria	
containing	collaterals		
 
Ongoing	 gray	 matter	 pathology	 even	 in	 NAGM	 in	 EAE	 might	 be	 a	 result	 of	 the	 proximal	
transport	 blockage	 and	 the	 ensuing	 dysregulatory	 mechanisms.	 This	 study	 substantiated	
previous	observations	of	 a	 net	 deficit	 of	mitochondria	 due	 to	 a	 disparity	 of	 anterograde	 and	
retrograde	 organelle	 transport.	 	 In	 addition	 it	 demonstrated	 that	 even	 in	 those	 axons	 that	
appeared	healthy	(with	CFP+	mitochondria)	a	mismatch	 in	distribution	with	 less	mitochondria	
within	 the	boutons	and	more	 in	 the	extra-synaptic	parts	 could	be	observed.	 It	 remains	 to	be	
discovered	 whether	 this	 is	 a	 pathological	 process	 or	 a	 compensatory	 one.	 Nevertheless	
synapses,	 even	 when	 deprived	 manage	 to	 survive	 even	 after	 weeks	 of	 chronic	 EAE.	 Future	
research	needs	to	be	directed	at	finding	ways	to	interrupt	this	detrimental	loss	of	mitochondria	
and	thereby	prevent	synaptic	pathology	and	axonal	degeneration.	 		
	
5.4	Back	to	the	roots	–	healing	with	vitamins		
	
During	 the	 past	 10	 years	 a	 variety	 of	 drugs	 for	 RRMS	have	 become	 available.	 For	 PPMS	 and	
SPMS	 the	 story	 is	 different.	 Drugs	 that	 have	 been	 approved	 for	 RRMS	 have	 failed	 trials	 for	
PPMS.	This	lack	of	therapeutic	options	might	be	due	to	a	predominance	of	neurodegenerative	
pathology	in	the	second	stage	of	disease.	Inflammation	is	still	present,	though	mainly	intrinsic	
to	the	CNS	behind	an	 intact	BBB	(Witte	et	al.	2014,	Lassman	et	al.	2012,	Frischer	et	al.	2009,	
Magliozzi	 et	 al.	 2010).	 Since	 immunosuppressive	 treatments	 do	 not	 affect	 the	 progressive	
course	long	lastingly,	one	has	to	direct	treatment	at	limiting	axonal	degeneration	and	oxidative	
stress	and	inducing	remyelination.		
Consequently,	 the	 current	 focus	of	 research	has	 shifted	 from	examining	processes	 inside	 the	
inflammatory	lesion	to	discovering	insidious	pathology	in	the	NAWM	and	NAGM.	We	know	that	
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the	 extent	 of	 early	 inflammation	 correlates	with	 neuronal	 damage	 in	 the	 progressive	 phase.	
However	even	with	the	most	effective	treatments	at	our	disposal	the	majority	of	patients	with	
RRMS	will	develop	SPMS	after	10	to	20	years	(Fitzner	&	Simons,	2010;	Lublin	&	Reingold,	1996).	
We	are	thus	in	need	for	therapeutic	strategies	that	target	the	non-inflammatory	components	of	
MS	pathology	and	effectively	prevent	neurodegeneration.		
	
5.4.1	Targeting	mitochondria	
As	described	in	detail	above,	mitochondria	have	a	variety	of	tasks	to	fulfill.	Their	locations	are	
closely	regulated	and	diverse	quality	control	mechanisms	collaborate	to	achieve	equilibrium	of	
fission,	 fusion,	 recruitment	 towards	 the	 areas	 of	 energy	 demand	 as	 well	 as	 mitophagy	 and	
removal	of	damaged	goods.	 
From	 other	 diseases	 and	 physiological	 conditions	 we	 know	 that	 in	 mitochondria	 under	
increased	 oxidative	 stress,	 transport	 no	 longer	 functions,	 ATP	 production	 is	 reduced,	 Ca2+	 is	
released	 from	 stores,	 and	 fission	 and	 fusion	 processes	 are	 altered.	 These	 processes	 lead	 to	
disruption	of	the	membrane	potential	and	ultimately	to	release	of	cytochrome	C	and	activation	
of	the	apoptosis	cascade	or	mitophagy.	This	depends	on	the	number	of	mitochondria	damaged	
and	 the	 intensity	 of	 the	 toxic	 stimulus	 (Witte	 et	 al.,	 2014).	 Mutations	 in	 mitochondrial	 ATP	
production,	 fission	 and	 fusion	 systems,	 and	 transport	 proteins	 can	 predispose	 to	 a	 lower	
capacity	 to	 deal	 with	 oxidative	 stress.	 In	 Parkinson’s	 disease,	 mutations	 in	 several	 proteins	
important	 for	mitochondrial	 transport	 or	 fission	 and	 fusion,	 such	 as	 parkin,	α-synuclein	 and	
PINK1,	have	been	discovered	 (Federico	et	al.,	2012).	 In	MS,	 the	mitochondrial	 involvement	 is	
not	as	obvious.	While	 it	 is	quite	likely	that	mitochondrial	 involvement	in	MS	is	of	a	secondary	
nature,	 i.e.,	 caused	 by	 inflammation	 or	 demyelination	 it	 is	 possible	 that	 such	 acquired	
mitochondrial	dysfunction	contributes	to	progression	in	the	later	stages	of	the	disease.	In	this	
context	it	is	interesting	to	note	that	so	far	only	one	mitochondrial	mutation	has	been	linked	to	
increased	susceptibility	for	MS.	It	 is	found	in	the	promoter	sequence	of	UCP2	known	to	cause	
decreased	ATP	and	ROS	production	(Vogler	et	al.,	2005;	Witte	et	al.,	2014).	Since	mitochondria	
are	a	natural	source	of	ROS,	which	may	have	important	signaling	functions,	it	is	not	surprising	
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that	an	imbalance	in	regulation	can	easily	upset	this	tightly	regulated	system	(M.	T.	Lin	&	Beal,	
2006).	
	
Microglia/Macrophage	 invasion,	myelin	breakdown,	 transport	 failure,	ATP	deficiency,	 channel	
dysfunction,	ion	shift	and	excessive	ROS	production,	all	culminate	in	a	metabolic	imbalance	and	
energy	failure.	To	break	through	this	chain	of	events	requires	a	substance	that	could	buffer	or	
even	 counteract	 ROS	 mediated	 damage.	 A	 great	 part	 of	 the	 intracellular	 ROS	 accumulation	
stems	from	microglia	and	macrophages	but	mitochondria	represent	a	significant	source	as	well,	
especially	 when	 the	 usual	 counteractive	 anti-oxidant	 pathways	 fail	 (van	 Horssen,	 Witte,	
Schreibelt,	 &	 de	 Vries,	 2011).	 Van	 Horssen	 suggested	 non-mutually	 exclusive	 theories	 for	
increased	mitochondrial	 ROS	 production.	 First,	 upon	 demyelination	mitochondria	 have	 been	
found	 to	 accumulate	 (Hogan	 et	 al.,	 2009).	 Larger	 quantities	 of	 mitochondrial	 biomass	 will	
ultimately	 lead	 to	 an	 increased	 production	 of	 ROS.	 	 Secondly,	mitochondria	 	 show	 structural	
and	 functional	 abnormalities	 even	 inside	 intact	 axons	 in	 inflammatory	 lesions,	which	 implies	
that	changes	in	the	energy	balance	of	the	cell	are	amongst	the	first	steps	to	neurodegeneration	
and	could	possibly	pose	a	 target	 for	 therapy	 (Nikić	et	al.,	2011).	 	Thirdly,	mitochondria	 travel	
through	the	entire	length	of	the	axon	and	have	a	half-life	of	30	days.	On	their	way	they	could	
accumulate	 damage	 to	 their	 electron	 transport	 chain	 and	 ROS	 production	 could	 gradually	
increase	 thereby.	 Fourth,	 an	 environment	 rich	 in	 ROS	 secreted	 by	 immune	 cells	 will	 prompt	
mitochondria	to	secrete	more	ROS	(van	Horssen	et	al.,	2011).		
As	depicted	in	Fig.	1-5	excessive	mitochondrial	ROS	production	can	lead	to	disrupted	signaling	
cascades,	dysfunctional	enzymes	and	a	leakage	of	ROS	into	the	cytosol.	Due	to	this	relative	lack	
of	anti-oxidant	mechanisms	it	seems	reasonable	that	antioxidative	therapy	could	help	slow	this	
detrimental	 process.	 In	 EAE	 a	 direct	 application	 of	 a	 ROS/RNS	 scavenger	 could	 revert	
mitochondrial	changes	and	transport	deficits	(Nikić	et	al.,	2011;	C.	D.	Sorbara	et	al.,	2014).	Still	a	
local	administration	in	MS	is	hardly	possible.	Mao	and	colleagues	used	MitoQ	a	lipophilic	cation,	
triphenylphosphonium,	 attached	 to	 ubiquinone	 as	 an	 intraperitoneally	 administered	 agent	 in	
treatment	 of	 EAE.	 The	 MitoQ	 treated	 group	 showed	 decreased	 neurological	 disability	 and	
reduced	 inflammatory	 markers	 such	 as	 IL-6	 (Mao,	 Manczak,	 Shirendeb,	 &	 Reddy,	 2013).	
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Coenzyme	Q10,	Vitamin	E	and	resveratrol	are	also	being	 investigated	for	their	possible	use	 in	
EAE	 and	 clinical	 MS	 (Goudarzvand,	 Javan,	 Mirnajafi-Zadeh,	 Mozafari,	 &	 Tiraihi,	 2010;	
Nimmagadda	et	al.,	2013;	Price	et	al.,	2012;	Soleimani,	Jameie,	Barati,	Mehdizadeh,	&	Kerdari,	
2014).		
	
5.4.2	Targeting	synapses	
Synaptic	 pathology	 starts	 early	 in	 EAE.	 Already	 at	 day	 7	 after	 induction	 even	 before	 T-cell	
infiltration	 and	microglial	 activation	 an	 increased	 turn-over	 and	 instability	 of	 boutons	 in	 the	
cortex	of	EAE	mice	has	been	reported	(Yang,	Parkhurst,	Hayes,	&	Gan,	2013).	These	alterations	
already	 begin	 in	 the	 presymptomatic	 phase	 of	 EAE	 and	 were	 found	 to	 be	 mediated	 by	
peripheral	 TNFα	 production	 (Yang	 et	 al.,	 2013).	 TNFα	 inhibition	 prevented	 this	 change	 in	
stability.	 TNFα	 inhibition	 in	 MS	 patients	 though	 unfortunately	 led	 to	 an	 increase	 in	 attack	
frequency,	duration	and	severity	in	a	randomized	control	trial	(The	Lenercept	Multiple	Sclerosis	
Study	 Group	 and	 The	 University	 of	 British	 Columbia	 MS/MRI	 Analysis	 Group.,	 1999).	 The	
negative	study	results	are	likely	related	to	the	pleiotropic	nature	of	TNF	that	mediates	distinct	
sometimes	even	opposing	effects	 through	 its	 two	receptors.	For	example	a	positive	effect	on	
remyelination	 of	 TNFα	 is	mediated	 by	 the	 TNF	 receptor	 2,	 whereas	 TNF	 receptor	 1	 (TNFR1)	
signaling	 contributes	 to	 demyelination	 (Arnett	 et	 al.,	 2001).	 A	 more	 specific	 approach	 is	
warranted	 for	 sole	 treatment	 of	 synaptic	 alterations	 without	 influencing	 oligodendrocyte	
function	and	remyelination	by	selective	TNFR1	modification	(McCoy	&	Tansey,	2008).		
	
Several	MS	drugs	 are	 currently	 being	 investigated	 for	 their	 specific	 properties	 in	 overcoming	
synaptic	deficits.	Electrophysical	alterations	and	dendritic	spine	loss	in	EAE	for	instance	can	be	
ameliorated	by	 fingolimod	application,	while	physiological	 transmission	was	unaffected	 (Rossi	
et	al.,	2012).	Glatirameracetate	as	well	has	been	shown	to	protect	neurons	against	glutamate	
toxicity	and	synaptopathy	in	EAE	(Gentile	et	al.,	2013).	However	most	of	these	effects	are	most	
likely	secondary	to	immunomodulation.	 
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5.5	Conclusion	
	
In	 my	 thesis	 I	 was	 able	 to	 demonstrate	 the	 distal	 effects	 of	 the	 transport	 deficit	 on	
mitochondrial	distribution	in	axon	collaterals	and	synapses	in	chronic	EAE.		
As	Sorbara	highlighted	in	our	publication,	organelle	transport	is	interrupted	in	the	vast	majority	
of	axons	in	a	neuroinflammatory	lesion	even	before	structural	changes	appear	(C.	D.	Sorbara	et	
al.,	2014).	Whereas	short	lasting	transport	interruptions	do	not	affect	the	distal	mitochondrial	
content,	 longer	 lasting	transport	deficits	as	observed	 in	models	of	chronic	neuroinflammation	
decrease	the	distal	mitochondrial	content	and	thereby	diminish	the	energy	supply	of	the	distal	
axonal	arbor.	
I	 found	 boutons	 depleted	 of	 mitochondria	 and	 although	 the	 number	 of	 boutons	 was	 not	
significantly	different,	the	average	bouton	volume	was	decreased.	It	appears	that	those	healthy	
looking	 axons	 that	 have	 survived	 the	 acute	 insult,	 are	 nevertheless	 subject	 to	 an	 insidious	
pathology.	One	can	suspect	that	this	ongoing	deprivation	ultimately	amounts	to	a	deficiency	in	
synaptic	 function	 and	 eventually	 synaptic	 and	 axonal	 atrophy.	 This	 indicates	 that	 distal	
mitochondrial	 depletion	might	 contribute	 to	 gray	matter	 pathology	 concomitant	with	 clinical	
deficits	seen	in	EAE	and	MS.		As	clinical	deficits	accumulate	over	time	and	are	unresponsive	to	
anti-inflammatory	treatment	 in	progressive	MS,	new	therapeutic	approaches	that	can	restore	
the	axonal	homeostasis	and	supporting	mitochondrial	function	should	be	explored.	Possibly	an	
antioxidative	 therapy	 with	 ROS	 scavengers	 could	 be	 used	 as	 adjuvants	 to	 anti-inflammatory	
therapy.	
The	picture	of	multiple	sclerosis	we	see	today	might	not	be	quite	as	peculiar	anymore	as	in	the	
times	 of	 Carswell	 and	 Charcot,	 still	 it	 leaves	 many	 questions	 unanswered.	 We	 have	 a	 fairly	
broad	 choice	 of	 disease	 modifying	 therapies	 for	 RRMS,	 still	 a	 very	 limited	 one	 for	 the	
progressive	disease	stage.	With	early	treatment	we	can	alter	the	clinical	course,	but	still	a	large	
proportion	of	the	patients	with	RRMS	will	at	some	point	convert	into	the	secondary	progressive	
stage.	Future	studies	need	to	be	directed	at	finding	substances	that	can	be	well	tolerated	and	
sustain	cell	function.	
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